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Acute lung injury (ALI) affects a significant proportion of patients requiring
critical care and is associated with high morbidity and mortality. Treatment is
currently only supportive, with no pharmacological treatment yet shown to
definitively improve outcome. There is evidence from murine models ofALI that
monocytes play a key role in the development of the neutrophilic lung
infiltration characteristic ofALI. Depletion of blood monocytes in mice given
intra-tracheal lipopolysaccharide (LPS) significantly reduces pulmonary
neutrophil influx, systemic neutrophilia and other markers of lung injury. In
humans, monocyte-like cells have been documented in the bronchoalveolar
lavage (BAL) fluid of patients with a variety of inflammatory lung conditions,
including ALI. This thesis describes novel work performed in healthy human
subjects to test whether, in an experimental model of human lung inflammation,
depletion of circulating blood monocytes can ameliorate systemic and
pulmonary inflammation.
LPS inhalation is an established method ofmodelling ALI in healthy human
subjects as it safely and consistently induces mild and self-limiting systemic and
pulmonary inflammation. A preliminary study in a group of 12 healthy subjects
confirmed the safety and efficacy of LPS inhalation compared to saline placebo.
LPS inhalation induced a marked blood neutrophilia together with a rise in body
temperature and heart rate and elevated BAL neutrophil and pro-inflammatory
cytokine concentrations. This study also used flow cytometry to confirm the
presence of pulmonary monocyte-like cells (PMLCs) in BAL fluid, which,
although distinct from blood monocytes, could be clearly divided into two
separate sub-types according to CD14/CD16 expression. LPS inhalation caused
a rise in the number of circulating classical monocytes in blood and an
expansion in the CD14++CD16" 'inducible' iPMLC subtype (reminiscent of
classical blood monocytes), compared to the CD14++CD16+ 'resident' rPMLC
subtype. This may represent transmigration of classical monocytes from blood
across the pulmonary endothelium.
In humans, mononuclear cell (MNC) leukapheresis provides a readily available
method of depleting circulating blood monocytes. A second preliminary study,
performed in a separate group of 6 healthy subjects, demonstrated that
leukapheresis of four total blood volumes could be safely employed to deplete
large numbers of circulating blood monocytes. Active recruitment ofmonocytes
into circulating blood during leukapheresis did, however, limit the reduction in
total circulating blood monocyte counts. This study also investigated, for the
first time, the potential pulmonary effects of leukapheresis. Despite a relative
prominence of iPMLCs in BAL fluid after leukapheresis, there was no evidence
of significant neutrophil influx or a clinically important pro-inflammatory effect
in the alveolar space.
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A randomised, double blind, placebo-controlled trial was then performed in a
third group of 30 healthy human subjects who all inhaled LPS at baseline. There
was no evidence that MNC leukapheresis (depletion group, n=15), compared to
a sham procedure (sham group, n=15), attenuated the systemic and pulmonary
inflammation induced by LPS inhalation, as measured by: blood neutrophil and
plasma C-reactive protein (CRP) levels; by the neutrophil, protein and pro¬
inflammatory cytokine content of BAL fluid; and by [18F]fluorodeoxyglucose
positron emission tomography ([18F]FDG PET)-derived measures of global lung
inflammation. MNC leukapheresis temporarily prevented the LPS-induced rise
in circulating classical monocytes and was also associated with a small
reduction in the estimated numbers of MNCs in BAL fluid. It did not, however,
appear to affect the LPS-induced expansion in the iPMLC subtype. Further
characterisation of the PMLC subtypes by flow cytometry/sorting and cell
culture demonstrated that the iPMLC subtype was more pro-inflammatory but
less mature and with a lower proliferation potential than the rPMLC subtype.
In summary, this work did not support a role for circulating blood monocytes in
the evolution of LPS-induced systemic or pulmonary neutrophilia in man. The
rise in circulating levels of classical blood monocytes and the dramatic
expansion of pro-inflammatory, immature iPMLCs in BAL fluid after LPS
inhalation do, however, suggest that monocytes migrate to the lung and are to
some extent involved in the pathogenesis of lung inflammation. Compared to
murine methods ofmonocyte depletion, leukapheresis could not achieve such
an extensive or sustained reduction in circulating blood monocyte counts, nor
was it likely to have influenced other (specifically patrolling or splenic)
monocyte pools. Future work in the drive to find treatments for ALI should
therefore investigate the potential of pre-emptive leukapheresis or the efficacy
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Chapter 1 will explore the background to my thesis, explaining how my
hypotheses were generated and how the studies I conducted aimed to answer
these hypotheses.
1 shall first consider the epidemiology, pathogenesis and consequences of acute
lung injury (ALI). Next, I shall describe in detail the development and use of
experimental models of human lung inflammation and the quest for effective
treatments for ALI. The potential role ofmonocytes in lung inflammation will
then be discussed, exploring the evidence available from murine models of lung
injury and from inflammatory lung disease in humans. I will next outline murine
studies ofmonocyte depletion in lung injury. I shall then describe the rationale
for using leukapheresis to deplete circulating blood monocytes in humans.
Finally, I will outline my hypotheses and provide an overview of the studies
carried out to test these hypotheses.
1.2 ACUTE LUNG INJURY
a) Definition and causes
The acute respiratory distress syndrome (ARDS) was first recognised in 1967
and reflects the more severe end of a spectrum ofALI. ALI is an inflammatory
lung condition, defined as the acute development of persistent and refractory
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Chapter 1: Introduction
hypoxaemia, in the presence of bilateral alveolar infiltrates on the chest x-ray
(CXR), where there is no clinical evidence of a cardiogenic aetiology (raised left
atrial pressure). ALI is characterised by a partial pressure of arterial oxygen
(Pa02) to fraction of inspired oxygen (Fi02) ratio of <300mmHg (G R Bernard et
al., 1994). ARDS (severe ALI) is diagnosed when the Pa02 to Fi02 ratio is
<200mmHg; although this is an arbitrary threshold, lower ratios are associated
with higher mortality rates (Brun-Buisson et al., 2004).
A relatively recent report by an expert panel aimed to update the consensus
definition (Ferguson etal., 2012; ARDS Definition Task Force etal, 2012). The
validity of this new 'Berlin' definition was tested on a large, international cohort
ofmore than 4000 patients and aimed to improve reliability in relation to
patient care and future research. The report defined ARDS (rather than ALI) as a
Pa02 to Fi02 ratio <300mmHg in the presence of a positive end-expiratory
pressure (PEEP) of >5 cm H2O. It recommended stratifying patients into three
categories of severity: mild ARDS (Pa02 to Fi02 ratio >200mmHg), moderate
ARDS (Pa02 to Fi02 ratio >100mmHg) and severe ARDS (Pa02 to Fi02 ratio
<100mmHg) (Ferguson et al., 2012; ARDS Definition Task Force et al., 2012). It
was also agreed that a pulmonary artery wedge pressure <18mmHg does not
fully exclude the presence of ARDS, in particular after large-volume fluid
resuscitation (Wheeler and G R Bernard, 2007). It is as yet unclear whether this
newer definition will be widely adopted. In this thesis, to maintain clarity, I shall




ALI affects a heterogeneous patient group; it can be induced directly by an
intrinsic (pulmonary) cause such as pneumonia, gastric aspiration, inhalation
injury including near-drowning or pulmonary contusion, or indirectly by a
systemic cause, for example, sepsis, burns, extensive trauma, large-scale
transfusion of blood products, pancreatitis, cardiopulmonary bypass and fat or
amniotic fluid embolism (G R Bernard et al, 1994; Wheeler and G R Bernard,
2007). Complex genetic, host and environmental factors are thought to explain
why some patients with a typical predisposing event develop ALI and why some
do not; similarly, genetic and environmental factors are thought to influence
whether ALI resolves or progresses to cause multi-organ failure and death (Gao
and Barnes, 2009; Glavan etal, 2011).
b) Epidemiology of ALI
The worldwide incidence ofALI has been reported at anywhere between 2 and
75 cases per 100,000 person-years (Wheeler and G R Bernard, 2007). This wide
variation in estimated incidence is thought to stem from differences in baseline
population and patient identification and management. Approximately 190,000
cases occur annually in the U.S.A. (G R Bernard etal, 1994; Rubenfeld etal.,
2005) and ALI affects around 7-8% of critically ill patients in the intensive care
unit (ITU) setting in Europe and in Scotland (Brun-Buisson et al., 2004; M
Hughes etal, 2003).
Mortality from ALI was originally reported at more than 50%; although this
now appears to be declining, levels ofmorbidity and mortality remain
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unacceptably high (Rubenfeld, 2007; Erickson et al., 2009). Using the updated
Berlin Definition, mortality has recently been estimated at 27% for mild ARDS,
32% for moderate ARDS and 45% for severe ARDS (ARDS Definition Task Force
etal., 2012). The median duration ofmechanical ventilation also increases with
the stage of severity in survivors ofARDS, from 5 days in mild cases, to 7 days in
moderate cases and to 9 days in severe cases (ARDS Definition Task Force et al,
2012).
Despite wide-ranging research, at present treatment ofALI essentially remains
supportive, with no pharmacological therapy yet shown to reduce mortality.
The high morbidity and mortality ofALI, plus significant use of hospital
resources present ongoing drivers in the search for potential treatments.
Furthermore, patients who survive ALI frequently display long-term functional
consequences. Persistent impairment of pulmonary function, in particular
carbon monoxide diffusion capacity, is often mild and asymptomatic. Instead,
functional limitation is almost always due to neuromuscular or cognitive
dysfunction (Herridge etal., 2003; Rubenfeld, 2007).
c) Pathophysiology of ALI
ALI is a complex inflammatory state thought to represent an imbalance between
pro- and anti-inflammatory mechanisms, such that an initially protective host
immune response to an injurious stimulus evolves into an overwhelming,




ALI is characterised by neutrophil infiltration of the pulmonary vasculature,
interstitium and alveoli and reduced integrity of the barrier between the
pulmonary endothelium and alveolar epithelium. The increased permeability of
the 'blood-air barrier' results in the accumulation of protein-rich oedema fluid
within the alveoli (Holter et al, 1986; Matthay and Zimmerman, 2005). This is
detectable by a steep rise in protein levels detectable in bronchoalveolar lavage
(BAL) fluid. Respiratory failure develops due to reduced alveolar oxygenation,
increased pulmonary dead space, reduced lung compliance and increased
ventilation/perfusion mismatch (Wheeler and G R Bernard, 2007; Matthay etal.,
2012). Histological specimens demonstrate diffuse alveolar damage, with
oedema, inflammation, haemorrhage and hyaline membrane formation due to
fibrin deposition (Ware and Matthay, 2000; Matthay and Zimmerman, 2005).
The precise interactions ofmolecular and cellular mediators, pathways and
mechanisms in ALI remain unknown. It is also unclear how much these differ
depending upon the cause ofALI. Activation of the host's innate immune
response is triggered locally or systemically through the detection of pathogen-
or damage-associated molecular patterns (PAMPs and DAMPs) by pattern
recognition receptors (Calfee and Matthay, 2010; Zhang etal., 2010). Examples
of pattern recognition receptors include toll-like receptors (TLRs), which are
widely expressed by phagocytes and epithelial cells, and the receptor for




The accumulation of neutrophils within the alveolar space appears to represent
a key event in the majority of cases ofALI, although ALI can develop in
neutropenic patients (Laufe et al., 1986; Ognibene et al., 1986), indicating the
importance of other cell types including monocytes (whose role in ALI is
discussed in detail later in this chapter), macrophages, platelets and
lymphocytes. Higher levels of BAL neutrophils at an early stage are associated
with greater mortality in ALI caused by both sepsis and trauma (Steinberg etal.,
1994) and neutrophil depletion appears beneficial in most animal models ofALI
(Grommes and Soehnlein, 2011).
Activated neutrophils release a variety of harmful, cytotoxic substances that are
crucial to microbial killing and host defence. Excessive activation of neutrophils
can, however, cause tissue damage and, together with leucocyte migration itself,
compromise the integrity of the endothelial-epithelial barrier. Reactive oxygen
species (ROS) and cationic peptides, including defensins, are cytotoxic when
released outwith the phagosome (Zemans et al., 2009). Activated neutrophils
release lactoferrin and myeloperoxidase (MPO, a lysozomal enzyme that
catalyses the release of ROS) (Grommes and Soehnlein, 2011). Levels of
proteinases, including human neutrophil elastase (HNE) and matrix
metalloproteinases (MMPs) are raised in both plasma and BAL fluid of patients
with ALI, and can indicate severity (Donnelly etal., 1996; Zemans etal., 2009).
In addition to degradation of the extracellular matrix, MMPs play a role in
neutrophil migration (Davey etal., 2011).
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A variety of chemotactic cytokines are involved in the attraction of leucocytes to
the pulmonary vasculature adjacent to the site of inflammation. Neutrophil
chemotaxis occurs in response to the release of interleukin (IL)-8 and other
chemokines such as epithelial-derived neutrophil-activating peptide 78 (ENA-
78) by AMs and epithelial cells (Grommes and Soehnlein, 2011; Soehnlein and
Lindbom, 2010). Monocyte chemoattractant protein-1 (MCP-1), macrophage
inflammatory protein-1 alpha (MlP-la), lactoferrin, stromal cell-derived factor-
1 (SDF-1) and IL-8 are important mediators in monocyte chemotaxis (Gerszten
etal., 1999; Grommes and Soehnlein, 2011; Soehnlein and Lindbom, 2010).
SDF-1 attracts lymphocytes to sites of inflammation and may also be involved in
late neutrophil influx (Petty et al., 2007).
Early release of the pro-inflammatory cytokines tumour necrosis factor-alpha
(TNFa) and IL-ip is thought to initiate and augment the inflammatory process
(Park et al., 2001). IL-8 and MlP-la also have pro-inflammatory effects. An
imbalance between the levels of pro- and anti-inflammatory cytokines is
thought to underpin the development ofALI (Ware and Matthay, 2000). For
example, lower levels of anti-inflammatory cytokines, such as IL-10 and IL-1
receptor antagonist (IL-lra) in BAL fluid are associated with poorer outcomes
in patients with ALI (Donnelly et al., 1996; Park et al., 2001). Soluble TNF
receptors (sTNFR) exert an anti-inflammatory effect by binding circulating
TNFa (Grommes and Soehnlein, 2011). Some cytokines involved in the
pathogenesis ofALI have mixed pro- and anti-inflammatory properties, for
example, IL-6 and IL-12 (Park et al., 2001).
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Cytokine-mediated activation of pulmonary endothelial cells is thought to be
key to the sequestration of leucocytes and has been the focus of much
investigation. Although little is known about differences between leucocytes (in
particular, neutrophils, monocytes and lymphocytes], their transendothelial
migration into the pulmonary interstitium involves several steps (Imhof and
Aurrand-Lions, 2004; Ley etal., 2007).
Up-regulation of selectin (cell adhesion molecule] expression promotes initial
'capture' of leucocytes to the vascular endothelial wall, along which the
leucocytes can then 'roll' (Ley et al., 2007; Nourshargh et al., 2010]. L-selectin is
expressed by most leucocytes and is believed to play an important role in
leucocyte sequestration (Kuebler etal., 2000]; E-selectin and P-selectin are
expressed by activated endothelial cells (Zemans etal., 2009] and P-selectin is
also expressed by platelets (Zarbock and Ley, 2009]. Upregulation of other cell
adhesion molecules, for example intercellular and vascular adhesion molecules
(ICAM1 and VCAM1] by activated vascular endothelium encourages 'firm
adhesion' of leucocytes through the binding of transmembrane receptors called
integrins (Imhof and Aurrand-Lions, 2004; Ley etal., 2007]. Leucocytes then
tend to 'crawl' to the site of transendothelial migration, which can occur by
either a paracellular or transcellular route (Nourshargh et al., 2010].
After passing through the endothelial layer, leucocytes then cross the basement
membrane and pericyte sheath to enter the interstitium. Migration through the
interstitium appears to be driven by the priming effect of prior transendothelial
migration and rearrangement of the actin cytoskeleton within the cells (Ley et
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al., 2007; Nourshargh etal., 2010). Compared to transendothelial migration,
transepithelial migration remains poorly delineated. Integrins are involved in
leucocyte adherence to the basolateral epithelial surface. Leucocytes migrate
across the epithelium in groups, by the paracellular route between type I and
type II alveolar epithelial cells (Zemans et al., 2009).
Plasma levels of vonWillebrand factor (vWF) have been shown to act as a
marker of endothelial cell activation and injury and higher levels are associated
with poorer outcome in AL1 (Ware et al., 2004). Both production of surfactant
and alveolar fluid clearance are adversely affected by damage to alveolar
epithelial cells. Several biomarkers for alveolar epithelial damage have been
discovered (McAuley, 2009). Surfactant protein-D (SP-D) is a large collagenous
glycoprotein that acts as a marker of injury to type II alveolar epithelial cells; its
levels in plasma correlate with severity ofALI, as does lower alveolar fluid
clearance (Ware etal., 2010). RAGE is strongly expressed by type 1 alveolar
epithelial cells; BAL and plasma levels of soluble RAGE are higher in patients
with ALI and baseline levels are linked with outcome (Uchida etal., 2006; Calfee
et al., 2008). Clara cell secretory protein (CC-16) is mainly released by Clara
cells within the terminal bronchioles of the lung (Hermans and A Bernard,
1999). Serum levels of CC-16 are a sensitive marker of increased epithelial
permeability (Broeckaert and A Bernard, 2000; Determann et al., 2009);
however, higher levels of CC-16 in BAL fluid correlate with increased survival
(Jorens etal., 1995; Hermans and A Bernard, 1999).
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ALI is also characterised by altered haemostasis and the formation of platelet-
fibrin complexes within the alveolar space and pulmonary circulation (Ware et
al., 2007). Coagulation pathways become activated and there is higher
expression of tissue factor (TF) and lower levels of anti-coagulant proteins
(Giinther et al., 2000). For example, levels of protein C are reduced and this is
associated with greater mortality (Ware et al., 2007). There is also reduced
fibrinolytic activity, with a rise in the levels of plasminogen activator inhibitor-1
(PAI-1), an anti-fibrinolytic protein released by epithelium, endothelium and
fibroblasts within the lung, that again correlates with increased mortality
(Giinther et al., 2000). Activation of coagulation pathways is thought to induce
the release of pro-inflammatory cytokines and promote leucocyte
transendothelial migration (Ware etal, 2007; Schultz etal, 2009).
Finally, there is also increasing interest in the mechanisms involved in the
resolution ofALI, as these may be crucial to preventing the development of
multi-organ failure and death or the progression of inflammation to fibrosing
alveolitis (Matthay and Zimmerman, 2005). Neutrophil clearance and apoptosis
may be important; phagocytosis of apoptotic neutrophils appears to make AMs
express an anti-inflammatory phenotype (Savill etal., 2002). The role of
regulatory T (Treg) cells is also under investigation (Venet et al., 2009; Wang et
al., 2012). Improving alveolar oedema fluid clearance and re-establishing the
integrity of the endothelial-epithelial barrier are vital steps in the resolution of
lung injury; patients with better alveolar fluid clearance have reduced mortality
and are ventilated for shorter periods (Ware and Matthay, 2001). Various
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mediators, including MMPs, lipoxins and resolvins, appear to be involved in the
process of alveolar epithelial repair (Davey etal, 2011).
Further work is required to fully elucidate the pathophysiological mechanisms
underlying ALI and to identify further molecular and cellular targets for
treatment. The following section describes the avenues that have already been
explored in the drive to improve the outcome from ALI.
d) Treatment of ALI
Table 1A lists the various interventions that have been investigated in patients
with ALI. Despite extensive investigation, including several large multi-centre
clinical trials carried out by The ARDS Network group, no pharmacological
treatment has yet been shown to definitively reduce mortality from ALI
(Thompson and G R Bernard, 2011). More supportive measures, in particular
low tidal volume (lung protective) ventilation and now also prone positioning,
have offered the most encouraging results to date in the search for effective
treatments for ALL
There are several potential interventions that are currently undergoing further
investigation. The prophylactic use of p-agonists is currently being investigated
in patients undergoing oesophagectomy (Perkins etal., 2011). Large multi¬
centre RCTs are currently underway in both the UK and the U.S., investigating
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A randomised controlled trial (RCT) investigating the prophylactic use of
aspirin in patients at high risk of developing ALI is also underway (Kor et al.,
2012). A preliminary study is investigating whether IV keratinocyte growth
factor (KGF) can improve oxygenation (Cross etal., 2013).
A large study of extra-corporeal membrane oxygenation (ECMO) in critically ill
patients with severe acute respiratory failure demonstrated improved survival
without disability at 6 months; further work is, however, required to confirm
these results (Peek et al., 2009). Finally, the use of stem cell therapy (for
example, bone marrow-derived mesenchymal stem cells, MSCs) in ALI
represents a new area of research that appears to offer much potential and is
currently under investigation in a multi-centre phase II RCT (Matthay et al.,
2010). Stem cells release paracrine factors (including anti-inflammatory
cytokines, growth factors and antimicrobial peptides) and may play an
important role in cellular repair and restoration of endothelial/epithelial
permeability (Hayes etal., 2012).
The search for treatments that will improve the outcome from ALI has
therefore, so far, been relatively unsuccessful. This is probably partly due to our
relatively limited understanding of the complex pathophysiology ofALL It is
also difficult to identify patients early, before lung injury becomes established
(Levitt and Matthay, 2010; Gajic et al., 2011). A large amount of research into
ALI has been performed using animal models, which are valuable but also have




1.3 MODELLING LUNG INFLAMMATION IN ANIMALS
Ideas for potential new treatments for ALI often stem from clinical observations
of patients in intensive care and/or from in vitro work in the laboratory, for
example, studying cultured cell lines. Over the past two decades, a number of
animal models ofALI have evolved that can be used to test hypotheses relating
both to the pathogenesis ofALI and its treatment. For example, valuable
strategies often involve inhibition of potential key pathways or specific
mediators, or genetic manipulation to examine the role of specific genes and the
proteins they express.
The most frequently employed animal models ofALI are listed in Table IB with
a brief summary of their advantages and disadvantages. However, none of these
models induce all of the characteristic features of human ALL
Various animal species have been used to study ALI, including mice, rats,
rabbits, dogs, sheep, pigs and non-human primates. There are clearly multiple
differences between humans and other species that, at least to some extent,
explain the difficulty in translating promising new treatments from animal
models into effective treatments in human patients with ALI. For example, in
stark contrast to research in mice that indicates a beneficial effect of (3-agonists
in ALI, the human studies so far performed have not found any improvement in
mortality or markers of severity (Perkins et ah, 2006). In general, the animals
studied in such research tend to be young and otherwise healthy, compared to
human patients who are often relatively old with multiple comorbid conditions.
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The animals are also often genetically very similar to each other (Matute-Bello
et al., 2008). The extensive development of genetic manipulation in mice and the
wide availability of murine-specific kits and reagents for laboratory use are two
of the key advantages of studying lung injury in mice (Matute-Bello et al., 2008).
Their small size can, however, cause practical issues. Radiological assessment
and pre-mortem blood and BAL sampling are challenging in small rodents
(Matute-Bello etal., 2008). Physiological monitoring is also technically
challenging, especially considering the murine respiratory rate (RR) is around
250 to 300 breaths per minute (Matute-Bello etal, 2011). Using larger animals
that are genetically closer to humans is much more expensive and also raises
more ethical considerations, particularly in relation to non-human primates
(Bastarache and Blackwell, 2009).
There are also some key biological differences between animal species and
humans, especially with regards to innate immunity and the lungs (Mestas and
C Hughes, 2004). TLRs vary between species, as do monocyte subtypes (this is
discussed in detail later) and chemotactic cytokines (for example, the murine
homologues of human IL-8 are MIP-2 and keratinocyte chemoattractant)
(Mestas and C Hughes, 2004; Matute-Bello etal, 2008). There are also major
differences in macrophage populations, with pulmonary intravascular
macrophages present in some species such as sheep and pigs, but not in
humans, primates, rodents or rabbits. Interestingly, pulmonary intravascular
macrophages appear to facilitate the development ofALI following an injurious
stimulus (Matute-Bello etal., 2008). Other reported differences between mice
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and humans include NO pathways of microbial killing (Matute-Bello etal.,
2008), responses to oxidative stress (Gharib etal., 2010) and proportions of
circulating neutrophils (Matute-Bello etal., 2011). There are also some
anatomical differences between humans and other animal species and different
rates of alveolar fluid clearance (Proudfoot etal., 2011; Ware, 2008).
The problem of inter-species variability can be overcome by using human
models of lung inflammation, although animal models remain extremely useful
when studying the underlying pathophysiology of lung inflammation and for the
initial in vivo stage when testing potential treatments for ALL It remains difficult
to translate findings from animal models into patients, who represent a
heterogeneous group. The next section illustrates the increasing use of human
models ofALI with the aim of bridging the gap between research involving
animal models and clinical studies in sick patients with ALL
1.4 MODELLING LUNG INFLAMMATION IN HUMANS
a) Types of model
Human models ofALI vary from in vivo models, where certain surgical
procedures in the clinical setting are associated with high subsequent rates of
ALI, through experimental models in healthy human volunteers, to ex vivo
models using non-transplantable donor lungs (Table 1C).
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Phase II trials can be performed in high-risk patient groups, for example
patients undergoing one-lung ventilation (OLV) or cardiopulmonary bypass
(CPB), to establish the safety and efficacy of potential treatments and
preventative strategies for ALL However, the majority of patients develop ALI
for other reasons. The development of LPS challenge as a model of early lung
inflammation in healthy subjects has lead to increasing numbers of phase II
trials in healthy subjects, as a prelude to phase III clinical trials in patients with
ALI or the high-risk patient groups mentioned above.
The next sections will describe the discovery of LPS and the rationale for its use
in modelling lung inflammation, plus more details on the types of LPS challenge
available and their respective advantages and disadvantages. I will also report
the results of previous research using LPS challenge to model human ALL
b) The discovery of LPS and its inflammatory effects
LPS is purified bacterial endotoxin, which forms part of the outer leaflet of the
outer membrane ofGram-negative bacteria. Endotoxin was discovered more
than 100 years ago by Pfeiffer, who demonstrated that administering lysates of
heat-inactivated Vibrio cholerae to laboratory animals still induced shock
(endotoxin is heat-stable) (Beutler and Rietschel, 2003). Later, administration
of endotoxin itselfwas shown to induce pyrexia and leucocytosis (Bayston and
Cohen, 1990; Beutler and Rietschel, 2003). Further work was performed to
optimise the extraction and purification of LPS from endotoxin and the chemical
nature of LPS was eventually characterised by Westphal and Luderitz in the mid
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20th century (Bayston and Cohen, 1990). LPS consists of an O-specific chain (a
water-soluble polysaccharide component), which is linked by core
oligosaccharide to Lipid A (the glycophospholipid component). The O-specific
chain confers its unique antigenic properties, which vary between species and
determine LPS serotype (e.g. Escherichia (E.) coli 026:B6). Lipid A is responsible
for the biological activity of LPS (Bayston and Cohen, 1990).
LPS acts as a PAMP and the recognition of its presence by the innate immune
system has been extensively investigated. TLR-4 is the key transmembrane
receptor for LPS, forms a receptor complex with CD14 and is expressed by
macrophages and epithelial cells within the alveolar space (Beutler and
Rietschel, 2003). LPS binding to this receptor complex is dependent upon the
presence of LPS-binding protein (LBP) and MD-2 (also known as lymphocyte
antigen 96) (Beutler and Rietschel, 2003). LPS signalling to induce down-stream
effects such as cytokine production is mediated by adaptor proteins (mainly
MyD88) and occurs via the activation of the transcription factor nuclear factor-
kappa B (NF-kB) and protein kinases including mitogen-activated protein
kinases (MAPK) and phosphatidylinositol 3-kinases (Janssens and Beyaert,
2003).
Endotoxin is shed by Gram-negative bacteria and is therefore found widely in
the environment, including in the nasal and oral passages of animals and
humans and on plant, animal and soil surfaces (Radon, 2006). Endotoxin is
found in high concentrations in some occupational environments; much of the
early research on endotoxin and LPS was undertaken to investigate
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occupational lung disease caused by organic dust inhalation, for example in
relation to livestock and grain handling, textile production and waste processing
(Radon, 2006). It was noted that workers exposed to cotton dust could develop
transient 'flu-like symptoms, including pyrexia, cough, myalgia and tachycardia
(Thorn, 2001). Tolerance does develop, with a reduction in symptoms upon
repeated exposure and their reappearance after a period of no exposure, hence
why this phenomenon is sometimes termed 'Monday Fever' (Pernis etal, 1961).
The first description of experimental inhalation of purified endotoxin in humans
demonstrated that this could elicit symptoms identical to those observed after
cotton dust inhalation (Pernis etal., 1961).
Much of the early literature describes studies performed using un-purified
endotoxin or cotton-dust extract, often concentrating on the airways effects in
individuals with atopy or chronic lung disease (Thorn, 2001). In more recent
years, there have been many studies investigating the inflammatory effects of
purified LPS in healthy subjects (as well as in patients with atopy and chronic
lung disease). LPS challenge can be either systemic, by IV injection, or directly to
the lungs by inhalation or by segmental instillation using a fibreoptic
bronchoscope.
c) Intravenous LPS
IV LPS mainly induces systemic effects and is thus more useful as a model of
sepsis than specifically of lung injury. Most studies have used Clinical Reference
Centre Endotoxin (CCRE, which is LPS from E. coli 0113). It has been given,
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according to subject weight, in a dose of 1-4 ng/kg (Boujoukos et al., 1993;
Cannon et al., 1990; Copeland et al, 2005; Draisma et al., 2009; Franco et al.,
2000; Kuhns etal., 1995; Martich etal., 1991; Rodrick etal., 1992; Suffredini et
al., 1999; van Deventer etal., 1990). Interestingly, sensitivity to IV LPS provides
yet another example of differences between species, with mice requiring a much
higher dose relative to body weight (about 250 times greater than humans) to
achieve a similar cytokine response (Copeland et al., 2005).
The IV administration of LPS induces pyrexia (which is dose-dependent and
peaks around 3 to 5 hours), tachycardia, myalgia and a small fall in mean
arterial pressure, all of which resolve by 24 hours (Granowitz et al., 1993;
Kuhns etal., 1995; Suffredini etal., 1999; Copeland etal., 2005; Schinkel etal.,
2005). There is a rapid rise in the plasma concentrations of C-reactive protein
(CRP) and several pro-inflammatory cytokines, including TNFa (peaking at 1.5
hours), IL-ip (peaking at 2 to 3 hours), IL-6 and IL-8 (which peak at 2 to 4
hours) (Richardson etal., 1989; Cannon etal., 1990; Martich etal., 1991;
Granowitz etal., 1993; Kuhns etal., 1995; Suffredini etal., 1999; Copeland etal.,
2005; Draisma etal., 2009). This is mirrored by rises in the plasma levels of
anti-inflammatory mediators including IL-10, IL-lra and sTNFR, which peak
slightly later, at 3 to 6 hours (Spinas et al., 1992; Granowitz et al., 1993; Kuhns
et al., 1995; Copeland et al., 2005; Draisma et al., 2009).
Increased levels of plasma vWF (a marker of endothelial cell activation) are
detectable as early as 1.5 hours after the administration of IV LPS, and peak
around 6 hours (van Deventer et al., 1990; Draisma et al., 2009). Plasma levels
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of soluble (s)E-selectin (shed by activated endothelial cells) also peak around 6
hours (Kuhns et al., 1995).
The leucocyte response to IV LPS is characterised by a brief but clear fall in
circulating neutrophil numbers, followed by a rapid rise, with numbers peaking
around 4-6 hours (Richardson etal., 1989; P D Smith etal, 1994; Kuhns etal.,
1995; Suffredini etal., 1999; Copeland etal., 2005). Plasma granulocyte colony-
stimulating factor (G-CSF) levels also rise by 4 hours, indicating neutrophil
release from bone marrow and/or marginating pools (Kuhns et al., 1995). IV
LPS administration causes a fall in the circulating numbers of lymphocytes and
monocytes (visible between 1 and 4 hours) (Richardson etal., 1989; Suffredini
etal., 1999; Copeland etal., 2005).
IV LPS also causes a rise in the levels of plasma HNE and lactoferrin, a marker of
neutrophil degranulation (Kuhns etal., 1995; Suffredini etal., 1999; Draisma et
al., 2009). There are also increased plasma levels of sL-selectin, which is shed by
activated neutrophils (Solomkin etal., 1994; Kuhns etal., 1995; van der Poll et
al., 1997).
IV administration of LPS has characteristic effects on coagulation. Initially, there
is increased tissue-plasminogen activator (t-PA) activity and higher levels of
plasmin-a2-antiplasmin complexes and D-dimers, indicating that fibrinolysis is
transiently enhanced (Pajkrt et al., 1997; Suffredini et al., 1989; van der Poll et
al., 1997). This is followed by suppression of fibrinolysis, with increased PAI-1
concentrations (Pajkrt et al., 1997; Suffredini et al., 1989; van der Poll et al.,
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1997; van Deventer etal., 1990), and activation of coagulation, with a peak in
prothrombin fragments, TF mRNA expression and thrombin-antithrombin
(TAT) complexes in plasma by 3 hours (van Deventer et al., 1990; van der Poll et
al., 1997; Franco etal., 2000).
Although the initial neutropenia suggests circulating neutrophils rapidly
become marginated after IV LPS, there is only minimal neutrophil
transmigration into the alveolar space by 6 hours, with no clear rise in total BAL
cell or differential neutrophil counts (Boujoukos etal., 1993; P D Smith etal.,
1994; Suffredini etal., 1999). Systemic LPS does, however, induce a minor
impairment in pulmonary gas exchange and a subtle increase in lung epithelial
permeability (Suffredini etal., 1992). Furthermore, AMs retrieved 6 hours after
systemic LPS administration are primed, releasing greater concentrations of
TNFa and IL-lp when stimulated in vitro (P D Smith etal., 1994).
d) Inhalation of LPS
LPS inhalation has been employed in more than 50 human studies, involving
more than 1000 subjects, over the past few decades. Many of these studies have
been performed in healthy subjects (Table ID); however, some studies have
recruited patients. There has, for example, been significant interest in the
relevance of low-dose LPS in allergic sensitisation; many studies have now been
performed in atopic and asthmatic patients, using comparatively much lower
doses of LPS or incremental dosing protocols (Kitz et al., 2006; Kline et al., 1999;
Michel et al., 1989; Sundy et al., 2006). Interestingly, work in mouse models has
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suggested that low-level exposure to inhaled LPS primes T helper 2 (Th2) cells,
causing allergic sensitisation, compared to inhalation of higher concentrations
of LPS, which leads to Thl responses including release of pro-inflammatory
cytokines (Eisenbarth etal., 2002). This adds credence to the hygiene
hypothesis, whereby lower exposure to environmental endotoxin in childhood
has been linked to a greater risk of atopic conditions (Strachan, 1989). Indeed,
lower doses of inhaled LPS also appear to induce Th2-type responses rather
than neutrophilic inflammation in humans (Alexis etal., 2004). Tolerance to
repeated doses of LPS also appears to be linked to lower-dose LPS inhalation
(Loh, 2005).
There appears to be a threshold dose of inhaled LPS, of around 30-40pg, for
inducing clinical symptoms alongside a neutrophilic inflammatory response
(Thorn, 2001). Most studies employing LPS inhalation as a model of acute lung
inflammation have therefore used doses of at least 50pg (Table ID). The effects
of inhaling this dose of LPS have been measured by symptoms, spirometry (to
assess airways effects), peripheral blood samples (to gauge systemic effects)
and by transfer factor for carbon monoxide (DLCO), induced sputum and BAL
(to assess pulmonary effects).
Inhalation of higher doses of LPS induces significant pyrexia in the majority of
subjects, which may become noticeable as early as 4 hours and tends to peak
between 8 to 14 hours post-challenge (Clapp etal., 1993; Michel etal., 2001;
Maris, De Vos, Bresser, et al, 2005; Loh et al, 2006; Sundblad et al, 2009).
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A proportion of subjects report transient associated 'flu-like symptoms,
including headache, malaise and myalgia, whose prevalence correlates to the
dose of LPS inhaled (Nightingale etal., 1998; Thorn and Rylander, 1998; Michel
et al., 2001; Loh et al., 2006; Sundblad et al., 2009; Korsgren et al., 2011). LPS
inhalation may lead to a small rise in heart rate (HR) but does not alter blood
pressure (BP) or oxygen saturations (SaCh) (Maris, De Vos, Bresser, etal., 2005;
Loh et al., 2006; Shyamsundar et al., 2009).
Chest tightness and cough are less frequently reported and may indicate mild
LPS-induced bronchospasm (Jagielo, 1996). Although inhaled LPS can cause a
significant (if only temporary) fall in the forced expiratory volume in 1 second
(FEVi), there is conflicting evidence as to frequency, with several studies
reporting no significant change in spirometry (Michel et al., 1995; Wesselius et
al., 1997; Nightingale et al., 1998; Wallin et al., 2004; Maris, De Vos, Bresser, et
al., 2005; Michel et al., 2005; Loh et al., 2006; Shyamsundar et al., 2009). The
reason probably partly relates to the difference between statistical significance
and clinical significance (a clinically-significant fall in FEVi is usually defined as
a >10% fall from baseline) (Sundblad etal., 2009; Korsgren etal., 2011).
Secondly, any fall in FEVi probably occurs relatively early, peaking within one
hour (Cavagna et al., 1969; Clapp et al., 1993; Michel et al., 2001), and may
therefore be missed if the subject is asymptomatic.
LPS inhalation consistently leads to a sharp rise in circulating white blood cells
(WBCs) that is dose-related (Clapp et al., 1993; Michel et al., 2003; Loh et al.,
2006). This is due to an increase in the number of blood neutrophils, which
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becomes evident by 4 hours and peaks around 8 hours post-inhalation (Herbert
et al., 1992; Michel et al., 1995; Michel et al., 2007; Korsgren et al., 2011). WBC
and neutrophil counts return to baseline levels between 24 and 48 hours post-
challenge (Thorn and Rylander, 1998). LPS inhalation leads to even earlier
activation of blood neutrophils (detectable by 2 hours); by 24 hours, plasma
MPO is significantly raised (Thorn and Rylander, 1998).
LPS inhalation leads to elevated plasma levels of several pro-inflammatory
cytokines, including TNFa, IL-ip and 1L-6, which return to baseline by 24 hours
(Jagielo, 1996; Wesselius et al., 1997; Fouassier et al., 2009; Korsgren et al.,
2011). Plasma CRP shows a marked rise, peaking between 24 and 48 hours
(Michel et al., 1995; Michel et al., 2001; Michel et al., 2003; Michel et al., 2007;
Korsgren et al., 2011). Plasma LBP and sE-selectin also peak at 24 hours (Michel
et al., 2001; Michel et al., 2003; Michel et al., 2007). Plasma CC-16 levels are
elevated at 6-8 hours, returning to baseline by 24 hours (Michel et al., 2005).
In terms of local (pulmonary) effects, one study reported an early fall in DLCO
between 2-4 hours after LPS inhalation (Herbert etal., 1992). In induced
sputum, LPS inhalation causes a significant rise in total cell numbers and a steep
rise in both neutrophil content and absolute neutrophil numbers (Nightingale et
al., 1998; Loh et al., 2006; Michel et al., 2007; Sundblad et al., 2009). The
number of lymphocytes in induced sputum may also rise to a degree (Thorn and
Rylander, 1998; Michel et al., 2001). Along with sputum neutrophilia, there is a
rise in sputum MPO and HNE concentrations (Thorn and Rylander, 1998; Michel
et al., 2001; Korsgren et al., 2011), together with a rise in sputum TNFa, IL-8
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and MMP-9 levels (Nightingale et al., 1998; Michel et al., 2001; Michel et al.,
2007; Korsgren etal., 2011).
LPS inhalation causes a rise in total cell numbers in BAL fluid, which is apparent
as early as 1.5 hours (Wesselius et al., 1997). There is a steep rise in both
neutrophil content and absolute neutrophil numbers in BAL by 4-6 hours
(Jagielo, 1996; Wesselius etal., 1997; Wallin etal, 2004; Maris, De Vos, Dessing,
et al., 2005; Maris, De Vos, Bresser, et al., 2005). Although the proportion ofAMs
in BAL falls (due to elevated neutrophil content), absolute AM numbers remain
stable and may even rise (Wesselius et al., 1997; Wallin et al., 2004; Maris, De
Vos, Dessing, et al., 2005; Maris, De Vos, Bresser, et al., 2005). Total protein
levels in BAL fluid may show a small rise a few hours after LPS inhalation
(Wesselius et al., 1997). Along with a rise in neutrophil numbers, LPS inhalation
increases BAL levels of MPO, HNE and S100A12 (the latter is released by
activated neutrophils and acts as a ligand for RAGE) (Maris, De Vos, Bresser, et
al., 2005; Wittkowski et al., 2007). There are early rises in the BAL levels of pro¬
inflammatory cytokines including TNFa, IL-ip, IL-6 and IL-8, detectable as early
as 1.5 hours after LPS inhalation (Jagielo, 1996; Wesselius etal., 1997; Maris, De
Vos, Dessing, et al., 2005; Maris, De Vos, Bresser, et al., 2005; Roos-Engstrand et
al., 2005). Conversely, levels of IL-10 and IL-12p70 frequently remain
undetectable (Maris, De Vos, Dessing, etal., 2005; Maris, De Vos, Bresser, etal.,
2005). Levels of chemotactic cytokines, including ENA-78, MlP-la and MIP-ip,
are elevated in BAL after LPS inhalation (Maris, De Vos, Dessing, et al., 2005).
Tissue obtained by endobronchial biopsy demonstrates higher expression of
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phosphorylated p39 MAPK after LPS inhalation, which is thought to lead to up-
regulated inflammatory cytokine expression (Roos-Engstrand et al., 2005). BAL
fluid obtained after LPS inhalation induces much greater nuclear translocation
of NF-kB in stimulated monocyte-derived macrophages (Shyamsundar etal,
2009).
Of particular note, LPS inhalation activates coagulation pathways within the
alveolar space, as demonstrated by a rise in the levels of TAT complexes, soluble
TF and soluble thrombomodulin and a reduction in the levels of protein C and
APC in BAL fluid (Maris, De Vos, Bresser, et al., 2005; Maris et al., 2007).
Alveolar fibrinolysis is inhibited by LPS inhalation, with reduced levels of
plasminogen activator activity (PAA) and increased levels of PAI-1 present in
BAL fluid (Maris, De Vos, Dessing, et al., 2005; Maris et al., 2007). There is,
however, no evidence that inhaled LPS affects systemic coagulation pathways
(Fouassier etal., 2009).
e) Segmental LPS challenge
A few studies have used an alterative approach to LPS inhalation, by directly
instilling LPS into a single lung segment using fibre-optic bronchoscopy (Table
1C). The first study to describe segmental LPS challenge established the safety
and efficacy of a 4ng/kg dose of CCRE and analysed the time-course of the
inflammatory response by performing subsequent BAL at either 2, 6, 24 or 48
hours (O'Grady et al., 2001). Most subsequent studies have also employed a
dose of 4ng/kg and have used saline instillation into a segment of the
50
Chapter 1: Introduction
contralateral lung as a within-subject control. The effects of segmental challenge
have been measured using symptoms, spirometry, blood sampling, BAL and also
by [18F]FDG PET imaging, as an alternative means of assessing the pulmonary
effects of LPS challenge.
As with LPS inhalation, segmental challenge is associated with significant
pyrexia by 8 hours (O'Grady et al., 2001; Chen et al., 2006; Hoogerwerf et al.,
2008; Chen et al., 2009). Otherwise, the most frequently reported symptoms are
headache, myalgia and also cough (particularly at the time of bronchoscopy)
(O'Grady et al., 2001; Chen et al., 2009). With regards to clinical signs, mean
arterial pressure and HR dip to a nadir at about 4 hours (O'Grady et al., 2001;
Chen et al., 2006). There is also some evidence that segmental LPS challenge
causes a small but significant fall in Sa02 or Pa02 (O'Grady et al., 2001; Chen et
al., 2006). FEVi tends to fall to a small degree after LPS challenge; although this
varies between subjects, any decline in FEVi is only temporary and usually
asymptomatic (Chen et al., 2006; Chen et al., 2009).
As with inhaled LPS, segmental LPS challenge causes a rise in peripheral blood
leucocytes, with an approximately two-fold rise in circulating blood neutrophil
counts (O'Grady etal., 2001; Hoogerwerf eta/., 2008). Segmental LPS challenge
also causes a rise in the plasma levels of G-CSF, IL-lra, IL-6 and CRP (O'Grady et
al., 2001; Hoogerwerf etal., 2008).
In BAL fluid, segmental LPS challenge causes a marked rise (at least three-fold)
in absolute cell counts by 6 hours, peaking at 24 hours (O'Grady et al., 2001;
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Chen etal., 2006; Hoogerwerf etal., 2008; Glader etal., 2010). As with LPS
inhalation, there is a dramatic rise in the absolute number of neutrophils
present in BAL between 6 and 24 hours (O'Grady et al., 2001; Coldren et al.,
2006; Hohlfeld etal., 2008; Hoogerwerfetal., 2008; Glader etal., 2010). The
absolute numbers ofAMs/monocytes and lymphocytes also probably rise after
segmental LPS challenge, albeit to a much lesser extent and at a later stage
(peaking at 24-48 hours or later) (O'Grady et al., 2001; Hohlfeld et al., 2008;
Glader etal., 2010).
Levels of MPO and HNE are elevated in BAL fluid after segmental LPS challenge
(O'Grady etal., 2001; Hoogerwerf etal., 2008). Neutrophils retrieved from BAL
fluid demonstrate reduced spontaneous apoptosis as well as greater release of
superoxide anions (Coldren etal., 2006). Furthermore, there is a correlation
between the neutrophil count in BAL fluid and the level of NF-kB activation in
circulating blood neutrophils (Abraham etal., 2006).
There is a clearer rise in total protein content of BAL fluid after segmental LPS
challenge than that described after LPS inhalation (O'Grady et al., 2001; Nick,
2004). TNFa is detectable in BAL fluid between 2 and 16 hours, peaking at
around 6 hours (O'Grady et al., 2001; Nick, 2004; Hohlfeld et al., 2008;
Hoogerwerf etal., 2008). This is accompanied by a more persistent rise in the
BAL concentrations of sTNFRl and sTNFR2 (O'Grady etal., 2001; Hoogerwerf et
al., 2008). Levels of IL-6, IL-8 and MMP-9 are also elevated in BAL fluid after
segmental LPS challenge (O'Grady etal., 2001; Nick, 2004; Abraham etal., 2006;
Hohlfeld et al., 2008; Hoogerwerf et al., 2008). Small rises in the BAL
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concentrations of IL-1(3 and IL-lra can be detected, but [as with LPS inhalation)
levels of IL-10 and IL-12p70 remain undetectable after segmental LPS challenge
(O'Grady etal., 2001; Hoogerwerf etal., 2008).
BAL fluid concentrations of G-CSF, ENA-78, MCP-1, MlP-la and MIP-lp in BAL
fluid are elevated by 6 hours after segmental LPS challenge and normalise by 24
hours [O'Grady etal., 2001; Nick, 2004; Hohlfeld etal., 2008; Hoogerwerf et al,
2008). The level of sL-selectin in BAL fluid rises and remains high even at 48
hours after LPS challenge (O'Grady etal., 2001).
AMs exposed to in vivo LPS challenge demonstrate enhanced mRNA expression
for pro-inflammatory and chemotactic cytokines (including IL-ip, IL-6, IL-8,
MCP-1 and TNFa) and, after culturing in vitro, display increased spontaneous
release of IL-ip, IL-6 and IL-8, but not IL-10, IL-12p70 or TNFa (Hoogerwerf et
al., 2008; Hoogerwerf et al., 2010).
As with inhalation, segmental LPS challenge causes activation of alveolar
coagulation and suppression of fibrinolysis, with raised BAL levels of TAT
complexes, soluble TF and thrombomodulin, D-dimer and PAI-1 and reduced
levels of antithrombin, PAA, protein C and APC (Van Der Poll et al, 2005;
Hoogerwerf et al., 2009).
Studies using PET-derived markers of pulmonary inflammation have
demonstrated a dose-related rise in the rate of [18F]FDG uptake from LPS-
challenged lung segments when compared to control (saline-challenged)
segments (Chen etal., 2006; Chen etal., 2009). Interestingly, the rate of
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[18F]FDG uptake demonstrated only a weak correlation with the neutrophil
content of BAL after segmental LPS challenge (Chen et al., 2006).
f) Advantages and limitations of LPS models
LPS models of lung inflammation clearly offer a controlled, reliable and safe
method of activating the innate immune response in healthy subjects. The
effects of LPS challenge are acceptable, reproducible and reflect many of the
pulmonary and systemic changes seen in ALL Furthermore, they spontaneously
resolve without any known long-term consequences.
LPS challenge does, however, have a number of limitations. It is performed
rapidly and the time-course over which lung inflammation evolves does not
therefore reflect the 'real life' scenario. Patients can develop ALI due to
pulmonary or non-pulmonary causes; in this regard, IV LPS does not model a
pulmonary aetiology and LPS inhalation or segmental challenge do not model
systemic causes ofALL Safety is a key concern: the degree of lung inflammation
induced in human LPS models is by necessity much milder than that induced in
murine models of lung 'injury'. Idiosyncratic reactions, although rare, have been
reported in the literature, for example one subject developed a widespread rash
after LPS inhalation and another reported mouth ulcers as a side effect (Pernis
et al, 1961; Loh et al., 2006).
Subject variability represents another limitation. The LPS challenge studies
described above have used healthy subjects between the ages of 18-50, whereas
patients are often older, with other health problems. Gender may also influence
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results; one study described a greater systemic response to IV LPS in female
compared to male subjects (Van Eijk etal., 2007), although other studies have
demonstrated little or no difference (Kuhns etal., 1995; Coyle etal., 2006). In
vitro studies using peripheral blood have documented wide inter-subject
variability in the production of inflammatory cytokines (Park, 2002). Some
variability may be due to genetic differences; for example, single nucleotide
polymorphisms of the CD14 and TLR genes have been shown to influence the
inflammatory response to inhaled LPS (Michel et al, 2003; LeVan et al., 2008).
There have been substantial variations in the methodology of LPS inhalation
studies in the past; factors that may alter the effective delivered dose and
subject response to it include the type of LPS, its solvent, the type of nebuliser
and the inhalation technique itself. Most LPS inhalation studies have used LPS
from E.coli (Table ID). Animal studies indicate that LPS from different Gram-
negative bacteria have similar biological activity (Luchi and D C Morrison,
2000); using LPS from a single batch minimises any differences that might occur
in biological activity. LPS is more soluble in water than in saline; however, most
studies have used the latter, as inhalation of distilled water has been reported to
cause both bronchospasm (thus potentially altering inhaled distribution) and a
peripheral blood neutrophilia (Herbertetal., 1992).
The type of nebuliser and the technique of inhalation probably have the greatest
influence upon the dose of LPS actually delivered to the lower airways and, in
particular, to the alveoli. Continuous nebulisation over 15 to 20 minutes (for
example, by large volume reservoir delivery systems) has now largely been
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replaced by the use of inhalation-triggered dosimeter-nebulisers and a
standardised 5-breath technique similar to that used in methacholine challenge
(Popa, 2001). Important considerations when using dosimeter-nebulisers
include driving pressures, nebulisation onset and duration, using nose-clips and
closing additional flow valves/vents to prevent variable air in-flow (Ryan et al.,
1981; Hakkinen et al., 1999; Jogi et al, 1999; Popa, 2001).
Different dosimeter models produce different particles sizes, for example, the
particle mass median aerodynamic diameter (MMAD) is estimated at 3.4-4pm
for the Mefar MB3, compared to 3.5pm for the DeVilbiss 646 and 1.6pm for the
Spira Elektro dosimeter-nebuliser (J5gi etal., 1999; Nieminen etal., 1987).
Alveolar deposition of inhaled particles is increased when particle MMAD is
<5pm, and smaller MMADs (albeit >lpm) may potentiate this further (Hakkinen
etal., 1999; Brand etal., 2000; Heyder, 2004).
There is evidence that moderate, controlled inspiratory flow rates (for example,
up to 0.5 L/second) reduce extra-thoracic (upper airway) particle deposition
and reduce overall deposition variability, possibly by reducing turbulence
(Hakkinen etal., 1999; Brand etal., 2000; Heyder, 2004). Conversely, more
rapid inhalation has been demonstrated to reduce distal particle deposition in
the lung (Ryan et al., 1981). Depth of inspiration is also a factor; breathing to full
inspiratory capacity (as opposed to tidal breathing) is thought to minimise
inhalation-induced bronchospasm (Jogi etal., 1999; Kapsali etal., 2000;
Cockcroft, 2005). This may to some extent explain why inhalation to maximal
inspiratory capacity improves alveolar particle deposition (Ryan etal., 1981;
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Brand etal., 2000; Heyder, 2004; Moller etal, 2008). Furthermore, breath-
holding for 5 seconds at full inspiration is thought to improve gravitational
deposition of particles within the alveoli (Heyder, 2004).
It has been recommended that dosimeter-nebulisers should be calibrated every
20 uses, using the desired amount of sterile saline and weighing scales accurate
to 0.5mg (Popa, 2001). Estimations of dosing should be performed in triplicate,
using 10 slow inhalations, from functional residual capacity to maximal
inspiratory capacity, with a 5-second breath-hold each time (Popa, 2001). It has
been noted that both exhalation to the room (rather than re-breathing into the
nebuliser mouthpiece) and using triggered inspiration (rather than manual
activation) are important to avoid underestimation of dose during calibration
(Cockcroft, 2005; Davis etal., 2004; Todd etal., 2005).
LPS models also have limitations in terms of design and also in the
measurement of effects. Bronchoscopy to obtain BAL samples is clearly a more
invasive procedure than obtaining induced sputum, but offers distinct
advantages when modelling ALL BAL samples are more likely to reflect the
alveolar compartment, whereas induced sputum samples are more
representative of the proximal bronchial tree (Lensmar etal., 1998; Alexis etal.,
2001). As such, induced sputum samples tend to have lower numbers of total
cells and macrophages and greater numbers of neutrophils, when compared to
BAL samples (Lensmar etal., 1998; Antoniou etal., 2005). Furthermore,
macrophages from induced sputum samples display greater activation,
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oxidative burst and phagocytic activity than alveolar macrophages from BAL
samples (Lensmar et al., 1998; Alexis et al., 2000).
As well as being invasive, bronchoscopy and BAL techniques often vary between
studies and sample dilution can vary even when a standardised technique is
used (Haslam and Baughman, 1999). Methods of adjusting for sample dilution
also sometimes lack accuracy (Baughman, 1997; Walters and Gardiner, 1991).
Furthermore, BAL fluid is not representative of pulmonary inflammation in its
entirety, as BAL is only performed in one segment of one lobe; it also does not
sample cells attached to the alveolar epithelium or those within the interstitium.
Compared to BAL, [18F]FDG PET scanning provides a better measure of'whole'
lung inflammation, in that it can record data from all lobes of both lungs (Harris
and Schuster, 2007). [18F]FDG activity is also reflective of both alveolar and
interstitial neutrophils. It has its own limitations, however, in that it is not
specific to neutrophils and does not enable characterisation of cellular
phenotype or detailed function.
Provision of a control in LPS inhalation studies involves either a separate
placebo challenge (in the same subject) with an appropriate washout period, or
a separate control group where different subjects inhale placebo. Segmental LPS
challenge has the advantage that a simultaneous within-subject control (saline
challenge) can be performed using a segment within a contralateral lobe. It
does, however, necessitate two bronchoscopy procedures (if later BAL is
performed). It is also unclear whether saline or LPS instillation at baseline
bronchoscopy can have subtle, indirect effects on subsequent BAL samples.
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g) Interventional studies employing LPS challenge
Table IE summarises the studies that have been performed using LPS challenge
in healthy human subjects to test potential interventions in ALI, many of which
have then been followed by phase III RCTs in patients with ALI (as discussed
under 'Treatment ofALI', Page 26).
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TableIE:nterventionstudiesmployingLPSinh lati nors gmentalchall g TREATMENTSTUDYDETAILS
RESULTS
p-agonists
(Wallinetal.,2004)n=15double-b indesig 3weeksofsalmeterolvsplac b LPSinhalation;BAL3h
NosignificantreductioiLPS-indu edr sBALleucocyt s, neutrophilsort taprotein
(Maris,DeVosessingtal.,2005;ar 2007),n=32single-blindde ig Singlesalmeterolvsplac binha ation LPS/placeboinhalationt30minu es;BAL6h
Significantredu tioiLPS-inducedsBALneutrophillev ls andinBALMPOTNFalevels;non-significantreductioniLPS- inducedrisBALIL-8levels NoreductioninLPS-inducedactivationofcoagulation;significant enhancementofpulmonaryfibrino ysis
Corticosteroids
(Micheletal.,2005),n=15double-blindesig 6-daysofmethylprednisolonevsplac b LPS/placeboinhal tion;serialplasmasampl s
Significantredu tioiLPS-inducedr splasmaCC-16lev ls
(Micheletal.,2007),n=16double-blindesig 6daysprednisoloneorplacebo LPSinhalation;ducedsputum6h
NoreductioninLPS-inducedr ssput mleucocytesr neutrophilcontent;red c ioiLPS-induc dsblo d neutrophilcounts;red ctioniLPS-ind cedspla masE- selectinorLBP;signifi antreductioiLPS-indu edr spla m CRP
Phosphodiesterase-4 inhibitors
(Micheletal.,2007)n=16double-blindesig 6dayscilomilastvplacebo LPSinhalation,ducedsputum6h
NoreductioninLPS-inducedr ssputumleucocytesr neutrophilcontent;red c ioiLPS-induc dsblo d neutrophilcounts;red ctioniLPS-ind cedr splasmasE- selectinorLBP;trendtowardsreductioninLPS-inducedis plasmaCRPlevels
(Hohlfeldetal.,2008)n=37double-blinesig 28daysroflumilastrplacebo SegmentalLPS&sali econtrolha lenge;BALa 24h







(Nick,2004;VanDerPolletl.5)n=16, double-blindesig 16-hourrhAPCorplaceboinfusion SegmentalLPS&sali econtrolha lenge2 hours;BALat18h
SignificantreductioniBALleuco yteandeutrophilumb rs; changeinbloodeutrophilounts Nochangeintotalprotein,IL-68rMCP-1levelsBAL; Nosignificantchangeikinasephosphorylationneutrophile l death;significantreduc ioniIL-8-i ducedneutrophilchem t x s SignificantattenuationofLPS-inducedprocoagulante fect;o overalleffectnLPS-indu edinhibitionffibrinolysis
(Chenetal.,2009),n=12double-blindesig 29hoursrhAPCplacebo SegmentalLPSchallengea2hours;PET4h, BALat29h
TrendtowardseductioninLPS-induceds[18F]FDGuptake andreductionileucocyteneutrophilntsBAL
Recombinanthu a KGF
(Shyamsundaretl.,2010),n=36double-blind design 3dayspaliferminolacebo LPSinhalation;BAL6h
NoreductioninLPS-inducedsBALleucocytes,eutrophils, totalprotein,TNFa,IL-8rMCP-1
Statins
(Shyamsundaretl.,2009),n=30double-blind design 4dayssimvastatinorplacebo LPSinhalation;BAL6h
Significantredu tioniLPS-inducedBALeutrophilia,MPO,TNFa MMP-7and9tretowar sr ductioniIL-1(3 MMP-2levels;significantreductioiLPS-i ducedsplasma CRP;noreductioniBALtotalproteilevels
(Chenetal.,2009),n=12double-blindsig 2dayslov statin SegmentalLPSchallenge;PETa24h,BAL9
Significantredu tioniLPS- nduceds[1SF]FDGupt ke;t nd towardsreducedleucocyteann utrophilntiBAL
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1.5 THE ROLE OF MONOCYTES IN ACUTE LUNG INJURY
The previous section described the background and rationale for using LPS
challenge to model early ALI in healthy subjects and thus provide the
opportunity to test potential interventions. This section will present evidence
for the role ofmonocytes in ALI, describe work performed in animal models to
test the effects ofmonocyte depletion and will then go on to discuss monocyte
depletion in the human setting.
a) Circulating and marginating monocytes
Monocytes are involved in both the innate and adaptive immune response, with
multiple functions including release of cytokines and inflammatory mediators,
phagocytosis and antigen presentation (Auffray et al., 2009). Monocytes are
derived from macrophage and dendritic cell progenitors within the bone
marrow; these can also develop into classical and plasmacytoid dendritic cells
(DCs) (Auffray et al., 2009; Geissmann etal, 2010; Robbins and Swirski, 2010).
Upon maturation, monocytes are released from the bone marrow to circulate in
peripheral blood for up to 3 days (Gordon and Taylor, 2005; Whitelaw, 1972). In
mice, the release ofmonocytes from bone marrow appears to be CCR2-
dependent (Serbina and Pamer, 2006; Tsou et al., 2007). Circulating monocytes
do not appear to be capable of proliferation; for example, they do not express a
key protein called Ki-67 (Geissmann etal., 2003; Van Furth etal., 1979;
Whitelaw, 1972). Monocytes are believed to migrate into the tissues where they
evolve to become macrophages or 'inflammatory' DCs, a process that can be
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demonstrated in vitro by culture with IL-4 and GM-CSF (Gordon and Taylor,
2005; Geissmann etal., 2008).
Migration into tissues involves an intermediate step whereby monocytes
become attached to vascular endothelium (a process known as 'margination').
In animals, the marginating pool ofmonocytes is actually larger than the
circulating pool (Van Furth and Sluiter, 1986; Ohgami etal., 1991).
Furthermore, using fluorescent staining and intravital microscopy, one group
has demonstrated the presence of a large population of splenic monocytes in
mice (Swirski etal., 2009). These monocytes reside in the subcapsular red pulp
(rather than the splenic vasculature) and are more numerous than their
counterparts circulating in blood. It has not yet been confirmed whether a
similar splenic monocyte population exists in humans.
b) Murine monocyte subsets
The study ofmurine monocytes was accelerated by the use ofmice with green
fluorescent protein (GFP) 'knocked-in' to one of the fractalkine receptor alleles
(CX3C chemokine receptor 1, or CX3CR1) (Geissmann et ah, 2003; Gordon and
Taylor, 2005; Robbins and Swirski, 2010). Cells of the monocyte lineage in these
Cx3crl§fp/+ mice demonstrate green fluorescence when examined by microscopy
(Geissmann et ai, 2010). The intensity of GFP expression by murine monocytes
was noted to be either high or intermediate, indicating the existence of two
separate monocyte subsets that are present in equal proportions (Geissmann et
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al., 2003; Sunderkotter etal., 2004). Table IF lists the main phenotypic
differences in cell surface marker expression between the two subsets.













LFA-1 integrin Low High
CD43 Low High
Abbreviations: Ly6C, lymphocyte antigen 6C; Gr-1, granulocyte differentiation antigen 1 (also
known as Ly6G); LFA-1 integrin, lymphocyte function-associated antigen-1.
Data derived from (Auffray et al., 2009; Geissmann et al., 2003; Geissmann et al., 2008; Gordon
and Taylor, 2005; Grage-Griebenow etal., 2001; Ziegler-Heitbrock etal., 2010; Robbins and
Swirski, 2010; Tacke and Randolph, 2006; Sunderkotter et al., 2004; Weber et al., 2000; Wong et
al., 2011).
The 'inflammatory' subset is Ly6Ch'gh and consists of larger monocytes (average
diameter of 10-14pm), with a shorter half-life, that migrate to sites of
inflammation (Geissmann etal., 2010).
The second 'resident' subtype is Ly6Clow and consists of smaller monocytes
(average diameter 8-12pm) thatwere initially described as present in 'resting'
(non-inflamed) tissues (Geissmann etal., 2010). This subtype does, however,
demonstrate rapid recruitment to inflamed tissues, with marked but transient
release of TNFa (Auffray etal., 2009). One of the main functions of resident
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murine monocytes is thought to be in tissue repair and angiogenesis
(Geissmann etal., 2010).
There is conflicting evidence over whether these two murine monocyte subsets
represent a spectrum ofmaturation. Bone marrow monocytes appear to express
high levels of Ly6C, which fall over time [at least in ex vivo culture)
(Sunderkotter et al, 2004). Although in vivo monocyte depletion is followed by
sequential repopulation (first by Ly6Chi8h, followed by Ly6Clow monocytes)
(Sunderkotter et al., 2004), other research has shown that selective Ly6Chish
monocyte depletion does not affect the numbers of Ly6Clow monocytes
(Geissmann etal., 2010).
A similar division into two monocyte subsets has also been described in rats
and pigs (Auffray etal., 2009). The existence of a third murine monocyte subset
has recently been proposed, which is Ly6Cintermediate but which (unlike most
Ly6Chi§h monocytes) is also CD43h'gh (Sunderkotter et al., 2004; Ziegler-
Heitbrock et al., 2010).
c) Human monocyte subsets
Monocytes make up about 10% of circulating leucocytes in humans, compared
to only 2-4% in mice (Geissmann et al., 2008; Auffray et al., 2009). Human
monocytes were initially divided into two subsets, according to whether or not
they expressed CD16. More recently, three separate subsets have been
described, which can be clearly delineated by their relative intensity of CD14
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and CD16 expression, in addition to other cell surface markers (Table 1G)
(Ziegler-Heitbrock etal., 2010).
There has been some disagreement in the literature regarding homology
between human and murine subsets (Geissmann etal., 2003; Ingersoll etal,
2010). CD16+ monocytes were initially labelled as 'pro-inflammatory and
functionally akin to murine 'inflammatory' (Ly6Ch'gh) monocytes; they
demonstrated rapid migration to inflamed tissues and greater release of TNFa
and IL-ip (but less IL-10) in response to LPS (Ziegler-Heitbrock, 2007).
Table 1G: Key differences in cell surface marker expression between the three








CD14 ++ ++ +
CD16 - + ++
HLA-DR Low Very high High
CCR2 + Intermediate -
L-selectin + - -
CX3CR1 Low Intermediate High
LFA-1 integrin Low High High
CD64 High Intermediate Low
Abbreviation: HLA-DR, human leucocyte antigen-DR.
Data derived from (Auffray etal., 2009; Geissmann etal., 2008; Gordon and Taylor, 2005; Grage-
Griebenow etal., 2001; Robbins and Swirski, 2010; Tacke and Randolph, 2006; Weber etal.,
2000; Wong etal., 2011; Ziegler-Heitbrock etal., 2010).
CD14++CD16" 'classical' monocytes compose the predominant human subset
(Soehnlein et al, 2009). They are larger and denser than CD16+ monocytes and
more closely resemble Ly6Ch'gh (and CD43'°W) murine monocytes in phenotype
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(Table 1G) (Gordon and Taylor, 2005; Ziegler-Heitbrock etal, 2010). Classical
monocytes demonstrate marked chemotaxis in response to MCP-1, with release
ofIL-10 and IL-6 (Wonget al., 2011).
CD16+ monocytes are smaller than classical monocytes and are now defined as
two separate subsets. CD14+CD16++ 'non-classical' monocytes, as already
mentioned, demonstrate strong pro-inflammatory mediator release, but less
marked chemotaxis to MCP-1 (they do not express CCR2) (Ziegler-Heitbrock et
al., 2010; Wong et al., 2011). They are thought to play a key role in the
resolution of inflammation and correlate in phenotype to murine
Ly6ClowCD43hish monocytes (Ziegler-Heitbrocketal., 2010).
The third, CD14++CD16+, 'intermediate' monocyte subset is thought to represent
an intermediate step in monocyte maturation, between a less mature classical
phenotype and the more mature, macrophage-like (CD16++) non-classical
phenotype (Gordon and Taylor, 2005; Robbins and Swirski, 2010; Wong etal.,
2011). Intermediate monocytes demonstrate stronger expression of CD64 and
CCR5 and marked release of IL-10, compared to non-classical monocytes
(Grage-Griebenow et al., 2001; Tacke and Randolph, 2006; Weber et al., 2000).
Intermediate monocytes probably correlate with Ly6ChishCD43hi8h murine
monocytes (Ziegler-Heitbrock etal., 2010).
d) Pulmonary monocyte influx in animal studies
There is considerable evidence that AMs are indirectly derived from circulating
blood monocytes. Studies examining the AMs ofmice transplanted with GFP-
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labelled bone marrow following whole-body irradiation have demonstrated
slow replacement by cells of donor origin (at around one year) (Gordon and
Taylor, 2005; Maus etal., 2006). Landsman etal carried out a series of adoptive
transfer experiments using CDllc/diphtheria receptor toxin (CDllc.DTR)
transgenic mice given intra-tracheal diphtheria toxin (DT) to deplete lung
macrophages and DCs. They demonstrated that lung (interstitial) macrophages
are derived from circulating Ly6Clow monocytes (akin to non-classical human
monocytes) and that these then evolve to become alveolar macrophages
(Landsman etal., 2007; Landsman and Jung, 2007). Furthermore, they
presented evidence that Ly6Chi§h monocytes can transform into the Ly6Clow
subtype and then evolve into macrophages (Landsman etal., 2007).
It has been known for many years that monocyte influx accompanies pulmonary
neutrophil accumulation in animal models of lung inflammation, for example,
after intra-tracheal LPS administration (Doherty et ah, 1994; Henderson, 2003;
Maus et al., 2001). AM turnover is higher in the context of inflammation, due to
the increased recruitment and apoptosis ofmonocytes (Janssen etal., 2011;
Maus etal., 2006).
Monocytes entering the alveolar space are distinct from AMs and also
demonstrate greater CD14 expression and more TNFa release than circulating
blood monocytes (Maus etal., 2001; Srivastava etal., 2005). Experiments using
labelled neutrophils and monocytes in rats have demonstrated a significant
increase in neutrophil and monocyte numbers in both the pulmonary
interstitium and, to a greater extent, in BAL (Li et al., 1998). Another group
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utilised IV perfluorocarbon nanoemulsions in mice given intra-tracheal LPS to
detect both monocyte (and neutrophil) pulmonary influx at 24 hours using 19F
magnetic resonance imaging (MRI) (Ebner etal., 2010). Perfluorocarbons are
biochemically inert and phagocytosed by monocytes and, to a lesser extent, by
neutrophils.
Monocyte and neutrophil influx occur by different mechanisms; whereas
monocyte migration is dependent upon E-selectin, pi-integrins (including CD18
and Very Late Antigen-4), VCAM-1 and MCP-1, neutrophil migration occurs via
L- and P-selectin, [32-integrins, ICAMs and IL-8 (Henderson, 2003; Li etal., 1998;
Maus etal., 2003; Soehnlein etal., 2009).
Neutrophil transmigration across the pulmonary endothelium occurs rapidly
(within two hours) and was initially thought to precede later pulmonary
monocyte influx (Doherty etal., 1994; Kaplanski etal., 2003; Reutershan, 2005;
Soehnlein et al., 2009). In addition, neutropenia was observed to reduce
monocyte migration (Doherty et al., 1994; Janardhan et al., 2006). It is now
accepted that there is a more complex and interdependent relationship between
the transmigration of neutrophils and monocytes. Early monocyte influx,
independent of neutrophil migration, was first noted in an experimental model
of peritonitis (Henderson, 2003). A later study, using histological analysis of the
pulmonary interstitium in rats after intra-tracheal LPS, showed early monocyte
influx between 1 and 12 hours and a later, second wave ofmonocyte influx that
peaked after 24 hours (Janardhan etal., 2006).
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A key study using in vivo confocal imaging of dermis and mesenteric blood
vessels demonstrated that, in normal conditions, GFPh'gh (i.e. Ly6Clow)
monocytes 'crawl' along the vascular endothelium with extravasation occurring
only rarely (Auffray et al, 2007). This 'patrolling' behaviour is dependent upon
the interaction between LFA-1 and CX3CR1, enabling endothelial adherence. An
inflammatory stimulus (experimental peritonitis) rapidly causes Ly6Clow
monocytes to roll rather than crawl, followed rapidly by their extravasation,
which is the trigger for subsequent neutrophil chemotaxis and transmigration
(Auffray et al., 2007). Studies of lung injury using bone marrow transplantation
followed by adoptive transfer have demonstrated that neutrophil influx is
potentiated by later CCR2-mediated transmigration of Ly6Chi§h monocytes,
which peaks between 24 and 48 hours (Maus etal, 2002; Maus etal, 2003). A
second, much later peak (around 7 days) in Ly6Clow monocytes is thought to
demonstrate their role in the resolution of lung injury, at least in a mouse model
ofmyocardial ischaemia (Nahrendorf et al., 2007).
e) Pulmonary monocyte influx in human studies
Studies in patients who have previously undergone allogeneic bone marrow
transplantation have demonstrated gradual replacement ofAMs by cells derived
from circulating monocytes (Gordon and Taylor, 2005; Nakata etal., 1999;
Thomas etal., 1976). Small numbers of alveolar monocyte-like cells have been




During inflammation much larger numbers ofmonocytes transmigrate into the
alveoli, with a later peak in the number ofAMs (Steinberg et al., 1994]. Marked
monocyte transmigration has been reported in patients with chronic
obstructive pulmonary disease (COPD) (Frankenberger et al., 2004), interstitial
lung disease (ILD) (Hance et al., 1985; Hoogsteden et al., 1989; Kiemle-Kallee et
al., 1991; Krombach etal., 1996), HIV-related lung disease (Wasserman etal.,
1994), cystic fibrosis (CF) (Wright etal., 2009) and ALI (Rosseau etal., 2000).
Little is known about the phenotype of monocyte-like cells once they cross the
blood-air barrier and before they evolve into AMs; the exact nomenclature used
has therefore varied widely. Monocyte-like cells in sputum or BAL are
consistently smaller, less granular and less auto-fluorescent compared to
mature AMs (Frankenberger et al., 2004; Hance et al., 1985; Hoogsteden et al.,
1989; Rosseau et al., 2000; Wasserman et al., 1994; Wright et al., 2009).
Compared to mature AMs, monocyte-like cells in the alveolar space demonstrate
greater expression of CD14 and CDllb and lower expression of HLA-DR,
macrophage markers including CD71 (transferrin receptor), 25F9 and CD206
and the macrophage scavenger receptor MARCO; they also release higher
concentrations of pro-inflammatory mediators but have less marked phagocytic
activity (Frankenberger etal., 2004; Krombach etal., 1996; Rosseau etal., 2000;
Wasserman etal., 1994; Wright etal., 2009).
Similarly, after LPS challenge in healthy subjects, one study reported greater
numbers of 'monocytes' in BAL fluid, which were smaller than macrophages and
with stronger CD14 expression (O'Grady et al., 2001). Another study reported
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greater numbers of'small macrophages' in sputum (differentiated from AMs
simply by size and granularity) (Frankenberger et al, 2011).
Like the equivalent murine subset, human non-classical monocytes also appear
to exhibit LFA-l-mediated 'patrolling' of vascular endothelium (Cros etal.,
2010; Steppich etal., 2000).
1.6 EXPERIMENTAL MONOCYTE DEPLETION
a) Monocyte depletion in mice
Various means ofmonocyte depletion are available in mice, for example, using
CCR2 knockout mice, giving DT to CDllb-DTR transgenic mice, or using anti-
CCR2 monoclonal antibody or intra-peritoneal liposomal clodronate.
Firstly, a group testing CCR2+-dependent monocyte depletion reported an
unexpected reduction in alveolar neutrophil as well as monocyte accumulation
after giving intra-tracheal MCP-1 and LPS to induce experimental lung injury
(Maus etal., 2002). Intravital two-photon imaging was used by another group to
demonstrate that circulating monocyte depletion by liposomal clodronate
reduced transendothelial neutrophil transmigration after intra-tracheal
bacterial challenge (Kreisel etal., 2010).
Another study demonstrated significant pulmonary margination of Ly6Chi§h
monocytes (by histological analysis) after intra-peritoneal LPS plus high-stretch
ventilation (Wilson etal., 2009). Monocyte depletion by liposomal clodronate
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significantly reduced both the number of lung-marginated monocytes and the
severity of lung injury.
Dhaliwal etal (2012) used three methods ofmonocyte depletion to
demonstrate that the beneficial effect on pulmonary neutrophil accumulation
persisted at 48 hours and involved reduced neutrophil transendothelial
migration into the pulmonary interstitium. Intra-peritoneal liposomal
clodronate reduced monocyte and neutrophil influx to the lungs, with reduced
lung injury scores, reduced BAL total protein, lung oedema and vascular leak.
DT administration in CDllb-DTR mice dramatically reduced pulmonary
monocyte and neutrophil migration, the levels of total protein and SDF-1 in BAL
fluid and pulmonary leak. Interestingly, the rise in circulating blood neutrophils
that also occurred after intra-tracheal LPS administration was also significantly
reduced by monocyte depletion. An anti-CCR2 monoclonal antibody also
significantly reduced BAL neutrophilia and pulmonary vascular permeability.
Furthermore, adoptive transfer ofmonocytes derived from bone marrow
partially rescued LPS-induced pulmonary neutrophil influx (Dhaliwal etal.,
2012).
Several studies testing monocyte depletion in mice have therefore shown a
significant reduction in experimental lung inflammation, indicating that
monocyte depletion may represent a therapeutic option in patients with ALL
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b) Human monocyte depletion by leukapheresis
The term 'apheresis' means collecting a particular constituent of circulating
blood. 'Leukapheresis' provides a safe and readily available means of depleting
circulating blood leucocytes (including monocytes) in humans. Leukapheresis
can be performed using filtration columns, for example granulocyte and
monocyte adsorptive apheresis or, more commonly, by centrifugation (Freireich
etal, 1965; Linenberger, 2005a). Centrifugation leukapheresis uses a
continuous-flow system where blood is diverted from the patient, mixed with
citrate anticoagulant and pumped into a spinning centrifuge.Within the
centrifuge, cells sediment out according to their density and the speed of the
centrifuge, with red blood cells (RBCs) towards the bottom, neutrophils above
them, then mononuclear cells (MNCs) and platelets (together making up the
'buffy coat'), while plasma lies at the top (Feige and Sorg, 1984). The MNC
component can be collected into a bag and the remainder of the blood is
returned to the patient. The system is closed ('vein to vein') and uses disposable
tubing to avoid air embolus or infection (Buckner et al., 1969; Linenberger,
2005a).
In current clinical practice, centrifugation leukapheresis is used for reducing
leucocytosis in patients with leukaemia, or for collection of peripheral blood
stem cells (PBSCs) for autologous transplantation or collection of MNCs for ex-
vivo processing (e.g. photopheresis for cutaneous T-cell lymphoma), or immune
modulation (e.g. DC therapy), before later re-infusion (Linenberger, 2005b;
Nguyen et al., 2002; Okafor et al., 2010; Perseghin and Incontri, 2010). PBSC
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collection requires prior treatment with G-CSF (with/without chemotherapy) to
mobilise sufficient CD34+ cells into the circulation (Arslan and Moog, 2007).
Other types of therapeutic apheresis include red cell exchange in patients with
sickle cell anaemia, thrombocytapheresis in patients with thrombocytosis, or in
healthy donors to obtain platelet donations, and plasmapheresis to remove
circulating immunoglobulin in antibody-mediated diseases (for example,
thrombotic thrombocytopaenic purpura, antiphospholipid syndrome and
inflammatory polyneuropathies) (Linenberger, 2005b).
There is some evidence that MNC leukapheresis has a beneficial effect in other
inflammatory conditions, including inflammatory bowel disease and
rheumatoid arthritis (RA) (Cuadrado, 2009; Hidaka etal., 1999; Kohgo etal,
2002; National Institute for Clinical Excellence, 2005). Repeated leukapheresis
in patients with RA leads to repopulation of the blood by less activated
monocytes and reduced release of pro-inflammatory cytokines (TNFa and IL-
1P) (Hahn etal., 1993; Kashiwagi etal., 1998).
Large numbers of MNCs can be collected by large-volume leukapheresis, where
at least 3 total blood volumes (TBVs) or >15 litres of blood are processed
(Humpe et al, 2001; Reik et al, 1997). Large-volume leukapheresis does tend to
require higher flow rates and thus increase the risk of citrate-related side
effects (Arslan and Moog, 2007). Different cell separator machines vary to some
extent with regards to MNC yield; choice of programme also affects the degree
of contamination of the MNC product by other cells such as platelets and RBCs
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(A E Morrison et al., 2000; Strasser et al., 2003; Wolf et al., 2005). Of crucial
importance, the side effects of leukapheresis are usually mild and the risk of
serious side effects in healthy subjects is minimal (McLeod etal., 1999; Reik et
al., 1997; Strauss, 1996).
1.7 HYPOTHESES AND THESIS OVERVIEW
The aim of this work was to therefore build upon the evidence that monocyte
depletion in mice ameliorates experimental lung inflammation and, for the first
time, translate this into the human setting. As such, my hypotheses were:
A) That inhaled LPS in healthy subjects would consistently and safely produce
mild pulmonary and systemic inflammation when compared to saline placebo.
B) That MNC leukapheresis in healthy subjects would consistently and safely
remove large numbers ofmonocytes from circulating blood, with minimal
depletion of circulating neutrophils and without itself causing significant
inflammatory effects detectable in blood or BAL fluid.
C) That depletion of circulating monocytes by MNC leukapheresis in healthy
subjects would ameliorate experimental, LPS-induced systemic and pulmonary
inflammation when compared, in a randomised double blind study, to a sham
procedure.
My first additional aim was to closely scrutinise monocyte transmigration into
the alveolar space after inhaled LPS and to examine the phenotype and function
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ofmonocyte-like cells in BAL fluid. Secondly, I planned to analyse the effects of
both inhaled LPS and of MNC leukapheresis on circulating monocyte subsets.
I carried out two preliminary studies (A and B) to address the first two
hypotheses respectively. 1 then performed an RCT in 30 healthy subjects to
determine whether monocyte depletion could attenuate experimental lung
inflammation in the human setting. The exact aims of each study, as they relate
to my hypotheses, are outlined at the beginning of each of the relevant chapters.
Chapter 2 consists of the Methods and Materials used for all three studies.
Chapter 3 contains the results of Study A (the first preliminary study). Chapter 4
describes the results of Study B (the second preliminary study). Chapter 5
discusses the results of Study C (the RCT). The final chapter (6) summarises
how this work adds to our understanding of the role ofmonocytes in ALI and
discusses the priorities for further research in this area.
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CHAPTER 2: MATERIALS AND METHODS
2.1 OVERVIEW
I undertook three consecutive studies, consisting of two preliminary studies
followed by an RCT, with the aim of systematically addressing the hypotheses
outlined in Chapter 1.
This chapter begins by outlining the overall design of each of the three studies.
It goes on to describe the process of subject recruitment, screening and
enrolment, followed by details of the procedures performed during each of the
three studies. All of the clinical data and biological samples obtained from each
subject are specified, with details of the materials used to process the samples
and the scientific and laboratory techniques used to generate data. The methods
used for statistical analysis are described in detail at the end of the chapter.
2.2 STUDY DESIGN
a) Ethical approval, safety and clinical trial registration
Before commencing, the studies received approval from the Lothian Research
Ethics Committees (reference number 09/S1101/27) and the NHS
Lothian/University of Edinburgh Research and Development Office. The studies
were also registered under an International Standard Randomised Controlled
Trial Number (ISRCTN 42695423) before recruitment began. The studies were
conducted in accordance with Good Clinical Practice and relevant written
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informed consent was obtained before conducting screening visits or study
days. Subjects were informed that they could withdraw from the study at any
stage and for any reason. Subjects who took part in study days were
compensated financially for their time.
A Data Monitoring and Safety Committee (DMSC) was established and consisted
of three members [including one statistician) who were otherwise independent
from the trial. The DMSC met before any of the studies commenced. They then
received regular reports at pre-specified points during and after completion of
each study, detailing subject recruitment and enrolment, full blood count [FBC)
data for each subject and any expected symptoms or adverse events reported.
At each stage, the DMSC members were asked to approve the report before the
relevant study could continue with further subject recruitment.
An adverse event (AE) was defined as 'any untoward medical occurrence in a
clinical trial subject'. A serious adverse event [SAE) was defined as 'any
untoward medical occurrence or effect that results in death, is life-threatening,
requires prolongation of hospitalisation or results in permanent/significant
disability or incapacity'.
b) Design of Study A
Study A was a single-blinded study of 12 healthy subjects, comparing inhalation
of LPS (n=6) with inhalation of saline placebo (n=6) (Figure 2a). An initial
screening visit was used to identify potential exclusion criteria and confirm
eligibility (details are on Page 83). Six study days were held, with the 12
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enrolled subjects randomly allocated to these in pairs, in order of recruitment.
On each study day, one subject was allocated to inhalation of 0.9% normotonic
saline (placebo) and the second subject to inhalation of LPS.
























Figure 2a: Design of Study A
Subjects were randomly allocated in a single-blind fashion (according to date of recruitment) to
inhalation of either saline placebo or LPS. Leukapheresis was not performed and there was no
overnight stay or PET-CT (computerised tomography) scan on the second day.
* One volunteer from the LPS group was unable to tolerate bronchoscopy and therefore BAL
was only performed in n=5 subjects from that group.
Routine clinical observations (temperature, HR, BP, SaC>2 and RR) were
recorded at baseline and hourly thereafter. Each subject had a blood sample
taken at baseline (0 hours) and then inhaled LPS or saline as allocated. Further
blood samples were taken at 2, 4, 6 and 8 hours from baseline. Bronchoscopy
and BAL were performed between 8 and 9 hours from baseline. Each subject
was allowed home later the same evening, returning briefly the following
morning (24 hours from baseline) for a final blood sample and medical review.
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c) Design of Study B
Study B was an analysis of MNC leukapheresis in a further 6 healthy subjects
(Figure 2b).
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Figure 2b: Design of Study B
The 6 subjects all underwent active MNC leukapheresis. There was no preceding inhalation
challenge and there was no overnight stay or PET-CT scan on the second day.
As with Study A, each volunteer had passed an initial screening visit to
determine eligibility. Six study days were held, with a single subject attending
on each occasion. Routine clinical observations were taken as for Study A, with
the exception of BP during leukapheresis (to avoid interrupting blood flow)
unless the subject reported feeling light-headed or unwell. Blood samples were
taken as for Study A. After the baseline blood sample, subjects were simply
observed until the 2-hour time-pointwhen MNC leukapheresis of four total
blood volumes (TBVs) commenced. As in Study A, bronchoscopy and BAL were
performed between 8 and 9 hours. After a period of observation, the subjects
were again allowed home overnight, returning at the 24-hour time-point for a
medical review and the final blood sample.
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d) Design of Study C
Study C was a randomised double-blinded, placebo-controlled trial of 30 healthy
subjects who all received inhaled LPS at baseline, comparing the effects of MNC
depletion by leukapheresis (depletion group, n=15) versus a sham procedure
(sham group, n=15) (Figure 2c). The subjects had again been screened to
determine eligibility prior to their enrolment in the study. Thirty separate study

























Figure 2c: Design of Study C (the RCT)
All subjects inhaled LPS at baseline. Subjects were then randomised in a double-blind fashion to
either active leukapheresis with MNC depletion or a sham procedure. Bronchoscopy and BAL
were not performed in one subject from the sham group (due to a >10% fall in FEVi). As a
precaution, all subjects were kept in hospital overnight for observation. A sub-group of 20
subjects underwent a PET-CT scan on the second day.
Routine clinical observations were recorded as for Study B. After the baseline
blood sample had been taken, each subject proceeded to LPS inhalation before
undergoing randomisation. Leukapheresis (or sham) of four TBVs began 2
hours from baseline. Bronchoscopy and BAL were performed at 9 hours from
baseline. As a precaution, the subjects were then kept in hospital overnight for
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observation. The following morning, the 24-hour blood sample was taken and
the majority of the subjects (n=10 each arm) then underwent PET-CT scanning.
After a medical review, the subjects were discharged later that day.
e) Subject recruitment and screening (all studies)
Healthy male volunteers aged between 18 and 40 inclusive were recruited by
advertisement within the University of Edinburgh. Responders were sent
written information with details of the studies and interested volunteers were
then invited to attend a screening visit a maximum of 2 weeks before their
intended study day.
The screening visit incorporated a medical history, routine clinical observations,
cardio-respiratory examination, spirometry, routine blood tests and a chest
radiograph. Exclusion criteria are listed in Table 2A and were categorised as
absolute or temporary. If a subject was temporarily excluded from enrolling in a
study, they were given the option to return for a second screening visit at a
suitable interval (a minimum of two weeks later). No subject was allowed to
enrol for more than one study. Childhood asthma did not result in exclusion if it
had completely resolved before the subject left primary school. Non-complex
congenital valvular heart disease did not result in exclusion if it had been
completely corrected during early childhood.
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Table 2A: Exclusion criteria at the screening visit
History of chronic illness, including asthma, recurrent upper/lower
respiratory tract infection, bronchiectasis, congenital, valvular or
ischaemic heart disease, diabetes mellitus, chronic kidney disease
or recurrent urinary tract infection
Presence of any acute medical illness+
HISTORY Current medication+
Smoking within the previous year
Reported smoking history amounting to >2 pack-years
Reported alcohol intake >21 units/week+
Formal blood donation within the previous 12 weeks*
History of recurrent vasovagal episodes
Abnormal pulse rhythm (excluding sinus arrhythmia)
Persistent tachycardia (HR >90bpm over 15 minutes)+
Persistent tachypnoea (RR >20/minute over 5 minutes)+
sBP <90mmHg or dBP <60mmHg*
Temperature >37.3°C+
EXAMINATION Sa02 <95% breathing room air
Presence of any cardiac murmurs
Presence of added (non-physiological) heart sounds
Presence of abnormal chest expansion or breath sounds*, wheeze
or crackles*
Insufficient peripheral venous access for leukapheresis
Significant cardio-respiratory abnormalities on CXR j
FEVx or FVC <80% of predicted
FEVj/FVC ratio <0.70
INVESTIGATIONS Abnormal Hb, total WBC*, neutrophil*, lymphocyte*, monocyte* or
platelet count; abnormal sodium, potassium or bilirubin* levels
Raised eosinophils, ALT, random glucose or CRP*
eGFR <90ml/minute
+ denotes a potentially temporary exclusion criterion.
Abbreviations: FVC, forced vital capacity; Hb, haemoglobin; ALT, alanine aminotransferase;
eGFR, estimated glomerular filtration rate.
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f) Study days (all studies)
Each subject was admitted to the Wellcome Trust Clinical Research Facility
(WTCRF) at the Royal Infirmary of Edinburgh (RIE). Routine clinical
observations, a brief history and cardio-respiratory examination were repeated
to ensure the subject remained well and that the study day could proceed. At
each time-point (0, 2, 4, 6, 8 and 24 hours), 10ml venous blood was collected
and divided into a 2ml aliquot mixed with heparin sodium and a 7ml aliquot
mixed with ethylene diamine tetra-acetic acid (EDTA), which were both taken to
the Queen's Medical Research Institute (QMRI) laboratory on ice, plus a 1ml
aliquot collected into EDTA and sent to the RIE haematology laboratory to
obtain an automated full blood count (FBC).
In studies A and B, assuming the subject remained well 2 hours after completion
of bronchoscopy, they were allowed home to return the following morning (at
the 24-hour time-point) for a medical review and final blood sample. In Study C,
subjects were kept in the WTCRF overnight for observation and were allowed
home the following day (after the PET-CT scan, where applicable).
With all three studies, any reported symptoms or possible adverse events were
documented. Each subject was contacted within 24 hours after discharge to
ensure they remained well and to record any further symptoms. Any symptoms
or adverse events were followed up to resolution.
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g) Inhalation challenge (Studies A and C)
Prior to inhalation challenge, spirometry (FEVi and FVC) was measured at
baseline (Vitalograph alpha III spirometer, Vitalograph Ltd, Buckingham, UK).
For all spirometry measurements, the best reading from three consistent
attempts (with variation <5%) was recorded. The subjects were then instructed
how to perform the inhalation challenge, and allowed a 'practice run' using
0.9% saline placebo. Spirometry was then re-checked to ensure there was no
subsequent fall in FEVi (a drop of >10% being the pre-specified cut-off for not
proceeding with LPS inhalation). After LPS (or saline placebo) challenge,
spirometry was repeated at any time if the subject reported breathlessness,
cough or wheeze. If the FEVi fell by >10%, the subject was observed closely to
determine the need for bronchodilator treatment, and spirometry was then
repeated at regular intervals until the FEVi had returned to within 10% of
baseline.
An inhalation-synchronised dosimeter-nebuliser (Spira Elektro 2, Hameenlinna,
Finland) connected to a pressurised air cylinder was used for the inhalation
challenge (Image 2a). The air cylinder pressure was fixed at 2 bar (200kPa). The
nebuliser pot was filled with 1.6ml of sterile 0.9% saline for the practice
inhalation in all subjects and also for the placebo inhalation in the 6 control
subjects in Study A. For the remaining 6 subjects in Study A and all 30 subjects
in Study C, 2mg of LPS (from E. coli 026:B6, Sigma, Gillingham, UK) was
dissolved in 1.6ml sterile 0.9% saline to form a solution of 1.25mg/ml. This LPS
solution was freshly prepared, in sterile conditions, and kept on ice prior to
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inhalation. The dosimeter-nebuliser had been calibrated to produce an aerosol
of 9.6pl over 0.6 seconds. The subject was instructed to take 5 slow consecutive
inhalations from functional residual capacity, holding their breath at maximal
inspiration for 5 seconds before exhaling. A total dose of approximately 60pg
LPS was therefore inhaled by each subject over the 5 breaths.
Image 2a: The dosimeter-nebuliser equipment used for inhalation challenge
The dosimeter was programmed to commence nebulisation for 0.6 seconds at an inspired
volume threshold of 50ml. There was a flow-meter attached to guide inspiratory flow rate
(aiming for 0.5 L/s). The dosimeter display recorded inspired volume for each breath and the
total number of inspirations. Disposable nose-clips and exhalation filters were used.
h) Double-blinded randomisation (Study C)
During Study C, the nurse in charge of the RIE Cell Separator Unit (CSU)
performed randomisation of each subject once they had completed LPS
inhalation challenge. The subject's unique trial number, initials and date of birth
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were then entered into a dedicated randomisation website, which generated a
randomisation instruction for the CSU nursing staff to follow (MNC depletion or
sham leukapheresis). Randomisation was designed to occur in permuted blocks
often subjects so as to achieve balanced randomisation [equal treatment
assignment between study arms) after 10, then 20 and finally all 30 subjects
had been recruited.
Members of the research team were blinded as to treatment allocation during
Study C and until data entry was complete and validated and the statistician had
performed the initial statistical analysis for the primary and main secondary
end-points. For the duration of Study C, members of the research team had no
access to the RIE laboratory results system upon which the subjects' automated
cell count results were anonymously uploaded. During the study, there was a
mechanism available within the randomisation website for the research team to
'break the blind' for an individual subject should clinical need arise and
knowledge of treatment allocation become imperative. The details of any such
un-blinding activity were automatically recorded on the randomisation website.
i) MNC leukapheresis (Studies B and C)
Continuous flow centrifugation leukapheresis was performed in the CSU, using
the COBE® Spectra™ Apheresis System MNC Program [version 4.7, CaridianBCT,
Lakewood, CO, USA). The COBE® Spectra™ machine automatically calculated an
estimated TBV for each subject, based upon their height and weight and
according to Nadler's formula [Nadler et al., 1962):
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Estimated TBV = 0.3669 * (height in metres)3 + 0.03219 * (weight in kg) + 0.6041
Acid-citrate-dextrose solution A (ACD-A) was used as an anticoagulant at a ratio
of 13.5:1 (whole blood: ACD-A). The required white blood cell interface was
established using a 'colorgram' to achieve a collect line haematocrit of 1-2%. In
Study B subjects, and in those subjects randomised to the MNC depletion arm of
Study C, cell collection then commenced at lml/minute. Cell collection was NOT
commenced for the 15 subjects in the sham arm of Study C. During Study C, the
collection bags and associated tubing were completely covered throughout the
procedures (by CSU nursing staff) so that neither the subjects nor members of
the research team could determine whether true MNC depletion or a sham
procedure was taking place (Image 2b). During Study C, we restricted the total
duration of leukapheresis to a maximum of 6.5 hours.
All subjects were encouraged to have a milky drink prior to leukapheresis in
order to try to reduce the risk of citrate-induced hypocalcaemia. During Study B,
we found that a combination of oral and IV calcium was usually required to
minimise or abolish symptoms of hypocalcaemia during leukapheresis.
Therefore, in Study C, we gave oral calcium (Calcichew Forte® 1 gram tablets) if
needed during the first 2-3 hours, followed by IV administration of 10% calcium
gluconate in all subjects, commencing mid-way through the procedure.
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Image 2b: Leukapheresis/sham procedure (Study C)
The collection bag and tubing were covered so that it was impossible to tell whether MNCs were
being collected (depletion arm) or simply returned to the circulation (sham arm).
Randomisation thus remained double-blinded, with neither the subjects nor the investigating
team aware of treatment allocation.
At the end of the leukapheresis procedure, in both Study B and in subjects from
the depletion arm of Study C, a sample from the MNC collection was placed in
EDTA and taken to the haematology laboratory in the R1E for an automated cell
count. In Study B, the remainder of the MNC collection was placed on ice for
transfer to the laboratory and processed as described below. In Study C, the
sample from the MNC collection (for automated cell count) was only retrieved
once both the subject and research team had left the CSU, and the remainder of
the MNC collection was then discarded, in order to maintain blinding.
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j) Bronchoscopy and BAL (all studies)
Bronchoscopy and BAL were performed between 8 and 9 hours from baseline.
All subjects were fasted for at least six hours prior to bronchoscopy in order to
minimise the risk of aspiration during the procedure. Before proceeding to
bronchoscopy, in subjects from Studies A and C (i.e. those who had undergone
inhalation challenge), spirometry was re-checked. For safety reasons,
bronchoscopy was not performed if the FEVi had fallen by >10% from baseline.
All subjects received supplemental oxygen at 2-4 L/minute by nasal cannulae.
They were offered sedation in the form of IV midazolam. Topical lidocaine (local
anaesthetic) was applied to the throat and, after intubation of the vocal cords,
the airways. The RML was identified and the bronchoscope wedged in the
medial or lateral segment. 20ml of 0.9% sterile saline was instilled initially, left
to dwell for 10 seconds and then aspirated and discarded (the 'bronchiolar'
sample). Four separate aliquots of 50ml 0.9% sterile saline (i.e. a total of 200ml)
were then instilled, each time allowed to dwell for 10 seconds before aspirating
and the BAL fluid retrieved was then collated and stored on ice prior to transfer
to the QMRI laboratory.
k) PET-CT scanning (Study C)
10 subjects from Study C (n=5 each group) did not undergo PET-CT scanning
due to a delay in scanner installation and calibration. These subjects were
simply discharged on the morning of the second day after a medical review and
once their final blood sample had been obtained.
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The other 20 subjects (randomly assigned, n=10 each group) were allowed
water only (otherwise fasted) from midnight until after the scan was completed,
to minimise any fluctuations in plasma glucose concentrations. The PET-CT
scans were performed in the Clinical Research Imaging Centre (CRIC) at the
QMRI, approximately 27 hours from baseline. A Siemens Biograph mCT scanner
was used (Siemens Medical Solutions Inc., Knoxville, TN, USA). The CT topogram
was used to position the CT and PET beds from the dome of the diaphragm
upwards. A baseline thoracic CT scan was carried out for localisation and
attenuation correction purposes.
Approximately 200 megabecquerel (MBq) [18F]FDG was drawn up and
administered IV; the 60 minute PET scan then commenced immediately, using
'List Mode'. The last 10 minutes of data were reconstructed into a static image
for standardised uptake value (SUV) measurement. Nine venous blood samples,
each measuring 2ml, were taken at specific time-points during the scan from a
freshly placed IV cannula; each sample was collected into a heparinised tube,
numbered and stored together in a lead-lined container. Bedside capillary blood
glucose measurements were carried out at baseline, mid-point and end of the
PET scan to ensure that blood glucose levels remained stable.
Once the scan was complete, the subject was kept in CRIC for a further hour,
allowed to eat and drink and then discharged home following medical review.
Departmental protocols were followed throughout in order to adhere to
ionising radiation regulations.
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2.3 LABORATORY MATERIALS AND PROCEDURES
a) Materials and reagents
The vWF enzyme-linked immunosorbent assay (ELISA) kit (catalogue number
Abl08918) was from Abeam.
40pm BD Falcon™ Cell Strainers (352340), Anti-mouse and anti-rat Ig BD™
CompBeads (552843 and 552844), BD FACS™ Lysing Solution (349202), BD
Falcon™ polystyrene Round-Bottom Tubes (352001), BD Falcon polyprophylene
15ml & 50ml Conical Tubes (352096 and 352070) and BD Cytometric Bead
Array (CBA) Human Inflammatory Cytokines Kit, for IL-ip, IL-10, IL-12p70, IL-
6, IL-8 and TNFa, (551811) were from Becton Dickinson (BD) Biosciences
(Oxford, UK).
The following fluorochrome-conjugated antibodies were from BD Biosciences:
• Anti-human CCR2 Alexa Fluor® (AF)647; BD Pharmingen™, clone 48607,
mouse IgG2b, k (558406).
• Anti-human CD14 allophycocyanin (APC); BD Pharmingen™, clone M5E2,
mouse IgG2a k (555399).
• Anti-human CD16 fluorescein isothiocyanate (FITC); BD Pharmingen™,
clone 3G8, mouse IgGi k (556618).
• Anti-human CD3 FITC; BD Pharmingen™, clone UCHT1, mouse IgGi k
(555332).
• Anti-human HLA-DR V450; BD Horizon™, clone G46-6, mouse IgG2a k
(561359).
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The Quantichrom™ urea assay kit (DIUR-500) was from Bioassay Systems
(Hayward, CA, USA).
The following fluorochrome-conjugated antibodies were from Biolegend
(Cambridge, UK):
• Anti-human CDllb (integrin alpha M, ITGAM) phycoerythrin (PE)/Cy5;
clone ICRF44, mouse IgGi k (301308).
• Anti-human CD14 peridinin-chlorophyll-protein complex
(PerCP)/Cy5.5; clone HCD14, mouse IgGi k (325622).
• Anti-human CD16 PE; clone 3G8, mouse IgGi k (302008).
• Anti-human CD163 APC; clone GHI/61, mouse IgGi k (333610).
• Anti-human CD206 (mannose receptor) PE; clone 15-2, mouse IgGi k
(321106).
• Anti-human CD25 (IL-2 receptor a) PE; clone BD96, mouse IgGi k
(302606).
• Anti-human CD4 APC/Cy7; clone RPA-T4, mouse IgGi k (300518).
• Anti-human CD62L (L-selectin) APC/Cy7; clone DREG-58, mouse IgGi k
(304814).
• Anti-human CD64 PE; clone 10.1, mouse IgGi k (305008).
• Anti-human CD71 FITC; clone CY1G4, mouse IgG2a k (334104).
• Anti-human CX3CR1 FITC; clone 2A9-1, rat IgG2b k (341606).
• Anti-human Ki-67 PE; clone Ki-67, mouse IgGi k (350504).
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NucleoCassettes containing propidium iodide (941-0002) were from
ChemoMetec (Allerpd, Denmark).
96-well flat-bottom sterile microplates were from Corning (Lowell, MA, USA).
Flow Cytometry Staining Buffer (00-4222-26) and the following fluorochrome-
conjugated antibodies were from eBioscience (Hatfield, UK):
• Anti-human 25F9 (mature macrophage marker) AF647; clone eBio25F9,
mouse IgGi (51-0115-71).
• Anti-human CD127 (IL-7 receptor a) PE/Cy5; clone eBioRDR5, mouse
IgGiK (15-1278-42).
The HNE and SP-D ELISA kits were from Hycult Biotech (HK319 and HK335).
Dulbecco's Phosphate Buffered Saline (PBS) with Ca/Mg (14040) and Fetal
Bovine Serum (FBS) were from Invitrogen (Paisley, UK).
The Reastain Quick-Diff Kit (102164) was from Reagena (Toivala, Finland).
The following ELISA kits were from R&D Systems (Minneapolis, MN, USA):
• Duoset® kits for IL-6 (DY206), IL-8 (DY208), MCP-1 (DY279), RAGE
(DY1145), SDF-la (DY350) and TNFa (DY210).
• Quantikine® kits for CC-16 (DUGB00), MCP-1 (DCP11), MlP-la (SMA00),
MPO (DMYE00), SDF-la (DSA00) and CD62E (sE-selectin) (DSLE00).
• CD62L (sL-selectin) Immunoassay (BBE4B).
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Albumin from Bovine Serum (BSA) (A2153), EDTA (E6758), E-Toxate™ kit
(ET0300), Goat serum (G9023), Heparin sodium (H3149), LPS from E. coli
026:B6, y-irradiated, lyophilised powder purified by gel-filtration
chromatography (L2654, lot 079K4011) and Tween® 20 (P1379) were from
Sigma-Aldrich (Gillingham, UK).
The Pierce bicinchoninic acid (BCA) protein assay kit (23225) was from Thermo
Scientific (Pierce Biotechnology, Rockford IL, USA).
Round Base Tubes 3.5ml and caps (212-1821 and 217-7004), for performing
radioactivity counts in blood/plasma, were from VWR International Ltd
(Lutterworth, UK).
b) Automated cell counts (all studies)
FBC results (incorporating Hb, total and differential WBC count and platelet
count) were processed and recorded under anonymised subject number for
each time-point. A set of FBC safety parameters operated during each study day.
Both LPS inhalation and leukapheresis were expected to alter the FBC results,
but the Trial Manager checked each result as it became available and alerted the
research team in the event of any Hb level <100 or >180 g/L, total WBC count
<2.5 xl09/L, neutrophil count <1 xl09/L or platelet count <50 xl09/L. Any
results outwith these FBC safety parameters were also automatically classified
as an AE. To maintain blinding, during Study C, the research team otherwise had
no access to the FBC results until after preliminary statistical analysis, when the
study was un-blinded.
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Samples from the MNC collections sent to the RIE haematology laboratory for
automated cell counts (Studies B and C) were also processed and recorded
under anonymous subject number. During Study C, the research team had no
access to these results until after preliminary statistical analysis and study un-
blinding.
c) Extracting plasma from peripheral blood samples (all studies)
At each time-point, the 2ml heparinised blood sample and 2ml of the EDTA-
treated blood sample were centrifuged for 20 minutes (300g, 20°C). The plasma
layer was carefully aspirated by pipette and stored in small aliquots at -80°C.
Plasma assays were performed at a later date (see Pages 103 - 104).
d) Staining peripheral blood leucocytes for flow cytometry (all studies)
50pl of Flow Cytometry Staining Buffer was added to each 50pl aliquot of whole
blood (from the EDTA sample) and then incubated for 30 minutes (4°C, in
darkness) with the appropriate antibody mixture or control (Table 2B). 750pl of
FACS Lysing Solution was added to each sample for 20 minutes (at 20°C) to lyse
red blood cells. 2ml of PBS was added and the samples centrifuged for 5 minutes
(350g, 4°C) before discarding the supernatant. Cell pellets were re-suspended in
500pl FACS Lysing Solution and stored at 4°C prior to flow cytometry.
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Table 2B: Fluorochrome-conjugated antibodies for flow cytometry/sorting
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BAL CD14 APC, CD16 PE, HLA-DR V450
e) Processing the MNC collection (Study B)
The cell collection was divided into 50ml aliquots and centrifuged for 20
minutes (350g, 4°C, no acceleration/brake). The top layer, consisting mainly of
plasma and platelets, was then aspirated and discarded. Red blood cells in the
remaining cell solution were lysed using ice-cold hypotonic and hypertonic
saline (as described above). The cell solution was centrifuged for 6 minutes
(350g, 4°C) and the supernatant discarded. The cell pellet was washed in 50ml
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PBS and then re-suspended in 10ml 0.1% BSA in PBS with Ca/Mg. Automated
total and viable cell counts were obtained using a NucleoCounter (ChemoMetec
(Allerpd, Denmark].
f) Staining cells from the MNC collection for flow cytometry (Study B)
lOOpl aliquots of MNC cells, in lOOgl 0.1% BSA in PBS with Mg/Ca, were
incubated with the relevant antibodies (Table 2B) or control for 30 minutes
(4°C, in darkness]. Lysis and wash steps were performed as for peripheral blood
leucocytes and the cell pellets were re-suspended in FACS Lysing Solution and
stored at 4°C for flow cytometry.
g) BAL cell counts and extraction of BAL fluid supernatant (all studies)
The volume of BAL fluid was measured and recorded for each subject.
Automated total and viable cell counts were obtained using the NucleoCounter.
BAL fluid was filtered through 40pm cell strainers into 50ml Falcon tubes and
then centrifuged for 10 minutes (300g, 4°C, no brake]. The BAL supernatant was
carefully aspirated using a pipette and stored in aliquots at -80°C. BAL
supernatant assays were performed at a later date (see below].
The cell pellet was re-suspended in 50ml PBS, centrifuged for 10 minutes (300g,
4°C] and the supernatant discarded. The BAL cells were then re-suspended in
0.1% BSA in PBS with Ca/Mg, at a concentration of lxlO6 cells/ml. Four
cytospins were prepared from each sample, using aliquots of 4 xlO4 cells
suspended in 200pl of fetal calf serum. Once dry, cytospins were fixed and
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stained with Reastain Quick-Diff. Differential cell counts were performed by two
independent blinded observers (including one pathologist) at x400
magnification, counting 500 nucleated cells for each subject. Cells were defined
as AMs, neutrophils or MNCs (lymphocytes and monocyte-like cells).
h) Staining BAL cells for flow cytometry (all studies)
The BAL cells were again centrifuged for 5 minutes (300g, 4°C) and the
supernatant discarded. The cell pellet was re-suspended for 45 seconds in 5ml
ice-cold 0.2% NaCl before adding 5ml 1.6% ice-cold NaCl for a further 45
seconds. The cells were washed in PBS, centrifuged for 5 minutes as before and
the supernatant discarded, before re-suspending in 0.1% BSA in PBS with
Ca/Mg at 1 xlO6 cells/ml.
lOOpl aliquots of BAL cells were mixed with an equal volume of 0.1% BSA in
PBS with Ca/Mg and incubated for 30 minutes (4°C, in darkness) with the
relevant antibody mixtures (Table 2B). 750pl of FACS Lysing Solution was
added for 20 minutes (20°C) and the samples were then washed in 2ml PBS,
centrifuged for 5 minutes (300g, 4°C) and the supernatant discarded. Cells were
re-suspended in 500pl of FACS Lysing Solution and stored at 4°C before flow
cytometry.
i) Staining BAL cells for flow sorting (Study C)
The remaining BAL cells were incubated with the relevant antibodies (Table 2B)
for 30 minutes (4°C, in darkness). The sample volume was adjusted to 50ml
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using PBS and the cells were centrifuged as before and the supernatant
discarded. The cell pellet was resuspended in 1% autologous serum in PBS and
flow sorting was then performed immediately.
j) Flow cytometry (all studies)
A BD SORP LSRFortessall cell analyser (calibrated daily) and FACSDiva software
(BD Biosciences) were used for flow cytometry. A minimum of 150,000 events
was captured for each sample. Compensation was calculated automatically but
verified manually for each antibody, using anti-mouse or anti-rat Ig CompBeads.
Voltage parameters were kept consistent throughout each study.
Multiple experimental controls were employed. Unstained samples were
prepared for each sample/time-point. Single antibody stains and isotype
controls were also used for blood samples (at baseline) and for BAL and MNC
collection samples. Fluorescence-minus-one controls were used for CCR2 and
CX3CR1 staining (these excluded the antibody of interest, replacing it with the
appropriate isotype control).
k) Flow sorting (Study C sub-group)
Flow sorting was performed using a BD FACSAria II with FACSDiva software to
collect separate populations of AMs and monocyte-like cells. Each cell
population was collected into 10% autologous serum in PBS and checked for
purity. Cells were incubated with or without lOOnM dexamethasone in standard
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tissue culture conditions for 24 hours. Cell culture supernatants were extracted
and frozen in aliquots at -80°C.
I) Analysing data from flow cytometry (all studies)
Data generated by flow cytometry was analysed using Flowjo version 9.1
(TreeStar, Ashland, OR, USA). For whole blood samples, differences in cellular
size and granularity visible on forward scatter-area (FSC-A) versus side scatter-
area (SSC-A) plots were used to gate on populations ofmonocytes, lymphocytes
and neutrophils. Within the monocyte gate, HLA-DR+ cells were selected (thus
excluding any HLA-DR- neutrophils) and the proportions of classical
(CD14++CD16), intermediate (CD14++CD16+) and non-classical (CD14+CD16++)
monocytes were determined (see Figure 3d, Page 120). For each monocyte
subtype, the expression of CDllb, L-selectin, CD64, CCR2, CX3CR1 and HLA-DR
was defined by calculating relative geometric mean fluorescence (GMF)
intensity; relative expression was categorised as low, intermediate or high.
Within the neutrophil gate, HLA-DR- cells were selected and relative expression
ofCDllb, CD16, L-selectin and CD64 was determined. For lymphocytes, CD3+
cells were selected from within the lymphocyte gate, and the relative
proportions of CD4+ and CD8+ T-lymphocytes were calculated. Regulatory T
(Treg) cells were defined as CD25+CD127- cells within the CD3+CD4+ T-cell
population (see Figure 3f, Page 123).
For monocytes within the MNC collection, CD14 and CD16 expression in HLA-
DR+ monocytes were used to differentiate the classical, intermediate and non-
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classical subtypes and calculate the relative proportion of each (see Figure 4d,
Page 157).
In BAL fluid, plots of FSC-A versus SSC-A were also used to gate on AM,
neutrophil, lymphocyte and monocyte-like cell populations (see Figure 3i, Page
129). Within the monocyte-like cells gate, HLA-DR- cells (neutrophils) were
excluded and the remaining HLA-DR+ cells were further distinguished into two
distinct subtypes (CD14++CD16 and CD14++CD16+) (see Figure 3j, Page 130).
m) Measuring protein and urea concentrations (all studies)
Protein concentrations were assayed in plasma at baseline and at 8 hours and in
BAL fluid supernatant (9 hours). The colorimetric BCA protein assay was
conducted according to the manufacturer's instructions. This test relies upon
the protein-mediated reduction of Cu2+ to Cu1+ in alkaline conditions. Molecules
of BCA chelate with Cu1+ to form a water-soluble purple-coloured complex
whose absorbance at 562nm displays a linear correlation with protein
concentration (between 20-2000 pg/ml). For each plate analysed, a standard
curve was generated from known concentrations of BSA and the optical density
(OD) readings for standards and samples were recorded using a microplate
reader.
Urea concentrations were assayed in 8-hour plasma samples and in BAL fluid
supernatants. The Quantichrom™ kit employs a chromogenic reagent that
complexes with urea to form a yellow-coloured complex whose absorbance at
520nm is linearly correlated with urea concentration. Plasma samples (5pi
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aliquots) were incubated with working reagent for 20 minutes and the OD at
520nm was compared to that from two standard concentrations (Omg/dL and
50mg/dL). For BAL fluid supernatant samples, the 'low urea' method was used;
50gl aliquots of sample were incubated with working reagent for 50 minutes
and the OD at 430nm was measured (standard concentrations were Omg/dL
and 5mg/dL).
The following equation was used to determine urea concentrations in the
samples (where DF is the dilution factor; high standard concentration was 50
mg/dL for plasma and 5 mg/dL for BAL fluid supernatant):
[urea, mg/dL] = fOD sample - OD zero standard) x DF x [high standard]
(OD high standard - OD zero standard)
Urea concentrations in plasma and BAL supernatantwere then used to calculate
the volume of epithelial lining fluid (ELF) (Rennard etal, 1986):
ELF volume, ml = [BAL urea, mg/ml] x BAL volume, ml
[plasma urea, mg/ml]
Dividing the volume of BAL supernatant by the volume of ELF gives a dilution
factor for each BAL sample. Cytokine and protein concentrations in BAL
supernatant can then be adjusted according to the degree of BAL dilution.
n) Enzyme-linked immunosorbent assays (all studies)
Samples of plasma at baseline and 24 hours were sent to the RIE biochemistry
laboratory for automated analysis of CRP levels. Other ELISAs were performed
in the QMR1 laboratory as per manufacturer's instructions (Table 2C).
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Table 2C: Inflammatory cytokines and markers of cellular injury measured in
plasma, BAL supernatant and flow-sorted cultured BAL cell supernatants
CYTOKINE OR
CELL MARKER
TYPE OF ASSAY SAMPLES TESTED
LOWER LIMIT OF
DETECTION
STUDIES A AND B
IL-6 ELISA Duoset* BAL 9.4 pg/ml
IL-8 ELISA Duoset* BAL 31.3 pg/ml
IL-10 ELISA Duoset* BAL 31.3 pg/ml
MCP-1 ELISA Duoset* BAL 15.6 pg/ml
TNF-a ELISA Duoset* BAL 15.6 pg/ml
STUDY C
CC-16 ELISA Quantikine* BAL & plasma 70.0 pg/ml
IL-lp CBA kit BAL* & plasma 7.2 pg/ml
IL-6 CBA kit BAL* & plasma 2.5 pg/ml
IL-8 CBA kit BAL* & plasma 3.6 pg/ml
IL-10 CBA kit BAL* & plasma 3.3 pg/ml
IL-12p70 CBA kit BAL* & plasma 1.9 pg/ml
MCP-1 ELISA Quantikine* BAL & plasma 5.0 pg/ml
MlP-la ELISA Quantikine* BAL & plasma 10.0 pg/ml
MPO ELISA Quantikine* BAL & plasma 0.1 ng/ml
HNE ELISA kit BAL & plasma 0.4 ng/ml
RAGE ELISA Duoset* BAL & plasma 62.5 pg/ml
SDF-la ELISA Quantikine* BAL & plasma 18.0 pg/ml
sE-selectin ELISA Quantikine* BAL & plasma 9.0 pg/ml
sL-selectin ELISA kit BAL & plasma 0.3 ng/ml
SP-D ELISA kit BAL & plasma 6.3 ng/ml
TNFa CBA kit BAL* & plasma 3.7 pg/ml
vWF ELISA kit BAL & plasma 2.5 mU/ml
* includes BAL fluid supernatant and supernatants from flow-sorted cultured BAL cells.
The sE-selectin ELISA was performed on heparinised plasma (not EDTA, as it is
a Ca2+-dependent molecule); all other ELISAs were performed on plasma from
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EDTA-treated blood. BAL fluid supernatant results were also adjusted for BAL
dilution (i.e. the volume of ELF) using the urea method, as detailed above
(Rennard etal, 1986).
o) LPS assay (Study C)
LPS levels were measured in BAL fluid supernatant samples from Study C. The
semi-quantitative E-Toxate™ assay is based upon the Limulus Amoebocyte
Lysate (LAL) test and was performed according to the manufacturer's
instructions.
p) Measuring [1SF]FDG activity in plasma (Study C sub-group)
Whole blood and plasma radioactivity were measured for each blood sample
using a Packard Cobra II Auto-Gamma counting system (GMI Inc., Ramsey, MN,
USA). The radioactivity of each aliquot ofwhole blood was counted over 1
minute. The blood samples were then centrifuged (300g, 20°C, 10 minutes) and
the plasma extracted into separate, labelled tubes. The radioactivity of each
aliquot of plasma was then counted over 1 minute. The radioactivity counts for
whole blood and plasma samples were individually corrected for sample weight,
background radioactivity (calculated from an empty control tube) and decay
time to give decay-corrected whole blood or plasma activity (Bq/ml).
Apollo® quantitative lung imaging software (VIDA Diagnostics, Coralville, IA,
USA) was used to segment lungs and lobes within the CT images. All lung
segmentation volumes were shrunk by 25% to avoid contamination from
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myocardium (which demonstrates very high FDG uptake). For each subject, the
[18F]FDG activity in lung tissue and in plasma was used to generate time-activity
curves, construct Patlak plots using linear regression and thereby calculate
influx constant (Ki) (Patlak et al., 1983; Patlak and Blasberg, 1985). The Patlak
plot is a graphical tool for analysing the uptake of a radioactive tracer in a two-
compartmental model, with plasma representing the reversible compartment.
Upon cellular uptake (for example, within the lungs), [18F]FDG becomes
phosphorylated by hexokinase and is irreversibly trapped within the cell
(Harris and Schuster, 2007). After sufficient time has elapsed to create
equilibrium between the two compartments, the curve of the Patlak plot
becomes linear, with the slope equivalent to Ki (Chen et al., 2004). Ki corrected
for intercept was used to adjust for volume of distribution (Chen et al., 2006;
Jones etal., 1997).
Mean SUVs were calculated from the PET images obtained during the final 10-
minute frame. SUV is the semi-quantitative ratio of tissue radioactivity
([18F]FDG uptake) within the region of interest to the injected [18F]FDG activity,
adjusted for body weight (Thie, 2004).
2.4 STATISTICAL ANALYSIS
When designing Study C, a power calculation was performed to determine the
minimum subject numbers required to achieve a 90% chance of detecting a
clinically and statistically significant reduction in blood neutrophil count. Based
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on previous work, LPS inhalation was expected to cause an increment of about
5.5 xl09/L in blood neutrophil count (Shyamsundar etal., 2009); a reduction of
>2 xl09/L was deemed to be significant, based on a predicted standard
deviation of 1.4 xl09/L. The minimum subject number was calculated at n=24; a
pre-specified total of 30 subjects were enrolled into Study C to ensure that any
early withdrawals from the study did not compromise the statistical power.
For all three studies, the majority of data analysis was undertaken using
GraphPad Prism version 4.0 (GraphPad Software, La Jolla, CA, USA). A P value of
<0.05 was considered statistically significant. 95% confidence intervals (CI.95)
are given where appropriate. Data with a normal distribution were expressed as
mean (standard deviation, SD) and analysed by 2-sample t-test, or paired t-test
(for paired data). Data that were not normally distributed were expressed as
median [interquartile range, IQR] and analysed by MannWhitney U (MWU) test
(unpaired data) orWilcoxon signed rank test (paired data). Pearson's test was
used to calculate correlations. Differences in the frequency of adverse events
between study groups were analysed using Fisher's exact test.
Ranked tests (i.e. MWU orWilcoxon signed rank) were used to analyse
concentrations of cytokines and other plasma/BAL markers; concentrations
that were undetectable (below the lower limit of detection of the assay) were
assigned an arbitrary ranked value equivalent to 50% of the lower limit of
detection prior to statistical analysis.
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In Study C, cytospin counts of BAL cell populations (from two blinded,
independent observers) were compared by the study statistician. Observer
agreement was displayed using Bland-Altman plots, aiming for a 95% limit of
agreement. According to these limits, the initial counts for 1 subject did not
demonstrate sufficient observer agreement and a re-count was performed
(which then demonstrated satisfactory consistency between the two counts).
The effects of treatment (in Study A and Study C) on changes in parameters by 8
hours (compared to baseline), or by 24 hours, were assessed using analysis of
covariance (ANCOVA) with baseline value as covariant (Minitab, version 15,
Minitab Inc., Pennsylvania, USA). Repeated-measures ANCOVA was used to
assess the effects of treatment when comparing changes in a variety of
parameters between baseline and 8 hours, while incorporating the intermediate
(2, 4 and 6-hour) time-points (SPSS version 17, IBM Corporation, New York,
USA).
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CHAPTER 3: RESULTS OF STUDY A
3.1 OVERVIEW
This chapter reports the results of Study A, which compared inhalation of LPS
with inhalation of saline placebo in a group of twelve healthy volunteers (n=6 in
each group).
The main aims of this study were:
• To ensure the safety and efficacy of LPS inhalation as a model of
pulmonary and systemic inflammation in healthy subjects
• To determine the presence and phenotype of monocyte-like cells in
BAL fluid, in particular after LPS inhalation
Data on recruitment and subject demographics at baseline will be presented
first, followed by the effects of LPS inhalation on symptoms, adverse events and
clinical parameters, compared to saline placebo. I shall then describe in detail
the effects of LPS inhalation on FBC parameters (especially blood neutrophil
counts), blood monocyte subsets and Treg cells. Finally, the effects of LPS
inhalation on the cellular, protein, cytokine and inflammatory marker content of
BAL fluid will be presented, with a particular emphasis on the proportions and
phenotype of monocyte-like cells in BAL fluid when compared to control
subjects.
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3.2 SUBJECTS
a) Subject recruitment
Six subjects were recruited into each group. Recruitment, enrolment and follow-
up are illustrated in Figure 3a. There were no withdrawals from the study;
however, one subject from the LPS group was unable to tolerate bronchoscopy
despite midazolam sedation and the procedure was abandoned without
intubation of the vocal cords. BAL data were therefore only available for 5 out of
the 6 subjects within the LPS group.
Figure 3a: CONSORT* diagram illustrating volunteer recruitment, enrolment and
follow-up during Study A
t Reasons for exclusion: abnormal total/differential WBC (n=5), ALT (n=l) or bilirubin (n=l);
current medication (n=l); recent formal blood donation (n=l).
* (CONSORT guidelines are described in Schulz etal, 2010; Schulz etal., 2010}
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b) Subject demographics
The baseline characteristics of subjects were very similar between the two
groups (Table 3A). All subjects successfully completed inhalation challenge to
receive an approximate dose of 60pg of either LPS or saline placebo.
Table 3A: Subject characteristics at baseline
BASELINE CHARACTERISTICS SALINE GROUP LPS GROUP
Age (years) 24.7 (5.0) 24.8(6.2)
Ethnicity 5/6 Caucasian 5/6 Caucasian
Height (metres) 1.81 (0.14) 1.77 (0.04)
Weight (kg) 81.9(17.2) 79.6 (20.7)
FEVX (litres) 4.69(1.21) 4.30 (0.41)
FVC (litres) 5.61(1.36) 5.10 (0.58)
Temperature (°C) 36.3 (0.3) 36.3 (0.5)
Heart rate (beats/minute) 71(12) 71(10)
Oxygen saturations (%) 98 (2) 98(1)
Data are presented as mean (SD); n=6 in each group. Subject characteristics were very similar in
the two groups.
c) Symptoms and adverse events
There were no reported SAEs and there were no FBC results that fell outside of
the pre-specified safety parameters (see Page 96). All reported symptoms were
attributable to either LPS inhalation or to bronchoscopy and all resolved
promptly (Table 3B).
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One subject from the saline group reported transient pyrexial symptoms
occurring about 15 hours from baseline; these had fully resolved by the
following morning and were attributed to a recognised adverse effect of BAL.
Table 3B: Reported symptoms and adverse events during Study A
SYMPTOM/ADVERSE EVENT SALINE GROUP LPS GROUP
Sore throat 3 (50) 4(67)
Cough 1(17) 2 (33)
Pyrexia (temperature >37.4 °C) 1(17) 5(83)+
Myalgia 0 1(17)
Data are presented as frequency (percentage); n=6 in each group; t only 2 subjects in the LPS
group actually reported symptoms of pyrexia; no subjects reported breathlessness, wheeze or
chest discomfort.
3.3 THE EFFECTS OF LPS ON CLINICAL PARAMETERS
LPS inhalation was associated with a significant rise from baseline in mean
maximum temperature, when compared to saline inhalation (mean temperature
36.3 (SD 0.5)°C at baseline and maximum 37.7 (0.5)°C in the LPS group, versus
36.3 (0.3)°C and 37.0 (0.4)°C respectively in the saline group; P=0.03) (Figure
3b). The mean maximum temperature of subjects in the saline group tended to
rise during the course of the day, consistentwith natural diurnal patterns in
human body temperature (Lowry, 2003; Martinez-Nicolas etal., 2011).
Inhalation of LPS also caused a significant increment in mean maximum HR
when compared to saline placebo (mean HR 71 (SD 10) minute1 at baseline and
maximum 97 (14) minute-1, versus 72 (12) minute-1 and 76 (12) minute-1
respectively in the saline group; P=0.003) (Figure 3b).
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Figure 3b: Maximal changes in temperature and heart rate during the study
Data are displayed as box (median/IQR) and whiskers (range); n=6 each group; between-groups
statistical analysis was by ANCOVA, with baseline value as covariate; *P<0.05; **P<0.005.
There were very small changes from baseline in mean maximum RR and mean
minimum Sa02 that were felt unlikely to be of clinical significance and which did
not vary between the saline and LPS groups (Table 3C). In both groups, neither
LPS nor saline inhalation appeared to have any significant effect on mean FEVi
and mean FVC values at 8 hours (Table 3C).
Table 3C: Maximal changes in other clinical parameters throughout the study
PARAMETER GROUP BASELINE MAXIMUM/MINIMUM P VALUE
RR (minutex)
Saline 13 (2) 17 (2)
0.83
LPS 13(1) 17 (2)
Sa02 (%)




Saline 4.69 (1.21) 4.68(1.14)
0.36
LPS 4.30(0.41) 4.22 (0.42)
FVC (litres)
Saline 5.62 (1.36) 5.52 (1.41)
0.99
LPS 5.10 (0.58) 5.00 (0.61)
Data are expressed as mean (SD), n=6 in each group; between-groups statistical analysis was by
ANCOVA, using baseline as covariate.
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3.4 THE EFFECTS OF LPS INHALATION AS MEASURED IN BLOOD
a) Blood neutrophil counts
LPS inhalation was associated with a significant rise in mean peripheral blood
neutrophil count by 8 hours that was not evident in the saline group subjects
(mean blood neutrophil count 2.90 (SD 0.49) xl09/L at baseline and 8.14 (2.11)
xl09/L at 8 hours in the LPS group, versus 2.68 (1.09) xl09/L and 2.56 (0.88)
xl09/L in the saline group; P=0.0002) (Figure 3c, Panel A). By 24 hours, mean
circulating blood neutrophil counts were at similar levels in the two groups
(falling to 6.25 (SD 3.00) xl09/L in the LPS group and rising to 5.46 (4.48)
xl09/L in the saline group; P=0.78 for between-groups comparison with
baseline). There was a particularly marked rise in peripheral blood neutrophil
count (to 13.86 xl09/L) in the subject from the saline group who had reported
transient pyrexial symptoms post-BAL. He was asymptomatic with normal
clinical parameters by the time of medical review at the 24-hour time-point.
b) Blood monocyte counts
There was a trend towards a rise in blood monocyte count at 8 hours in the LPS
group that did not quite reach significance (mean blood monocyte count 0.49
(SD 0.15) xl09/L at baseline and 0.68 (0.19) xl09/L at 8 hours in the LPS group,
versus 0.53 (0.25) xl09/L and 0.49 (0.17) xl09/L in the saline group; P=0.05
(Figure 3c, Panel B). By 24 hours, mean blood monocyte count was 0.57 (SD
0.17) xl09/L in the LPS group versus 0.67 (0.29) xl09/L in the saline group
(P=0.55 for between-groups comparison with baseline).
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c) Blood lymphocyte counts
LPS inhalation had no effect on blood lymphocyte counts between baseline and
8 hours when compared to the saline group (mean blood lymphocyte count 2.06
(SD 0.51) xl09/L at baseline and 1.88 (0.62) xl09/L at 8 hours, versus 1.96
(0.55) xl09/L and 2.21 (0.41) xl09/L in the saline group; P=0.17) (Figure 3c,
Panel C). Mean blood lymphocyte counts remained similar at 24 hours in both
groups (1.97 (SD 0.48) xl09/L in the LPS group versus 1.92 (SD 0.42) xl09/L in
the saline group; P=0.96 for between-groups comparison with baseline).
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Figure 3c: Circulating blood neutrophil (A), monocyte (B), lymphocyte (C) and
platelet (D) counts between baseline and 8 hours
n=6 in each group; between-groups statistical analysis was by ANCOVA, comparing the change
in circulating blood cell count between baseline and 8 hours, using baseline count as covariate;
NS non-significant; *** P<0.0005.
d) Blood platelet counts
Compared to the saline group, LPS inhalation had no significant effect upon the
change in mean blood platelet count between baseline and 8 hours (228 (SD
45.1) xl09/L at baseline and 213 (45.1) xl09/L at 8 hours, versus 203 (30.7)
xl09/L and 200 (37.1) xl09/L at 8 hours; P=0.07) (Figure 3c, Panel D). Mean
blood platelet counts remained similar at 24 hours in both groups (226 (SD
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47.3) xl09/L in the LPS group versus 209 (31.9) xl09/L in the saline group;
P=0.35 for between-groups comparison with baseline).
e) Blood monocyte subsets
Flow cytometry was used to determine the proportion of each monocyte subset
in blood at each time-point. Figure 3d demonstrates the gating strategy
employed to identify classical, intermediate and non-classical monocytes in
blood. There were only small variations in the proportions of each blood
monocyte subset (as a % of total, HLA-DR+ monocytes) between baseline and 24
hours, the most obvious being a non-significant trend towards a greater
proportion of classical monocytes in the LPS group, compared to a lower
proportion in the saline group, by 8 hours (90.6 (SD 4.0) % classical monocytes
at baseline and 92.2 (2.6) % at 8 hours in the LPS group, compared to 93.2 (5.4)
% at baseline and 87.7 (5.8) % at 8 hours in the saline group; P=0.08). These
data were extrapolated, adjusting for total circulating blood monocyte counts;
whereas the estimated numbers of circulating classical blood monocytes fell by
8 hours in the saline group (from 0.50 (SD 0.2) to 0.43 (0.2) xl09/L), they rose
in the LPS group (from 0.44 (0.1) to 0.65 (0.2) xl09/L; between-groups
comparison, P<0.01).
Each of the blood monocyte subsets was further characterised by the relative
intensity of expression of a number of cell surface markers: HLA-DR, CX3CR1,
CCR2, CD64, CDllb and CD62L. The pattern of expression of these markers by
each monocyte subset was not altered by LPS inhalation, when compared to
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saline. The results showed clear differences between the two CD16+ monocyte
subsets, with intermediate monocytes demonstrating stronger expression of
CCR2, CD62L and CD64 than non-classical monocytes, whereas non-classical,
unlike intermediate, monocytes strongly expressed CX3CR1 (Table 3D).








HLA-DR + ++ ++
CD14 ++ ++ +
CD16 - + ++
CCR2 + + -
CX3CR1 - + ++
CDllb ++ ++ +
CD62L ++ + -
CD64 ++ ++ -
The expression of cell surface antigens by each monocyte subset is defined as high (++),
intermediate (+) or low/negative (+/-) according to the RFI for GMF.
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f) Cell surface marker expression by blood neutrophils
Flow cytometry was also used to identify blood neutrophils at each time-point
(Figure 3e). Levels of expression of CD16, CDllb, CD62L and CD64 by blood
neutrophils did not change after LPS inhalation.
g) Blood CD4+ T cells and Treg cells
CD4+ and CD8+ T cells and Treg cells in blood were identified as shown in Figure
3f. The proportion of peripheral blood CD4+ T cells (out of total CD3+ T cells)
was not influenced by LPS inhalation (mean of 54.9 (SD 4.2) % at 0 hours and
51.5 (2.2) % at 8 hours in the LPS group, versus 61.0 (5.2) % and 58.7 (7.8) % in
the saline group; P=0.44). Likewise, the proportion of Treg cells (out of total CD4+
T cells) in peripheral blood remained stable after LPS inhalation (mean 8.1 (SD
2.4) % at 0 hours and 7.6 (1.6) % at 8 hours in the LPS group, versus 8.7 (1.2) %
and 8.3 (0.7) % in the saline group; P=0.98).
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3.5 THE EFFECTS OF LPS INHALATION AS MEASURED IN BAL FLUID
a) BAL volume and total cell count
There was greater variability in the volume of BAL fluid collected from subjects
in the LPS group compared to the saline group accompanied by a trend towards
a lower mean volume of BAL fluid collected from the LPS group, although this
did not quite reach significance (mean of 79 (SD 35) ml in the LPS group, versus
111 (12) ml in the saline group; P=0.06) (Figure 3g).
In both groups, the mean % of non-viable cells was <16% of the total automated
cell count. There were a significantly greater number of total viable cells per ml
of BAL fluid in the LPS group, when compared with saline placebo (mean of 3.12
(SD 1.35) xl05/ml in the LPS group, versus 1.10 (0.35) xl05/ml in the saline
group; P=0.006) (Figure 3g).
Figure 3g: Volume of BAL fluid retrieved (A) and total viable cell counts per ml (B)
Data are displayed as box (median/lQR) and whiskers (range); n=6 for the saline group and n=5
for the LPS group. Statistical analysis was by 2-sample t-test; * P<0.05.
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b) BAL cell content (light microscopy)
Cytospins of BAL fluid demonstrated a prominent BAL neutrophilia in subjects
who had inhaled LPS compared with very few neutrophils in the BAL fluid of
subjects who had inhaled saline placebo (Image 3a).
Image 3a: Cytospins of BAL fluid viewed using a light microscope
Representative images of BAL cells photographed at 400x magnification, from one subject from
the saline group (Panel A] and one subject from the LPS group (Panel B).
Differential cell counts confirmed a much greater relative proportion of
neutrophils (as a % of total BAL cells) and a much smaller relative proportion of
AMs in the LPS group when compared to the saline group (Table 3E).
Distinguishing other types of BAL cells by simple light microscopy is widely
acknowledged to be less straightforward. Indeed, it can be difficult to accurately
distinguish monocytes from other leucocytes within peripheral blood (Robbins
and Swirski, 2010); likewise, monocyte-like cells in BAL vary in appearance and
may resemble smaller alveolar macrophages, but they can also be confused with
large, activated T lymphocytes (Ward and Walters, 2001). Lymphocytes and
monocyte-like cells were therefore counted as a single 'mononuclear cell'
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category: the relative proportion ofmononuclear cells was similar between the
groups.
Table 3E: Relative proportions of each cell type present in 6AL fluid
CELL TYPE SALINE GROUP LPS GROUP
Alveolar macrophages 97.4 (0.7) 73.8(18.4) *
Mononuclear cells 2.0 (0.7) 3.2 (1.3) NS
Neutrophils 0.6 (0.4) 23.1 (18.4) *
Data are expressed as mean (SD); n=6 for saline group; n=5 for LPS group; statistical analysis
was by 2-sample t-test; * P<0.05.
As could be anticipated from the greater relative proportion of neutrophils
present in the BAL fluid of the LPS subjects, adjusting for total viable cell
number demonstrated a significantly greater absolute number of neutrophils
per ml of BAL fluid in the LPS group (mean of 172.3 (SD 187.0) xl03/ml, versus
0.7 (0.4) xl03/ml in the saline group; P=0.04) (Figure 3h).
Despite the lower relative proportion ofAMs present in the BAL fluid of LPS
subjects, adjusting for total viable cell number still revealed a significantly
greater absolute number ofAMs per ml of BAL fluid in the LPS group compared
to the saline group (mean of 213.4 (SD 58.3) xl03/ml in the LPS group, versus
107.2 (33.8) xl03/ml in the saline group; P=0.004) (Figure 3h).
Adjusting for total viable cell number also revealed a much greater absolute
number of MNCs per ml of BAL fluid in the LPS group (mean of 10.6 (SD 6.6)
xl03/ml, versus 2.3 (1.2) xl03/ml in the saline group; P=0.01) (Figure 3h).
126
Chapter 3: Results of Study A
Figure 3h: Estimated numbers of (A) AMs, (B) MNCs and (C) neutrophils, per ml of
BAL fluid
Data are presented as box (median/IQR) and whiskers (range); n=6 for the saline group and
n=5 for the LPS group; statistical analysis was by 2-sample t-test; * P<0.05; ** P<0.005.
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c) BAL cell content (flow cytometry)
Unlike light microscopy, flow cytometry enabled accurate distinction of
monocyte-like cells from small AMs or large lymphocytes. The effect of LPS
inhalation on the proportions of monocyte-like cells in BAL could then be
determined.
Flow cytometry plots of FSC-A versus SSC-A revealed clear differences in BAL
cell populations between the saline and LPS groups (Figure 3i). High numbers of
neutrophils were again clearly evident in BAL from subjects within the LPS
group. Furthermore, another clear population of cells distinct from neutrophils,
lymphocytes or AMs was present in the FSC-A versus SSC-A plots of BAL from
subjects in the LPS group (albeit this population was less clear in the flow
cytometry plots for the saline group subjects). Further analysis of these cells
showed that, unlike neutrophils, they were HLA-DR+ and that, like peripheral
blood monocytes, they could be divided into subsets according to their relative
expression of CD14 and CD16 (Figure 3j). These cells were termed 'pulmonary
monocyte-like cells' (PMLCs).
As shown in Figure 3j, a CD14++CD16+ subset (reminiscent of intermediate
blood monocytes) was predominant in BAL from the saline subjects. These cells
were termed 'resident' (rPMLC subset). In BAL from the LPS subjects, however,
there was a dramatic expansion in the proportion of the CD14++CD16" subset
(reminiscent of classical blood monocytes). These cells were therefore termed
'inducible' (iPMLC subset). Table 3F illustrates the marked difference in the
relative % of rPMLC and iPMLC in the LPS and saline groups.
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Table 3F: The relative % of rPMLC and iPMLC in BAL fluid
PMLC SUBTYPE SALINE GROUP LPS GROUP SIGNIFICANCE
rPMLC (CD14++CD16+) 65.1 (18.1) 11.6(5.9)
** P=0.0008
iPMLC (CD14++CD16) 34.9(18.1) 88.4 (5.9)
Data are presented as mean (SD) % of total PMLCs (rPMLC plus iPMLC) identified in BAL fluid;
n=6 in the saline group and n=5 in the LPS group; statistical analysis was by 2-sample t-test; **
indicates a significance level of P<0.005.
Therefore, unlike light microscopy, flow cytometry allowed clear distinction of
PMLCs from AMs and lymphocytes using size and granularity. Analysis of cell
surface antigen expression showed that, like blood monocyte subsets, PMLC
subsets could be distinguished by relative CD14 and CD16 expression, although
no CD14+CD16++ PMLC subset (equivalent to non-classical monocytes) was
present in BAL fluid from either group. Unlike DCs, PMLCs expressed CDllb and
high levels of CD14. PMLCs also differed from blood monocytes in that they
expressed CD206, a marker ofmonocyte maturation (Figure 3k).
Figure 3k: CD206 expression by (A) blood monocytes and (B) PMLCs in BAL
Representative plots are shown for a subject from the saline group. Similar CD206 expression
was seen in subjects from the LPS group. The blue lines represent CD206 negative
(isotype/unstained] controls and the red lines represent CD206 expression by each of the cell
populations.
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The proportion of Treg cells in BAL was calculated as for blood, as a proportion
of total CD3+CD4+ cells (Figure 3f, Page 123). A significantly lower proportion of
Treg cells was present in BAL fluid after LPS compared to saline inhalation (3.4
(SD 0.7) % versus 6.8 (0.7) % respectively; P=0.01); however, total cell numbers
(and estimated MNC numbers) were much higher in BAL fluid from subjects
who had inhaled LPS. It is therefore unlikely that the absolute numbers of Treg
cells in BAL were lower after LPS inhalation.
d) Levels of protein in BAL fluid supernatant
There was much greater variability in mean protein concentration in the BAL
supernatants from subjects in the LPS group and a trend towards a higher mean
protein concentration, although this did not quite reach significance (median
BAL protein of 0.15 [IQR 0.1 - 0.4] g/L in the LPS group, versus 0.08 [0.06 -
0.09] in the saline group, P=0.08 (Figure 31).
The dilution factor was calculated for each BAL fluid sample, using plasma and
BAL urea concentrations (as outlined in Methods, Chapter 2, Page 103). There
was a non-significant trend towards more concentrated BAL in the LPS group
(mean BAL dilution factor of 17.6 (SD 4.5), versus 27.0 (7.7) in the saline group;
P=0.09). The BAL protein concentrations were adjusted for BAL dilution; there
was no significant difference in ELF protein concentrations between the groups
(median ELF protein of 2.9 [2.0 - 4.8] g/L in the LPS group compared to 2.2 [1.4
~ 2-9] g/L in the saline group; P=0.31) (Figure 31).
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Figure 31: Protein concentrations in BAL fluid supernatant (Panel A) and in ELF,
after adjustment for BAL dilution (Panel B)
Data are displayed as box (median/IQR) and whiskers (range); n=6 for the saline group, n=5 for
the LPS group. Statistical analysis was by MWU test.
e) Levels of inflammatory markers in BAL fluid supernatant
Compared to subjects who had inhaled saline, there were significantly higher
concentrations of IL-6 and MCP-1 in BAL fluid supernatant from subjects who
had inhaled LPS (Table 3G). There was also a trend towards higher
concentrations of IL-8 in the LPS group subjects; this became significant after
adjustment for BAL dilution factor. 1L-10 levels were undetectable in all subjects
from both groups. Levels of TNFa were undetectable in 5 subjects from the
saline group, compared to 2 subjects from the LPS group.
133
Chapter 3: Results of Study A
Table 3G: Cytokines and inflammatory markers in BAL fluid supernatant
CYTOKINE/MARKER SALINE GROUP LPS GROUP
IL-6 (pg/ml) 56 [x - 94] 159 [139-349] **
IL-8 (pg/ml) x [x-51] 79 [67-120]+
MCP-1 (pg/ml) x [x - 26] 81 [60-117] **
RAGE (pg/ml) 1980 [834-2890] 1690 [544 - 2780] NS
TNFa (pg/ml) x [x -17] 34 [x-51] NS
Data are presented as median [IQR]; n=6 in the saline group; n=5 in the LPS group. Statistical
analysis was by MWU test, x denotes a concentration below the lower limit of detection of the
assay (9.4 pg/ml for IL-6, 31.3 pg/ml for IL-8,15.6 pg/ml for MCP-1 and TNFa and 62.5 pg/ml
for RAGE], ** P<0.005; + P=0.03 after correction for BAL dilution; NS non-significant.
3.6 CONCLUSIONS FROM STUDY A
a) Safety of LPS inhalation
As discussed in Chapter 1, LPS inhalation is an established model of early acute
lung inflammation in healthy human volunteers. Critically, it appears to be safe,
typically producing only mild and short-lived 'flu-like symptoms. Furthermore,
LPS inhalation, at a dose similar to that used in this study, induces pulmonary
and systemic inflammation characteristic of changes seen in early AL1 (Maris, De
Vos, Dessing, et al., 2005; Michel et al., 1997; Shyamsundar et al., 2009).
Consistentwith this previous literature, in this study LPS inhalation appeared
safe, causing no serious adverse events. Furthermore, all symptoms attributable
to LPS inhalation (including pyrexia, myalgia and cough) were mild and self-
limiting. At the dose used (60 gg), there was no clearly discernible effect on
spirometry. Two subjects reported cough (and this may have been a side effect
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of bronchoscopy) but there were no reports of chest tightness, wheeze or
breathlessness suggestive of bronchospasm. One subject from the saline group
reported symptoms of pyrexia, occurring several hours after BAL. Post-BAL
pyrexia is a recognised phenomenon occurring in about 10-30% of cases
(Ettensohn etal, 1988; Krause etal., 1997).
b) Efficacy of LPS inhalation as a model of inflammation
As intended, LPS inhalation was associated with clinical and biological evidence
of inflammation, both systemically in blood and locally in BAL fluid. Firstly,
compared to inhalation of saline placebo, inhalation of LPS caused significant
rises in temperature and heart rate. Secondly, inhalation of LPS induced a sharp
rise in peripheral blood neutrophil counts, peaking at 8 hours from baseline.
The mean increment by 8 hours in circulating blood neutrophils in LPS subjects
was 5.2 xl09/L, compared to a reduction of 0.1 xl09/L in the saline group
subjects. There was, however, a later (albeit mostly much smaller) peak in blood
neutrophil counts in the saline group, at 24 hours. This is most likely to be
secondary to a direct inflammatory effect of BAL, which has been previously
documented to cause a rise in blood neutrophil counts in healthy volunteers
(Terashima, 2001; Essen etal., 1991). Indeed, there was an extremely
pronounced blood neutrophilia at 24 hours in the subject from the saline group
who had reported post-BAL pyrexia, although his symptoms had already
resolved and he otherwise remained well.
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In terms of pulmonary inflammation, the total number of cells per ml of BAL
fluid was almost three times greater in the LPS than the saline subjects,
indicating LPS-induced cellular influx into the alveolar space. Both microscopic
and flow cytometry analysis of BAL fluid demonstrated much larger numbers of
neutrophils present after inhalation of LPS. There was also a clear trend
towards higher protein levels in BAL after LPS inhalation, although this did not
reach significance. Furthermore, IL-6 and MCP-1 concentrations were
significantly higher in BAL from subjects who had inhaled LPS compared to
saline placebo.
c) Pulmonary monocyte-like cells (PMLCs)
Using light microscopy to accurately identify monocyte-like cells in BAL proved
problematic for the reasons already mentioned; however, we successfully used
flow cytometry to confirm the presence ofmonocyte-like cells in the human
alveolar space and then to further investigate their phenotype. As discussed in
detail in the Introduction (Page 70), monocyte-like cells have been described in
human sputum or BAL, using varying nomenclature, in several inflammatory
conditions (including COPD, ILD, HIV-related lung disease, CF and ALI) and, in
much smaller numbers, in healthy volunteers. However, their exact phenotype
and similarity to blood monocytes has not been previously investigated.
In agreement with previous studies, monocyte-like cells in BAL were smaller
and less granular than AMs. Although reminiscent of circulating monocytes,
monocyte-like cells appeared phenotypically distinct from blood monocytes, in
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particular with regards to their expression of CD206 (a marker of
monocyte/macrophage maturation). To my knowledge, this has not been
previously demonstrated and these cells were therefore termed PMLCs.
Furthermore, for the first time, I have further characterised these cells
according to CD 14 and CD 16 expression into two clear subtypes. Small numbers
of PMLCs were present in the control subjects who had inhaled saline and these
were mainly CD14++CD16+ ('resident', rPMLCs, reminiscent of intermediate
blood monocytes). After LPS inhalation, much larger numbers of PMLCs were
present and the predominant subtype was CD14++CD16" ('inducible', iPMLCs,
reminiscent of classical blood monocytes).
An accumulation of iPMLCs in the alveolar space therefore appears to be part of
the LPS-induced inflammatory cascade. These cells are likely to correspond to
the 'alveolar monocytes' described previously in patients with ARDS (Rosseau et
al., 2000) although further work is clearly required to confirm this. As described
in the Introduction (Page 62), studies in Cx3crlgfP/+ mice using intravital
microscopy have demonstrated accumulation of the Ly6Chish monocyte subset
(equivalent to the human classical monocyte subset) in ischaemic myocardial
tissue (Swirski et al., 2009). In this study, I have demonstrated a rise in the
estimated number of circulating classical blood monocytes after LPS inhalation.
It is therefore interesting to speculate that the alveolar accumulation of iPMLCs
seen in this study may represent LPS-induced transmigration of classical blood
monocytes across the pulmonary endothelial-alveolar epithelial barrier.
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There was no PMLC subtype akin to non-classical blood monocytes in the BAL
fluid of any of the subjects. It has been argued that non-classical blood
monocytes represent the more mature end of a spectrum (Gordon and Taylor,
2005; Robbins and Swirski, 2010; Wong et al., 2011); perhaps the absence of a
CD14+CD16++ PMLC subset indicates direct maturation of other PMLC subtypes
into AMs.
d) Blood monocytes and Treg cells
As discussed in the Introduction (Page 65), there is now clear evidence to
support three distinct human monocyte subsets, which has lead to a new
classification system where CD16+ monocytes can be subdivided into
intermediate and non-classical types (Ziegler-Heitbrock etal., 2010). In line
with previous research, I have shown that classical monocytes are CD14++CD16"
and that they strongly express CCR2, CDllb, CD62L and CD64. Non-classical
monocytes were CD14+CD16++ and demonstrated very strong expression of
CX3CR1 and HLA-DR, with weaker expression ofCDllb and no expression of
CCR2, CD62L or CD64. Intermediate monocytes were CD14++CD16\ also
strongly expressed HLA-DR and displayed intermediate expression of CDllb,
CD62L and CD64. These findings strongly support the new blood monocyte
nomenclature.
Swirski's group demonstrated the presence of a large monocyte reservoir
within the murine spleen, which (unlike monocytes from bone marrow) is
rapidly mobilised after coronary ligation (Swirski et al., 2009). It is not known if
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there is a similar splenic monocyte reservoir in humans. In this study, I have
shown a trend towards a rise in total blood monocyte counts 8 hours after LPS
inhalation. Furthermore, when compared to saline, LPS inhalation caused a
significant rise in the estimated numbers of circulating classical monocytes at 8
hours. Higher proportions of classical monocytes in human blood have been
linked to greater cardiovascular risk and also to increased mortality in stroke
patients (Berg et al., 2012; Urra et al., 2009).
Other cell types have also been implicated in the pathogenesis ofALI
(Caudrillier et al., 2012; D'alessio et al., 2009; Looney et al., 2009; Venet et al.,
2009). LPS inhalation did not appear to affect blood lymphocyte counts,
CD4:CD8 ratio or the proportion of Treg cells, when compared to saline control.
Platelet levels were also unaffected by LPS inhalation. Although the proportion
of BAL Treg cells (as a % of CD3+CD4+ cells) dropped after LPS inhalation, the
dramatic rise in total BAL cell numbers in BAL could mean that absolute
numbers of Treg cells in BAL rise after LPS. Treg cells are thought to be involved in
the resolution phase of the inflammatory cascade and there is preliminary
evidence that their numbers increase in BAL fluid from patients with ALI
(D'Alessio etal., 2009).
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3.7 LIMITATIONS OF STUDY A
a) Subject demographics arid sample size
The groups were well matched in terms of baseline characteristics; however,
the low mean age and gender restriction may have limited the relevance ofmy
results, especially as gender may influence the response to IV LPS (Coyle et al.,
2006; Van Eijk et al., 2007). All three ofmy studies were restricted to subjects
between the ages of 18 and 40, in order to limit the risk of undetected health
problems that could compromise subject safety and data interpretation. All the
studies were restricted to male subjects to maintain a consistent approach
(ethical approval for Study C depended upon removing any potential radiation
exposure from PET-CT scanning to an unborn foetus).
The main limitation of this study was the small sample size of six subjects in
each group. This limited statistical power, in particular with regards to whether
inhaled LPS causes a definite rise in circulating blood monocyte count (a finding
that would support the early mobilisation of a human splenic monocyte
reservoir in response to inflammation, equivalent to that seen in mice). The
estimated numbers of classical monocytes did appear to rise after LPS; however,
this (and the effect upon numbers of other monocyte subsets) requires further
confirmation using a larger sample size.
Small sample size is also likely to explain why the trends toward higher BAL
protein and IL-8 levels after LPS inhalation did not reach significance, as they
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have done in previous studies (Maris, De Vos, Dessing, etal., 2005;
Shyamsundar et al, 2009).
b) Cell identification by light microscopy
Another limitation of this study relates to the difficulties in accurately
distinguishing monocyte-like cells by light microscopy, as they can resemble
large lymphocytes or small AMs (Ward and Walters, 2001). We therefore aimed
to categorise monocyte-like cells along with lymphocytes as 'mononuclear cells'.
As expected, there was a rise in the number ofMNCs present in BAL after LPS
inhalation. Although the overall proportion ofAMs in BAL fell after LPS
inhalation, when corrected for total cell number there was actually a rise in the
number ofAMs per ml of BAL after LPS inhalation; this may reflect partial
misclassification ofmonocyte-like cells as small AMs rather than an actual
proliferation ofmacrophages within the alveolar space. Flow cytometry allowed
us to more accurately classify BAL cell types, although it did not provide us with
absolute cell numbers (estimated numbers of each cell type were instead
derived from the cell proportion multiplied by the total, automated cell count).
c) BAL as a means of analysing alveolar inflammation
Analysing BAL fluid provides extremely useful information in the drive to
understand the pathophysiology of lung inflammation; however, it does have
some inherent limitations. The concentration of ELF within a sample of BAL
fluid is dependent upon the sample dilution. Although the same volume of
lavage fluid was used in each subject, this cannot guarantee that an equal BAL
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return volume or concentration is obtained (Baughman, 1997). Indeed, there
was a trend towards lower and more variable BAL fluid volumes in the subjects
who had inhaled LPS (which may, from simple observation, have been due to an
increased tendency for the LPS subjects to cough during bronchoscopy).
Adjusting for BAL dilution using the urea method (Rennard et al., 1986) did not
have a great impact upon the results, indicating that variable BAL dilution was
not likely to be a major issue. Another potential drawback of BAL is that only
one lobar segment is sampled, which may mean that BAL fluid is not
representative of overall alveolar inflammation throughout both lungs.
Furthermore BAL only samples the alveolar space, not the pulmonary
interstitium, and is therefore potentially not representative of'whole' lung
inflammation (Reynolds, 2000; Schultheis and Bassett, 1991). The process of
BAL itself can induce inflammation (as seen by the rise in blood neutrophil
counts in the saline subjects at 24 hours). It is also difficult to ethically justify
performing BAL at more than one time-point in healthy subjects. Many previous
LPS inhalation studies have used induced sputum instead of BAL to analyse
alveolar inflammation (for example Michel etal., 1997; Michel etal., 1997;
Thorn and Rylander, 1998). Although obtaining induced sputum is a less
invasive procedure than bronchoscopy and can be more easily repeated (i.e.
data can be easily obtained from more than one time-point), sputum is less
likely than BAL to contain cells from the alveolar space and much more likely to
contain a significant number of cells originating from the proximal bronchial
tree (Alexis et al., 2001; Antoniou et al., 2005; Lensmar et al., 1998).
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Despite the limitations above, BAL remains a valuable research tool; this study
used a consistent, standardised method for both bronchoscopy and BAL to try to
minimise variability (Haslam and Baughman, 1999).
d) The LPS inhalation model
The LPS model of lung inflammation has some limitations. It activates the innate
immune system transiently, whereas true pathological stimuli are likely to be
more prolonged. ALI is a heterogeneous condition in that it has many different
causes; inhalation of LPS models only pulmonary (as opposed to non-
pulmonary) causes ofALI. Distribution of LPS throughout the lungs may be
uneven when it is given by inhalation, although careful administration should
minimise this (Brand etal, 2000; Hakkinen etal., 1999; Popa, 2001). Some
studies of LPS-induced lung inflammation have used bronchial (segmental)
instillation to enable more controlled deposition while also providing an intra-
subject control (using saline lavage of a lobar segment of the opposite lung),
although this procedure requires bronchoscopy at baseline and is therefore a
much more invasive technique to use in healthy volunteers (Chen etal., 2006;
Hoogerwerf etal., 2008; O'Grady etal., 2001). Despite its limitations, LPS
inhalation as performed in this study provides a controlled, consistent model of
early pulmonary inflammation that is safe and acceptable to healthy subjects.
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3.8 SUMMARY OF STUDY A
In conclusion, Study A fulfilled its primary objective as a preliminary test of the
safety and efficacy of LPS inhalation prior to commencing the RCT. Furthermore,
I was able to use flow cytometry to demonstrate the presence of PMLCs in
human BAL fluid which were distinct from peripheral blood monocytes and that
could be clearly divided into two subtypes. Finally, I showed an LPS-induced
accumulation of the iPMLC subtype that may represent transmigration of
classical monocytes from blood and that may be integral to the development of
the alveolar neutrophilia typical ofALL
Having completed Study A, I performed a second preliminary study in a
separate group of healthy subjects, this time examining the use of leukapheresis
for blood monocyte depletion.
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CHAPTER 4: RESULTS OF STUDY B
4.1 OVERVIEW
This chapter describes the results of Study B, which looked at MNC depletion by
leukapheresis in a group of six healthy subjects.
The main aims of this study were:
• To ensure the safety and efficacy of leukapheresis as a means of
monocyte depletion in healthy subjects
• To examine the extent ofmonocyte depletion achieved by
leukapheresis
• To determine whether leukapheresis itself has any direct systemic or
pulmonary inflammatory sequelae, in particular whether it affects
blood neutrophil counts or BAL neutrophil, protein and cytokine content.
This chapter will first outline subject recruitment and demographic data,
symptoms, adverse events and the effects of leukapheresis on clinical
parameters. It will then provide data on the extent and nature of cell depletion
by MNC leukapheresis in relation to the FBC data. The effects of leukapheresis
on the cellular, protein and inflammatory marker content of BAL fluid will also
be presented.
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4.2 SUBJECTS
a) Subject recruitment
Six subjects were recruited into the study as illustrated in the CONSORT
diagram (Figure 4a). Blood and BAL data are complete for all six subjects;
however, antibody staining of the MNC collection for flow cytometry was only
successful in three of the six subjects.
Figure 4a: CONSORT diagram illustrating volunteer recruitment, enrolment and
follow-up during Study B
+ Reasons for exclusion: elevated bilirubin (n=l); current smoker (n=l).
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b) Subject demographics
The baseline characteristics of the subjects are outlined in Table 4A. These were
broadly similar to the characteristics of the Study A subjects (see Table 3A, Page
112), although mean age was slightly lower and mean spirometry values were
slightly higher.
Table 4A: Study B subject demographics at baseline
BASELINE CHARACTERISTIC MNC LEUKAPHERESIS GROUP
Age (years) 20.5(1.0)
Ethnicity 6/6 Caucasian
Height (metres) 1.83 (0.05)
Weight (kg) 75.7 (4.9)
FEVi (litres) 5.01 (0.53)
FVC (litres) 5.77 (0.56)
Temperature (°C) 35.9 (0.5)
Heart rate (minute *) 66 (9)
Oxygen saturations (%) 98(1)
Data are presented as mean (SD); n=6.
The subjects' mean estimated TBV was 5.335 (SD 0.293) L. All six subjects had 4
TBVs processed during leukapheresis (mean of 4.1, SD 0.1), equivalent to a
mean processed blood volume of 21.6 (SD 1.2) L. The mean duration of
leukapheresis was just over 6 hours, at 370 (SD 29) minutes. There was little
variability in the amount ofACD-A used for anticoagulation during the
procedure (mean 1701 (SD 190) ml).
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c) Symptoms and adverse events
Four subjects reported a mild sore throat following bronchoscopy, all symptoms
resolving within 24 hours of discharge. Three volunteers described facial
and/or digital paraesthesiae during their leukapheresis procedure consistent
with citrate-induced hypocalcaemia, all of which resolved with treatment. The
first subject required 6 doses of oral calcium in total; the other 5 volunteers
were therefore given a combination of oral and IV calcium supplementation
during leukapheresis, which effectively minimised symptomatic hypocalcaemia.
4.3 THE EFFECTS OF LEUKAPHERESIS ON CLINICAL PARAMETERS
There was a small but significant rise in mean temperature during the course of
leukapheresis (mean temperature of 35.9 (SD 0.5) °C at baseline compared to
36.6 (0.1) °C after leukapheresis; P=0.02) (Table 4B). Other clinical parameters
were unaffected by MNC leukapheresis.
Table 4B: Clinical parameters at baseline and after leukapheresis
CLINICAL PARAMETER AT BASELINE AFTER LEUKAPHERESIS
Temperature (°C) 35.9 (0.5) 36.6 (0.1) *
HR (minute1) 72(14) 66 (9) NS
sBP (mmHg) 123 (28) 119 (32) NS
RR (minute_1) 14 (13 -14) 15(14-16) NS
Sa02 (%) 98(1) 99 (1) NS
Data are presented as mean (SD] or median [IQR]; n=6. Statistical analysis by paired t-test or
Wilcoxon signed rank test; * P<0.05.
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4.4 CELL RETRIEVAL AND YIELD FROM LEUKAPHERESIS
a) Cell retrieval
The MNC collections retrieved by leukapheresis varied little in volume (mean of
0.345 (SD 0.029) litres). Table 4C lists the numbers of each cell type collected by
MNC leukapheresis, derived from automated cell counts performed on a
representative sample. As anticipated, leukapheresis removed large numbers of
monocytes, lymphocytes and platelets but very few neutrophils, basophils or
eosinophils. Indeed, a small number of neutrophils (0.98 xlO9) were only
sequestered in the MNC collection of one of the six subjects.
Table 4C: Cell counts in the mononuclear cell collections
CELL TYPE TOTAL CELL NUMBER (xlO9)
RBCs 165 (37.9)
Platelets 986 (137)






Data are presented as mean (SD] or median [IQR]; n=6.
b) Monocyte yield
There was a very strong correlation between the total number ofmonocytes
depleted (and therefore present in the MNC collection at the end of
leukapheresis) and the respective total circulating monocyte count at baseline
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(r=0.98 [CI0.95 0.82,1.00]) (Figure 4b, Panel A). The median yield ofmonocytes
from leukapheresis (the total number ofmonocytes in the MNC collection
divided by the total number of baseline circulating blood monocytes) was 2.3
[IQR 2.2 - 3.1].
c) Lymphocyte yield
Panel B in Figure 4b shows the correlation between the total number of
lymphocytes depleted by leukapheresis and the respective total circulating
lymphocyte count at baseline (r=0.83 [CI0.95 0.04, 0.98]. The mean yield of
lymphocytes from MNC leukapheresis was 2.1 (SD 0.32).
d) Platelet yield
There was also a correlation between the total number of platelets depleted and
the respective total circulating platelet count at baseline (r=0.87 [CI0.95 0.19,
0.99]) (Figure 4b, Panel C). Mean platelet yield from leukapheresis was 0.85 (SD
0.09).
e) RBC yield
There was no clear correlation between the total number of RBCs depleted by
leukapheresis and the respective total circulating RBC count at baseline (r=-0.34
[CI0.95 -0.90, 0.65]) (Figure 4b, Panel D). Mean RBC yield was 0.006 (SD 0.002).
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Figure 4b: Correlations between (A) baseline blood monocyte, (B) lymphocyte, (C)
platelet and (D) RBC counts and the corresponding MNC collection cell counts
n=6; statistical analysis by Pearson's test.
4.5 THE EFFECTS OF LEUKAPHERESIS AS MEASURED IN BLOOD
a) Circulating blood neutrophil counts
Mean circulating blood neutrophil count remained stable at 8 hours (3.25 (SD
2.00) xl09/L, compared to a baseline mean of 3.13 (1.71) xl09/L; P=0.65)
(Figure 4c, Panel A). There was, however, a significant rise in mean circulating
blood neutrophil count by 24 hours when compared to baseline (5.38 (SD 1.79)
xl09/L; P=0.03). As before, the sixth subject had obviously higher circulating
blood neutrophil counts at all time-points, including at baseline.
b) Circulating blood monocyte counts
There was a significant fall in median circulating blood monocyte count by 8
hours (to 0.32 [IQR 0.21 - 0.65] xl09/L, from a baseline of 0.50 [0.30 - 0.86]
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xl09/L; P=0.03) (Figure 4c, Panel B). Median circulating blood monocyte count
at 24 hours had recovered to a level just above baseline (0.59 [IQR 0.53 - 0.87]
xl09/L; P=0.22). The sixth subject had higher counts at all time-points, including
at baseline, although the pattern over time was otherwise similar.
c) Circulating blood lymphocyte counts
There was a significant fall in mean circulating blood lymphocyte count by 8
hours (to 1.61 (SD 0.32) xl09/L, compared to a baseline of 2.14 (0.41) xl09/L;
P=0.0004) (Figure 4c, Panel C). This fall in mean circulating blood lymphocyte
count persisted at 24 hours (with a mean of 1.60 (SD 0.29) xl09/L; P=0.02).
d) Circulating blood platelet counts
There was also a significant fall in median circulating blood platelet count by 8
hours (to 93 [IQR 76 - 133] xl09/L, from a baseline of 196 [188 - 285] xl09/L;
P=0.03) (Figure 4c, Panel D). This fall in median circulating blood platelet count
persisted at 24 hours (103 [IQR 88 - 144] xl09/L; P=0.03).
e) Circulating RBC counts
Mean circulating RBC count fell significantly by 8 hours, from a baseline of 4.96
(SD 0.08) xl012/L to 4.61 (0.07) xl012/L (P=0.0004) (Figure 4c, Panel E). Mean
circulating RBC count had, however, recovered to baseline levels by 24 hours
(mean of 4.88 (SD 0.16) xl012/L; P=0.29).
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Figure 4c: Circulating blood neutrophil (A), monocyte (B), lymphocyte (C), platelet
(D) and RBC (E) counts between baseline and 8 hours
MNC leukapheresis began at 2 hours and ended at around 8 hours. n=6; statistical analysis of the
change in blood cell counts between baseline and 8 hours was by paired t-test (for neutrophils,
lymphocytes and RBCs) or by Wilcoxon signed rank test (for monocytes and platelets); * P<0.05;
*** P<0.005.
f) Blood monocyte subsets
As for Study A, flow cytometry was used to calculate the relative proportions of
each blood monocyte subset, as a proportion of total HLA-DR+ monocytes, at
each time-point (see Figure 3d, Page 120). The mean proportion of classical
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monocytes at baseline was similar to the proportions seen in the Study A
subjects at baseline (93.0 (SD 1.7) %, compared to 93.2 (5.4) % in the saline
group and 90.6 (4.0) % in the LPS group), but rose significantly by the
completion of leukapheresis to 98.8 (1.0) % (P=0.01). After adjusting for the fall
in total circulating blood monocyte count after leukapheresis, the estimated
numbers of classical blood monocytes demonstrated a less marked reduction
(from 0.47 [0.38 - 0.81] to 0.32 [0.28 - 0.56] xl09/L at 8 hours) compared to
intermediate and non-classical monocytes. The proportion of classical
monocytes remained elevated at 98.7 (0.9) % at 24 hours (P=0.01), with the
estimated numbers of classical monocytes recovering to (and beyond) baseline
levels (0.59 [0.53 - 0.85] xl09/L).
4.6 MONOCYTE SUBSETS RETRIEVED BY LEUKAPHERESIS
Flow cytometry was also used to identify monocytes and their subsets within
three of the MNC collections retrieved by leukapheresis, using a gating strategy
similar to that used for blood (Figure 4d). The mean proportion of classical
monocytes within the MNC collections was 84.1 (SD 9.2) %; this compared to
93.1 (1.0) % in peripheral blood at baseline in the same subjects. Intermediate
monocytes made up a mean of 8.0 (SD 6.2) % ofmonocytes within the MNC
collections, compared to 1.7 (0.2) % in baseline peripheral blood. The mean
proportion of non-classical monocytes within the MNC collections was 7.9 (SD
4.3) %, compared to 5.2 (1.9) % at baseline in peripheral blood.
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4.7 THE EFFECTS OF LEUKAPHERESIS AS MEASURED IN BAL FLUID
a) BAL volume and total cell count
The mean volume of BAL fluid collected was 72 (SD 44) ml (slightly lower than
the mean of 111 (12) ml retrieved from the Study A saline subjects). The median
total viable cell count in BAL was 2.18 [IQR 1.38 - 4.80] x 105/ml, higher than
the mean of 1.10 (SD 0.35) xl05/ml in the Study A saline subjects. The mean
proportion of non-viable cells was <20% of the total automated cell count.
b) BAL cell content (light microscopy)
As discussed in the previous chapter, accurately identifying cell types in BAL
fluid by light microscopy proved difficult. Lymphocytes and monocyte-like cells
were therefore again counted under a single MNC category. The median
proportion of AMs in BAL fluid was 96.7 [IQR 89.7 - 98.5], compared to 97.4
[96.7 - 98.1] in the saline group from Study A. Neutrophils made up a median
proportion of 1.7 [IQR 0.2 - 8.2] %, compared to 0.7 [0.2 - 0.9] % in the saline
group from Study A. Interestingly, the sixth subject (who had higher circulating
neutrophil and monocyte counts at all time-points, including at baseline, and
who was the only subject to demonstrate neutrophil sequestration during
leukapheresis) also demonstrated an unexpectedly high BAL neutrophil content
of 10.3%. Finally, the median proportion of mononuclear cells in BAL fluid was
1.7 [IQR 0.8 - 2.7] %, compared to 2.1 [1.4 - 2.7] % in the saline group from
Study A.
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After adjusting for total cell counts, there was a median of 214.8 [IQR 132.7 -
431.5] xlO3 AMs/ml of BAL fluid, a median of 3.4 [0.1 - 38.3] xlO3
neutrophils/ml and a median of 3.0 [1.4 - 10.2] xlO3 MNCs/ml.
c) BAL cell content (flow cytometry)
As in Study A, flow cytometry was used to identify AMs, lymphocytes,
neutrophils, PMLCs and PMLC subtypes in BAL fluid. The cell populations visible
on FSC versus SSC plots (Figure 4e) appeared similar to those of the saline
group subjects from Study A (see Figure 3i, Page 129). However, in contrast to
the saline group subjects from Study A, the inducible (CD14++CD16) subtype of
PMLCs was more prominent, although not to the extent seen in the LPS group
subjects from Study A (see Figure 3j, Page 130). A mean of 56.7 (SD 8.7) % were
of the iPMLC subtype (reminiscent of classical monocytes), compared to 34.9
(18.1) % in the Study A saline subjects. A mean of 43.3 (8.7) % were of the
rPMLC subtype (CD14++CD16+, reminiscent of intermediate monocytes),
compared to 65.1 (18.1) % in the Study A saline subjects. As in Study A, there
was no clearly discernible population of CD14+CD16++ PMLCs (akin to non-
classical monocytes) in the BAL fluid of any of the six subjects.
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Figure 4e: Identifying PMLCs in BAL fluid after MNC leukapheresis
Example flow plots are shown from one representative subject (of n=6). Panel A demonstrates
the gate drawn to incorporate PMLCs and neutrophils on a FSC-A versus SSC-A plot. HLA-DR+
cells were then positively selected, in order to exclude HLA-DR neutrophils (Panel B). The two
PMLC subsets (rPMLCs and iPMLCsj were distinguishable using relative CD14 and CD16
expression (Panel C). Panel D is a contour plot containing the same cellular data as Panel C.
d) Levels of protein and inflammatory markers in BAL fluid supernatant
Mean BAL protein content was 0.11 (SD 0.06) g/L (very similar to the median
BAL protein content of 0.08 [IQR 0.06 - 0.09] g/L in the Study A saline subjects).
Concentrations of inflammatory markers in BAL fluid supernatant are presented
in Table 4D. As in the Study A saline subjects, BAL concentrations of TNFa were
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either undetectable or very low. Levels of RAGE were also very similar to those
in the saline subjects from Study A, although levels of IL-6 and IL-8 tended to be
a little higher (for comparison with Study A, see Table 3G on Page 134).
Table 4D: Concentrations of inflammatory markers in BAL fluid supernatant
INFLAMMATORY MARKER CONCENTRATION IN BAL (pg/ml)
IL-6 115 [49.5-167]
IL-8 51.0 [41.0-138.0]
MCP-1 24.0 [x- 72.0]
RAGE 2300 [1610-2680]
TNFa x [x -19.0]
Data are presented as median [IQR]; n=6. x denotes a concentration below the lower limit of
detection of the assay (9.4 pg/ml for IL-6, 31.3 pg/ml for IL-8,15.6 pg/ml for MCP-1 and TNFa
and 62.5 pg/ml for RAGE).
4.8 CONCLUSIONS FROM STUDY B
a) Safety of leukapheresis
Leukapheresis of four TBVs was safely used to deplete MNCs from circulating
blood in six healthy subjects, with no serious adverse events. As expected, the
procedure was well tolerated; the most common symptoms reported (facial and
digital paraesthesiae) were attributable to citrate-induced hypocalcaemia. The
prevalence of symptoms relating to citrate toxicity (50%) was higher in our
study than is reported in the literature (Donmez et al., 2011; McLeod et al.,
1999; Reik et al., 1997; Strauss, 1996), presumably due to the large volumes of
blood processed.
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The first volunteer had recurrent citrate-related symptoms requiring six doses
of oral calcium supplements. Previous studies of plasmapheresis and PBSC
collection have demonstrated effective control of citrate toxicity using IV
calcium infusions (Bolan, 2002; Weinstein, 1996). Therefore from the second
volunteer onwards, irrespective of symptoms, we commenced an IV calcium
infusion midway through leukapheresis which, together with oral calcium
supplements as needed, lead to prompt resolution of any paraesthesiae.
Crucially, none of the subjects developed any sign of infection as a consequence
of MNC leukapheresis. As discussed, one subject demonstrated evidence of a
possible subclinical infection, with higher blood monocyte counts and higher
blood and BAL neutrophil counts; however, he also had higher blood monocyte
and neutrophil counts at baseline. Despite this, he did not become unwell during
or after leukapheresis.
Despite the large volumes of blood processed and the long duration of the
procedures, none of the subjects reported feeling light-headed. Vasovagal
events have been estimated to occur in up to 5% of subjects undergoing
leukapheresis (Strauss, 1996).
b) Efficacy of leukapheresis for monocyte depletion
I processed a greater volume of blood (around 21 L) than is described in most of
the previous leukapheresis literature, and retrieved a median of 5.6 xlO9
monocytes. This further supports previous evidence of a strong correlation
between processed blood volume and the number ofmonocytes retrieved by
162
Chapter 4: Results of Study B
leukapheresis (Nguyen et al., 2002; Svensson et al., 2005; Wolf et al., 2005). For
example, three previous studies in healthy subjects processing 4.5 L, 9 L and 10
L blood have demonstrated retrieval of 0.98 xlO9 (Wolfeta/., 2005), 2.55 xlO9
(Svensson etal., 2005) and 2.09 xlO9 (Strasser etal., 2003) monocytes
respectively and a study in cancer patients demonstrated retrieval of 3.2 xlO9
monocytes after processing 11.7 L blood (Nguyen etal., 2002).
In line with this previous literature, I also found a very strong correlation
between the baseline circulating blood monocyte count and the number of
monocytes retrieved by leukapheresis. Furthermore, in my study, the number of
monocytes collected by leukapheresis was actually 2.3 times higher than the
number of circulating blood monocytes at baseline. This phenomenon has been
well documented, indicating monocyte repopulation of circulating blood during
leukapheresis (thus obtaining a 'collection efficiency' of >100%, or a
'recruitmentfactor' >1) (Alteri and Leonard, 1983; Bojanic etal., 2011; Strasser
et al., 2005; Svensson et al., 2005; Wolf et al., 2005).
c) Monocyte recruitment during leukapheresis
The extent ofmonocyte recruitment into circulating blood is demonstrated by
comparison of the pre- and post-leukapheresis blood monocyte counts. In this
study, the mean blood monocyte count at 8 hours was only 35% lower than that
at baseline, despite removal during leukapheresis ofmore than twice the
number of baseline circulating monocytes. Such a discrepancy is typical, with
many studies noting a much smaller than anticipated fall in circulating blood
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monocyte counts (Alteri and Leonard, 1983; Knudsen etal., 2001; Nguyen etal,
2002; Strasser etal., 2005; Wolf etal., 2005). This, together with the overshoot
seen in blood monocyte counts at 24 hours in this study (which were 20%
higher than baseline), provides further evidence for active large-scale
recruitment ofmonocytes into circulating blood during and after leukapheresis.
The exact origin of these newly recruited monocytes remains unclear.
Monocytes present in blood immediately post-leukapheresis do appear
temporarily immature in terms of chemotactic responses, perhaps indicating
early release from bone marrow (Alteri and Leonard, 1983). The rapidity and
extent ofmonocyte release is, however, surprising. More recent studies have
confirmed the existence in mice of both a marginating monocyte pool (Auffray
etal., 2007) and a reservoir ofmonocytes in the red pulp of the spleen (Swirski
etal., 2009). Furthermore, Swirski's group demonstrated rapid release of
splenic monocytes into the circulation in response to an inflammatory stimulus
(myocardial ischaemia), with no change in bone marrow monocyte content. If
splenic and/or marginating monocytes also exist in humans, their release into
circulating blood may explain the rapid monocyte repopulation seen during
leukapheresis.
In this study, I saw a small but significant rise in the proportion of classical
monocytes present in blood after leukapheresis. After adjusting for the overall
reduction in total blood monocyte count by 8 hours, this equated to a less
marked fall by 8 hours, and a quicker recovery by 24 hours, in the numbers of
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classical monocytes compared to intermediate and non-classical monocytes
after MNC leukapheresis.
Cell depletion by leukapheresis is dependent upon cell density; classical
monocytes are larger and more dense than the CD16+ subsets (Geissmann et al,
2008; Robbins and Swirski, 2010) and it is therefore possible that CD16+
monocytes are more likely to be removed by leukapheresis, thus explaining the
apparent rise in the proportion of classical monocytes in post-leukapheresis
blood. Analysis ofmonocyte subset proportions within the MNC collections was
based upon a very small sample size (of n=3); comparing these numbers with
those in circulating blood at baseline does suggest possible greater depletion of
non-classical and intermediate than classical monocytes although a larger study
is clearly required to confirm these findings. A previous study in patients with
malignancy undergoing peripheral blood stem cell collection demonstrated
preferential depletion of CD16+ (intermediate and non-classical) monocyte
subsets; however, the effects ofmalignancy and pre-mobilisation with
chemotherapy and G-CSF are unclear (Tanaka etal., 1999).
It is also possible that monocytes newly recruited to the blood during
leukapheresis may be more likely to be classical in phenotype. If this is the case,
it may better explain the greater proportion (and lower fall in number) of
classical monocytes by 8 hours and the overshoot at 24 hours. In mice, initial
repopulation of blood after monocyte depletion by liposomal clodronate is
predominantly by Ly6Chish monocytes, thought to be equivalent to classical
monocytes in humans (Sunderkotter etal., 2004). However, both subtypes of
165
Chapter 4: Results of Study B
murine monocyte appear to be released from spleen after an inflammatory
stimulus (Swirski etal., 2009).
The significance of a greater proportion of circulating classical monocytes is
unknown. Although originally labelled as the 'pro-inflammatory' subset,
classical monocytes have also been shown to release anti-inflammatory
mediators such as IL-10 (Robbins and Swirski, 2010; Soehnlein and Lindbom,
2010). Higher levels of circulating classical monocytes do, however, appear to
predict future risk of cardiovascular events (Berg et al., 2012) and also correlate
with greater mortality and poorer outcome in stroke patients (Urra etal., 2009).
d) Pulmonary effects of leukapheresis
Filtration leukapheresis has been shown to induce pulmonary neutrophil
sequestration and impair gas exchange but, unlike centrifugation leukapheresis,
also causes systemic neutropenia (Hammerschmidtetal., 1978). There have
not, to my knowledge, been any previous studies on the potential pulmonary
effects of centrifugation leukapheresis.
None of the six subjects reported any respiratory symptoms potentially
attributable to leukapheresis. Total cell counts in BAL after leukapheresis were
slightly higher than anticipated when compared to the saline control group in
Study A, but not to the extent seen after LPS inhalation in Study A. Alveolar
neutrophil influx was evident in only one subject, who had higher baseline
circulating neutrophil and monocyte counts in blood, but who was not clinically
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unwell during the study. Otherwise, mean proportions ofAMs, MNCs and
neutrophils in BAL were within the ranges normally seen in healthy subjects.
As in Study A, flow cytometry was used to analyse the proportions of PMLCs in
BAL fluid. After leukapheresis, there was a clear population of the CD14++CD16+
rPMLCs (reminiscent of intermediate blood monocytes) in BAL, similar to the
saline control subjects from Study A. Compared to these historical controls,
however, there was also a distinct population of CD14++CD16" iPMLCs (akin to
classical blood monocytes) present in BAL fluid, although not as prominent as
that seen within the BAL fluid of the LPS group from Study A.
This finding raises the question of whether leukapheresis induces monocyte
influx across the pulmonary vascular endothelium and into the alveolar space.
This study has clearly shown that removal ofmonocytes by leukapheresis
induces rapid and extensive monocyte recruitment into peripheral blood, with
an overshoot beyond baseline in the 24-hour blood monocyte count. Classical
monocytes have been shown to rapidly migrate to sites of inflammation
(Swirski et al., 2009); it is possible that the rise in the proportion of classical
blood monocytes after leukapheresis may be responsible for the apparent influx
of iPMLCs to the alveolar space, without requiring a local (pulmonary)
inflammatory stimulus. Perhaps relevant to this is the increased risk of
pulmonary leucostasis seen in patients with the monocytic subtype of acute
myeloid leukaemia (Azoulay etal., 2003).
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Levels of protein in BAL were also slightly higher than in the historical control
subjects from Study A, as were concentrations ofIL-6,1L-8 and MCP-1, although
none to the extent seen after LPS inhalation in Study A. It is therefore possible
that MNC leukapheresis has a subclinical effect within the pulmonary
compartment. Other studies have also demonstrated subtle changes in the
pulmonary compartment (without discernible alveolar neutrophilia) after
systemic or non-local inflammatory stimuli. For example, IV LPS in healthy
human subjects increases lung permeability and the levels of pro-inflammatory
cytokines in BAL fluid (Boujoukos etal., 1993; Suffredini etal., 1992). In mice,
intra-peritoneal LPS has been shown to cause monocyte influx into the alveolar
space (Steinmuller etal., 2006).
4.9 LIMITATIONS OF STUDY B
a) Small sample size
This was only a small study, with six subjects undergoing MNC leukapheresis.
This sample number was sufficient for the main purpose of verifying the safety
and efficacy of the procedure for depleting blood monocytes from healthy
human subjects. However, the small sample size does limit the conclusions I can
otherwise draw from this study, in particular with regards to monocyte
populations within the MNC collections (where n=3). A larger study is therefore
needed to establish whether MNC leukapheresis causes preferential depletion of
CD16+ monocyte subtypes, whether it causes a rise in the proportion of classical
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monocytes in circulating blood and whether it does cause a subclinical effect in
the pulmonary compartment (in terms of a rise in BAL cell count, protein and
inflammatory cytokine levels and in the number of iPMLCs).
b) Non-depletion effects of leukapheresis
Study B was not designed to include a control group, as this was not required to
test safety and efficacy. I was able to compare the data from BAL fluid with the
historical control group from Study A, who had inhaled saline at baseline but
were otherwise very similar to the Study B subjects in terms of baseline
characteristics and blood and BAL sampling undertaken during the study.
The lack of a true control group within Study B meant, however, that I was
unable to ascertain whether MNC leukapheresis has any immune-modulating
effects beyond cellular depletion. Leukapheresis involves the extra-corporeal
diversion of blood followed by anticoagulation and centrifugation, with
separation of different cell layers. Although previous studies have frequently
employed a 'sham' leukapheresis procedure (identical except for actual cell
collection) in their control arms, little is known about whether sham
leukapheresis can itself activate cells or exert any other kind of inflammatory
effect. Crucially, monocyte chemotaxis appears unaffected by sham
centrifugation leukapheresis (Alteri and Leonard, 1983), but it remains possible
that leukapheresis can have other effects beyond cellular depletion that may be
responsible for the effects seen in BAL during this study.
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The subjects in this study did demonstrate a small rise in body temperature
similar to the historical control subjects from Study A. There is no mention in
the literature of an effect of leukapheresis on body temperature and this is likely
to simply reflect natural diurnal variation (Lowry, 2003; Martinez-Nicolas et al,
2011). The rise in blood neutrophil counts at 24 hours was also similar to the
historical control subjects in Study A and can be attributed to the inflammatory
effect of BAL rather than any delayed effect of leukapheresis (Terashima, 2001;
Essen eta/., 1991).
c) Extent of monocyte depletion
This study employed large-volume leukapheresis, processing on average more
than 20 L of blood over approximately 6 hours. Large numbers of circulating
monocytes were actively removed during the course of MNC leukapheresis.
Despite this, substantial monocyte recruitment during leukapheresis meant that
there was a much smaller drop in circulating blood monocyte counts than
would be otherwise anticipated. Processing even larger volumes of blood during
leukapheresis would be less acceptable, particularly in healthy subjects, due to
increasing duration and risk of citrate toxicity. Furthermore, processing larger
volumes during leukapheresis is unlikely to achieve a much greater fall in
circulating blood monocyte count, for the reasons already described.
d) Depletion of other cells
MNC leukapheresis is not selective for monocytes and does deplete other cells
from circulating blood. Leukapheresis removed a large number of lymphocytes,
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again demonstrating a collection efficiency of >100%. Blood lymphocyte counts
dropped by an average of only 24%, indicating that lymphocytes are also
recruited into circulating blood during leukapheresis, as has been suggested
previously (Strasser et al., 2005). However, the effect was probably not so
sustained as for monocytes, as blood lymphocyte counts remained low at 24
hours.
Large numbers of platelets were also removed from circulating blood, although
fewer than were present in circulating blood at baseline. Platelet yield was 0.85
but mean blood platelet count fell by 53% during the course of leukapheresis. A
relatively low level of recruitment of platelets has also been reported in other
studies (Nguyen et al., 2002; Strasser et al., 2005).
In comparison, neutrophils were only depleted from one subject, possibly due to
his higher circulating neutrophil count at baseline. MNC leukapheresis therefore
had no significant impact upon blood neutrophil counts, which was a key
consideration when designing the studies due to the primary end-point chosen
for the RCT (see Chapter 2, Page 107). Indeed, the MNC program on the COBE
Spectra™ apheresis machine was ideal for our purposes as it enables rapid
blood volume processing and minimises neutrophil and RBC contamination of
the resultant cell collection (Bellavita et al., 1997; Wolf et al., 2005).
The number of RBCs depleted during leukapheresis was extremely small
relative to their number in circulating blood; the transient fall in mean
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circulating RBC count seen post-procedure is likely to reflect dilution due to the
brief increase in circulating volume (caused by ACD-A infusion).
4.10 SUMMARY OF STUDY B
This study, for the first time, looked at the potential pulmonary effects of
leukapheresis; although leukapheresis appeared to increase the proportion of
iPMLCs in the lung, there was no significant neutrophil influx and no evidence of
a clinically important pro-inflammatory effect in the alveolar space. A larger,
controlled study is required to more closely analyse how blood monocyte
subsets are affected by leukapheresis and also whether leukapheresis has pro¬
inflammatory effects beyond cellular depletion.
In summary, MNC centrifugation leukapheresis was successfully used to
retrieve large numbers of circulating monocytes from the blood of six healthy
volunteers. Although leukapheresis did not achieve sustained monocyte
depletion on the scale achieved in mice by other methods (Dhaliwal et al., 2012;
Maus et al., 2002), it does provide a safe and readily available method of
monocyte depletion in humans, with evidence of benefit in other inflammatory
disorders.
Having established, with Studies A and B, the safety and efficacy of both LPS
inhalation for modelling human lung inflammation and MNC leukapheresis for
the depletion of circulating blood mononuclear cells, I was then able to proceed
to Study C, an RCT of MNC depletion in experimental human lung inflammation.
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CHAPTER 5: RESULTS OF STUDY C
5.1 OVERVIEW
This chapter describes the results of Study C, a randomised double-blind sham-
controlled trial of 30 healthy subjects (n=15 in each group).
The main aim of the study was to assess whether peripheral blood MNC
depletion by leukapheresis could ameliorate the systemic and pulmonary
inflammation induced by LPS inhalation. The pre-defined end-points were:
PRIMARY
• The rise in blood neutrophil count by 8 hours (from baseline)
SECONDARY
• Change in oxygen saturations
• Changes in plasma cytokines/cell injurymarkers and CRP (markers
of systemic inflammation)
• Changes in BAL fluid neutrophils, protein and cytokines/cell injury
markers (markers of alveolar inflammation)
• Changes in mean Ki and SUV derived from [18F]FDG PET imaging
(markers of global lung inflammation)
The secondary aim of this study was to further define the phenotype and
function of PMLCs in BAL, using flow cytometry to analyse the expression of
proliferation and maturation markers and using flow sorting to isolate BAL cell
populations for culture and assays of cytokine release.
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This chapter describes subject recruitment and demographic data, symptoms
and adverse events and the effects of MNC depletion on clinical parameters,
blood, BAL and PET markers of systemic and pulmonary inflammation. 1 will
then present additional data on the phenotype and function of PMLCs in BAL.
5.2 SUBJECT RECRUITMENT
Thirty subjects were recruited into the study and randomised into either the
depletion or the sham group as shown in the CONSORT diagram (Figure 5a).
Most data are complete for all 30 subjects; 'n' numbers are stated for each
analysis. One subject from the sham group did not undergo bronchoscopy, as
per the pre-defined safety criteria, because his FEVi had fallen by >10% below
his baseline level.
PET-CT scans were only performed in a sub-group of 20 subjects (n=10 in each
group). There were several reasons for this, including an initial delay with
scanner installation and calibration. After the first two PET-CT scans had been
performed (on the 5th and 6th subjects), further scans were temporarily put on
hold while an ethics amendment, including a revision of estimated total
radiation dose, received approval. One planned PET-CT scan was cancelled on
the day due to scanner malfunction (before any [18F]FDG was administered).
Staining of blood or BAL cells for flow cytometry was not performed for 2
subjects from the sham group and 1 subject from the depletion group due to
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absence of laboratory staff. Further analysis of PMLC phenotype and function
was performed on smaller sub-groups, as described in the relevant section.
Figure 5a: CONSORT diagram illustrating subject recruitment, randomisation,
intervention and follow-up during Study C
+ Reasons for exclusion: abnormal total/differential WBC (n=25), bilirubin (n=7) or ALT (n=4),
eGFR or urea (n=2) and platelets (n=l); FEVi/FVC <70% (n=l); recent formal blood donation
(n=l).
Three subjects had fewer than 3.5 TBVs processed: * vasovagal event (n=l, 2.4 TBVs processed
in 285 minutes); high estimated blood volume/time constraint (n=l, 3.3 TBVs processed in 390
minutes); * recurrent venospasm limiting flow rate during leukapheresis (n=l, 2.8 TBVs
processed in 395 minutes).
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5.3 SUBJECT DEMOGRAPHICS
Subjects in the two groups were well matched (Table 5A). Baseline
characteristics were also similar to those of the subjects from the preliminary
studies (see Table 3A, Page 112 and Table 4A, Page 147).
Table 5A: Subject demographics at baseline
BASELINE CHARACTERISTICS SHAM GROUP DEPLETION GROUP
Age (years) 22 [21-24] 23 [21-24]
Height (metres) 1.80 (0.05) 1.79 (0.04)
Weight (kilograms) 80.5 (12.5) 81.3(10.3)
FEVi (litres) 4.78 (0.51) 4.72 (0.54)
FVC (litres) 5.75 (0.60) 5.53 (0.64)
Temperature (°C) 36.2 (0.5) 36.4 (0.5)
HR (minute1) 74 (9) 72 (9)
sBP (mmHg) 130(10) 134(15)
Sa02 (%) 98(1) 98(1)
Data are presented as mean (SD) or median [IQR]; n=15 each group.
All subjects from both groups successfully completed inhalation challenge with
approximately 60pg of LPS. As intended, sham leukapheresis was almost
identical to the true procedure, incorporating extra-corporeal blood diversion,
anticoagulation and centrifugation but omitting actual cell collection (i.e. whole
blood was returned to the subject). Double blinding was maintained throughout
all procedures as described in Chapter 2 (Page 87) and emergency un-blinding
was not required in any subject.
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The groups did not vary significantly in estimated blood volume at baseline, the
number of TBVs processed, the duration of leukapheresis, the amount ofACD-A
anticoagulation required or the amount of oral and/or IV calcium
supplementation used (Table 5B).
Table 5B: Variables associated with the leukapheresis/sham procedures
VARIABLE SHAM GROUP DEPLETION GROUP
Estimated blood volume at baseline (L) 5.34 (0.54) 5.38 (0.39) NS
TBVs processed 4.0 [3.9-4.0] 4.0 [3.9-4.0] NS
Duration (hours) 5.8 (0.5) 5.7 (0.5) NS
Amount of ACD-A (L) 1.52 [1.44-1.63] 1.57 [1.51-1.61] NS
Oral calcium (g) 0 [0 -1] 0 [0 - 2] NS
IV calcium (ml) 20 [20 - 20] 20 [19-20] NS
Data are presented as mean (SD) or median IQR]; n=15 in each group.
5.4 SYMPTOMS AND ADVERSE EVENTS
There were no SAEs. None of the subjects' FBC results fell outwith the pre-
specified safety parameters (Chapter 2, Page 96).
The frequencies of reported symptoms did not vary significantly between the
groups (Table 5C). All symptoms were mild, predictable from the procedures
involved and of short duration. No subjects reported breathlessness or wheeze.
One subject from the sham group developed a cough just over an hour after LPS
inhalation which was associated with a fall in FEVi >10% below baseline;
however, he had no audible wheeze on auscultation and both the cough and fall
in FEVi resolved spontaneously within the next 2 hours.
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Paracetamol was given to 5 subjects in the depletion group (including one
subject who was given two separate doses), compared to 8 subjects in the sham
group.
Table 5C: Symptoms and adverse events occurring in each group
SYMPTOM/ADVERSE EVENT SHAM GROUP DEPLETION GROUP
Pyrexial symptoms * 10 (67%) 5 (33%)
Paraesthesiae (digital/facial)f 8 (53%) 7 (47%)
Headache 8 (53%) 6 (40%)
Sore throat 7 (47%) 9 (60%)
Cough * 5 (33%) 6 (40%)
Light-headedness ** 4 (27%) 4 (27%)
Chest tightness++ 4 (27%) 2 (13%)
Fall in FEV: >10% below baseline ** 4 (27%) 0 (0%)
Desaturation <92% 3 (20%) 3 (20%)
Bruising/discomfort due to venepuncture 3 (20%) 2 (13%)
Nausea 3 (20%) 0 (0%)
Myalgia 1 (7%) 1 (7%)
All symptoms/AEs were mild and resolved fully; they were grouped (post-hoc) into categories
and are expressed as frequency (%); n=15 each group; statistical analysis by Fisher's exact test
demonstrated no significant differences between the groups in the frequency of any
symptom/adverse event.
*
7 further subjects in the depletion group and the remaining 5 subjects in the sham group did
not report pyrexial symptoms despite recording a temperature >37.4 °C during their study day.
t all episodes of paraesthesiae began during leukapheresis and resolved with treatment of
presumed citrate-related hypocalcaemia.
* this does not include cough during bronchoscopy.
**
one subject from the depletion group developed a vasovagal episode with sudden-onset light¬
headedness during leukapheresis, plus transient bradycardia and hypotension which resolved
rapidly on lying flat. He was given 300ml 0.9% saline IV and, in the interests of safety,
leukapheresis was not recommenced.
t+ described as a sensation of slight restriction upon deep inspiration.
** associated with chest tightness in three subjects (and precluding bronchoscopy in one subject
but occurring after bronchoscopy in the other two subjects).
***
during bronchoscopy; all episodes were transient (resolving within 2 minutes either
spontaneously or with an increase in supplemental oxygen from 2 to 4 litres/minute); all
subjects had Sa02 >94% breathing room air by 2 hours post-procedure.
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5.5 THE EFFECTS OF MNC DEPLETION ON CLINICAL PARAMETERS
LPS inhalation caused a sharp rise in mean HR in the sham group subjects, from
74 (SD 9) minute 1 at baseline to a peak mean HR of 100 (11) minute 1
(P<0.0001). A very similar pattern occurred in the depletion group subjects,
where mean HR at baseline was 72 (SD 9) minute-1, compared to a peak of 97
(9) minute-1 (P=0.52 for between-groups comparison) (Figure 5b, Panel A). HR
had returned to baseline levels by 24 hours in both the sham and depletion
groups (mean HR of 70 (SD 10) minute 1 and 67 (SD 11) minute-1 respectively).
As expected, LPS inhalation caused a clear rise in mean temperature in subjects
from the sham group, from 36.2 (SD 0.5) °C at baseline to a mean peak
temperature of 38.3 (0.5) °C (P<0.0001). MNC depletion did not affect this LPS-
induced rise in temperature; the mean temperature of subjects in the depletion
group was 36.4 (SD 0.5) °C at baseline with a peak of 38.0 (0.6) °C (P=0.11 for
between-groups comparison) (Figure 5b, Panel B). By 24 hours, mean
temperature had fallen to baseline levels in both groups (36.3 (SD 0.3) °C in the
sham group and 36.5 (0.4) °C in the depletion group).
LPS inhalation caused a small rise in median RR in the sham group subjects,
from a median of 14 [IQR 12-14] minute-1 at baseline to a peak of 20 [16-20]
minute-1 (P<0.0001). A very similar pattern was seen in the depletion group
subjects, with a baseline median RR of 14 [IQR 14-14] minute-1 and a peak
median RR of 18 [16-20] minute-1 (P=0.79 for between-groups comparison)
(Figure 5b, Panel C). Median RR at 24 hours was similar to baseline readings in
all subjects (14 [IQR 14-16] minute-1 for both groups).
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Mean baseline SaCh were 98 (SD 1) % in both groups. During and/or after
bronchoscopy, there were small falls in mean SaC>2 readings in both groups
(mean nadir of 95 (SD 2) % in the sham group and 96 (1) % in the depletion
group (P=0.16 for between-groups comparison) (Figure 5b, Panel D). Mean Sa02
at 24 hours had recovered to baseline levels in both groups.
Mean sBP at baseline was similar in both groups (130 (SD 10) mmHg in the
sham group, compared to 134 (15) mmHg in the depletion group); the lowest
recorded sBP was slightly lower in both groups (mean of 117 (SD 11) mmHg in
the sham group and 114 (11) mmHg in the depletion group; between-groups
comparison P=0.14) (Figure 5b, Panel E). In both groups, mean sBP had risen
again by 24 hours (127 (SD 8) mmHg in the sham group and 124 (10) mmHg in
the depletion group).
The maximal fall in mean FEVi was less than 10% in both groups, falling from a
mean FEVi of 4.78 (SD 0.51) L at baseline to a nadir of 4.42 (0.57) L in the sham
group, compared to a baseline mean FEVi of 4.72 (0.54) L and a nadir of 4.49
(0.57) L in the depletion group. There was a greater range in fall of FEVi in the
sham group, but the overall between-groups comparison was not significant
(P=0.08; Figure 5c). The maximal fall in mean FVC was also small, with a
baseline mean FVC of 5.75 (SD 0.60) L and a nadir of 5.43 (0.60) L in the sham
group, compared to a baseline mean FVC of 5.53 (0.64) L and a nadir of 5.38
(0.63) L in the depletion group. Again, there was a greater range in % fall in FVC
in the sham group, which did not reach significance (P=0.06 for between-groups
comparison; Figure 5c).
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Figure 5b: Maximal changes in (A) HR, (B) temperature, (C) RR, (D) Sa02 and (E)
sBP during the study
Data are displayed as box (median/IQR) and whiskers (range); n=15 each group; between-
groups statistical analysis was by ANCOVA, using baseline value as covariate.
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Figure 5c: Maximal % falls in (A) mean FEVi and (B) mean FVC during the study
Data are displayed as box (median/IQR) and whiskers (range); n=15 for both groups; between-
groups statistical analysis was by ANCOVA, using baseline value as covariate.
5.6 CELL RETRIEVAL BY LEUKAPHERESIS
The volumes of the MNC collections obtained by leukapheresis in the 15
depletion group subjects were relatively consistent (median MNC collection
volume of 0.319 [IQR 0.288 - 0.330] L) and similar to the volumes collected
during Study B (see Page 147). The subject who had a vasovagal episode during
leukapheresis was a notable outlier (2.3 TBVs were processed, resulting in an
MNC collection volume of only 0.218 L).
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The total cell numbers removed by leukapheresis (derived from the automated
cell counts multiplied by the cell collection volumes) are presented in Table 5D.
As expected from Study B (see Table 4C, Page 149), leukapheresis depleted
large numbers of RBCs, platelets, lymphocytes and monocytes, but much
smaller numbers of neutrophils, basophils and eosinophils.
Table 5D: Cell counts in the MNC collections of the depletion group subjects









Data are presented as median [IQR] or mean (SD); n=15 [depletion group only).
5.7 CELL YIELD FROM LEUKAPHERESIS
a) Monocyte yield
There was a strong correlation between the number ofmonocytes present in
the MNC collections (i.e. depleted by leukapheresis) and the respective number
of circulating monocytes in baseline blood (r=0.84 [CI0.95 0.57, 0.94]) (Figure 5d,
Panel A). Monocyte yield was 2.3, i.e. the mean absolute number ofmonocytes
depleted by leukapheresis (7.67 (SD 2.33) xlO9) was equivalent to 2.3 times the
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mean absolute number ofmonocytes circulating in blood at baseline (3.32
(0.92) xlO9).
b) Lymphocyte yield
There was also a strong correlation between the number of lymphocytes
present in the MNC collections and the respective number in blood at baseline
(r=0.83 [CI0.95 0.55, 0.94) (Figure 5d, Panel B). Lymphocyte yield was 1.8 i.e. the
mean absolute number of lymphocytes removed by leukapheresis (23.4 (SD 7.3)
xlO9) was equivalent to 1.8 times the mean absolute number of lymphocytes
circulating in baseline blood (13.1 (2.8) xlO9).
c) Platelet yield
The number of platelets present in the MNC collections also correlated with the
respective number in blood at baseline (r=0.65 [CI0.95 0.21, 0.87]) (Figure 5d,
Panel C). Platelet yield was 0.8 (the mean absolute number of platelets removed
by leukapheresis (1013 (SD 172) xlO9) was 0.8 times the mean absolute
number of platelets circulating in baseline blood (1244 (222) xlO9).
d) Neutrophil yield
There was only a very weak correlation between the number of neutrophils
present in the MNC collections and the respective number in baseline blood
(r=0.3 [CI0.95 -0.27, 0.69]) (Figure 5d, Panel D). Indeed, six of the fifteen MNC
collections were completely free of neutrophils. The median absolute number of
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neutrophils removed by leukapheresis [0.74 [IQR 0 - 2.65] xlO9) was only 0.05
times the median absolute number of neutrophils circulating in baseline blood
[16.2 [12.8-21.7] xlO9).
e) RBC yield
The number of RBCs retrieved by leukapheresis also showed only a very weak
correlation with the respective number in blood at baseline [r=0.2 [CI0.95 -0.36,
0.64]] [Figure 5d, Panel E]. Indeed, the median absolute number of RBCs
present in the MNC collections [0.19 [0.13 - 0.28] xlO12) was just 0.007 times
the median absolute number of RBCs circulating in baseline blood [26.9 [25.9 -
29.1] xl0i2).
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Total circulating RBCs at baseline (xlO12)
Figure 5d: Cell counts within the MNC collections compared with circulating
counts in baseline blood, for (A) monocytes, (B) lymphocytes, (C) platelets, (D)
neutrophils and (E) RBCs
n=15 (depletion group only); statistical analysis of correlation was by Pearson's test.
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5.8 THE EFFECTS OF MNC DEPLETION AS MEASURED IN BLOOD
a) Circulating blood neutrophil counts
As expected, mean blood neutrophil count rose steeply after LPS inhalation,
from 2.97 (SD 0.68) xl09/L at baseline to 9.12 (1.65) xl09/L at 8 hours in the
sham group subjects (P<0.0001). Leukapheresis did not alter the primary end-
point: the mean circulating blood neutrophil count at baseline was 3.06 (SD
0.84) xl09/L compared to 9.22 (1.76) xl09/L at 8 hours in the depletion group
(P=1.00 for the between-groups comparison) (Figure 5e, Panel A).
Since neutrophils, albeit in small quantities, were sequestered in the MNC
collections of the subjects from the depletion group, this may have altered the 8-
hour circulating blood neutrophil counts and thus affected the primary end-
point. A second analysis was therefore performed to correct for the estimated
numbers of neutrophils directly removed by leukapheresis, which were added
to the respective 8-hour blood neutrophil counts to calculate adjusted blood
neutrophil counts at 8 hours (mean of 9.59 (SD 1.96) xl09/L). Even after this
correction for neutrophil removal, MNC depletion continued to have no effect
on the LPS-induced rise in blood neutrophil count (P=0.55 for between-groups
analysis).
A repeated-measures analysis, incorporating circulating blood neutrophil
counts at all the intermediate (2, 4 and 6-hour) time-points, confirmed that MNC
depletion had no effect on the LPS-induced rise in blood neutrophil count over
the entire 8-hour period when compared to sham (P=0.67).
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Figure 5e: Circulating blood (A) neutrophil, (B) monocyte, (C) lymphocyte, (D)
platelet and (E) RBC counts between baseline and 8 hours
Circles and error bars represent means and CIo.9s; n=15 for each group at each time-point,
except sham at 2 hours where n=14 (one blood sample clotted prior to processing); between-
groups statistical analysis was by ANCOVA, comparing the change in circulating blood cell count
between baseline and 8 hours, using baseline count as covariate; *** P<0.0005.
By 24 hours, circulating blood neutrophil counts in the sham group subjects had
begun to fall, although mean blood neutrophil count remained significantly
elevated above baseline level (7.73 (SD 1.9) xl09/L), possibly due to the effects
of intervening BAL. In the depletion group, mean circulating blood neutrophil
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count at 24 hours was slightly lower, at 6.47 (SD 2.3) xl09/L, although this did
not reach significance (P=0.09 for between-groups comparison with baseline).
b) Circulating blood monocyte counts
Mean blood monocyte count in the sham group subjects rose from 0.60 (SD
0.17) xl09/L at baseline to 0.77 (0.19) xl09/L at 8 hours (P<0.005). Conversely,
in the depletion group subjects (as would be expected by the large numbers of
monocytes removed during leukapheresis), mean blood monocyte count fell
from 0.62 (SD 0.17) xl09/L at baseline to 0.56 (0.10) xl09/L at 8 hours
(P=0.0001 for between-groups comparison) (Figure 5e, Panel B).
By 24 hours, mean circulating blood monocyte count remained elevated in the
sham group subjects (0.78 (SD 0.24) xl09/L) and, despite the earlier fall at 8
hours, was also elevated above baseline levels in subjects from the depletion
group (0.68 (0.23) xl09/L; between-groups comparison with baseline P=0.73).
c) Circulating blood lymphocyte counts
Mean blood lymphocyte count fell after LPS inhalation in the sham group
subjects, from a baseline of 2.41 (SD 0.50) xl09/L to 1.59 (0.46) xl09/L by 8
hours (P<0.0001). Mean blood lymphocyte count also fell in the depletion group
subjects, but not to a significantly greater extent (baseline mean of 2.44 (SD
0.48) xl09/L, compared to 1.39 (0.29) xl09/L at 8 hours; P=0.10 for the
between-groups comparison) (Figure 5e, Panel C). By 24 hours, mean
circulating blood lymphocyte count in the sham group subjects had partially
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recovered, rising to 2.08 (SD 0.43] xl09/L. In the depletion group subjects,
however, mean blood lymphocyte count had risen to a much lesser extent by 24
hours, remaining significantly below baseline levels (1.77 (SD 0.38) xl09/L;
P<0.01 for between-groups comparison with baseline).
d) Circulating blood platelet counts
After LPS inhalation, mean blood platelet count in the sham group was similar at
baseline compared to 8 hours (208 (SD 40) xl09/L and 187 (33) xl09/L
respectively; P=0.11). In comparison, there was a dramatic fall in mean blood
platelet count by 8 hours in the depletion group subjects, from 231 (SD 37)
xl09/L at baseline to 105 (23) xl09/L (P<0.0001 for the between-arms
comparison) (Figure 5e, Panel D). By 24 hours, mean circulating blood platelet
count again remained relatively stable in the sham group subjects, at 193 (SD
35) xl09/L. In the depletion group subjects, mean blood platelet count
remained much lower than baseline at 24 hours (115 (SD 24) xl09/L; P<0.0001
for the between-groups comparison with baseline).
e) Circulating RBC counts
There was a significant fall in mean RBC count by 8 hours in the sham group,
from 4.97 (SD 0.25) xl012/L at baseline to 4.50 (0.22) xl012/L (P<0.0001).
Mean RBC count fell to a similar extent in the depletion group, to 4.65 (SD 0.27)
xl012/L at 8 hours, from a baseline of 5.03 (0.25) xl012/L (P=0.12 for the
between-groups comparison) (Figure 5e, Panel E). By 24 hours, in both groups,
mean circulating RBC count had risen towards baseline levels (4.76 (SD 0.28)
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xl012/L in the sham group and 4.92 (0.32) xl012/L in the depletion group;
P-0.14 for between-groups comparison with baseline).
f) Blood monocyte subsets
The proportions of blood monocyte subsets, as a proportion of total HLA-DR+
monocytes, were determined at each time-point using flow cytometry. The
baseline proportion of classical monocytes was 91.4 (SD 1.7) % in the sham
group and 90.2 (3.6) % in the depletion group, similar to the baseline
proportions observed in the Study A and Study B subjects. There were only very
small changes in the proportions of each monocyte subset in blood over time,
with no clear effect from MNC depletion.
g) Plasma C-reactive protein levels
There was a steep rise in plasma CRP levels by 24 hours after LPS inhalation in
subjects from the sham group (34.8 (SD 15.3) ng/ml, versus 1.1 (1.3) ng/ml at
baseline; n=14, P<0.0001). This rise in plasma CRP was not influenced by MNC
depletion, with CRP levels increasing to a similar extent, from 0.9 (SD 0.8) ng/ml
at baseline to 34.6 (17.1) ng/ml at 24 hours in the depletion group subjects
(n=14; P=0.90).
h) Inflammatory and cell injury markers in plasma
The levels of several pro-/anti-inflammatory and chemotactic cytokines, soluble
cell adhesion molecules, markers of neutrophil activation and markers of
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epithelial and endothelial cell injury were measured in plasma at baseline and 8
hours (Table 5E). Levels of the major cytokines were also measured at 24 hours.
Plasma levels of the pro-inflammatory cytokines TNFa and IL-ip and the anti¬
inflammatory cytokines IL-12p70 and IL-10 were undetectable at baseline, did
not reach detectable levels at 8 hours and remained undetectable at 24 hours.
There were, however, small but clear rises in the plasma levels of the pro¬
inflammatory cytokines IL-6 and IL-8 in both the sham group and depletion
group subjects by 8 hours; levels of both had fallen again by 24 hours, and
although levels of plasma IL-6 remained slightly higher than baseline in the
sham group subjects, the pattern of change in plasma [IL-6] levels between 0
and 24 hours was not significantly different between the groups.
There was a non-significant trend towards lower plasma levels of MCP-1 (a
chemotactic cytokine for monocytes) by 8 hours in both groups. Plasma levels of
MlP-la, another chemotactic cytokine, were undetectable in both groups at
baseline and at 8 hours. In comparison, plasma levels ofSDF-la (a chemotactic
cytokine for monocytes and lymphocytes) fell significantly between baseline
and 8 hours in both groups.
There were significant rises in the levels of plasma HNE and MPO (markers of
neutrophil activation and function) by 8 hours, which were comparable
between the sham and depletion groups.
LPS inhalation had no effect, in either group, on plasma levels of the soluble cell
adhesion molecule sE-selectin. Plasma sL-selectin levels, however, had fallen
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significantly in both groups by 8 hours; there was a trend towards a greater fall
in plasma sL-selectin levels in subjects from the sham group, although this did
not reach statistical significance.
There was no significant difference in the 8-hour levels of plasma CC-16 (a
marker of alveolar epithelial injury) in the sham and depletion groups. Levels of
plasma RAGE (an injury marker for type I alveolar epithelial cells) rose
significantly after LPS inhalation, to a similar extent in both groups; by 24 hours,
plasma RAGE levels had fallen back towards baseline levels and, although this
fall was not quite so marked in subjects from the sham group, there was no
statistical difference between the groups. In contrast, LPS inhalation had no
effect upon plasma levels of SP-D (a marker of alveolar epithelial type 2 cell
injury) in subjects from either group. There was also no significant change in






































































































































































































Datareexpressedmedian[IQR];denot sreadingb l wthlow ri toft ctios y;=14indivi uali e-p intsnd= 3f rir d analysesbetweentime-poi tsforhshamgroup;n>14depl t onup.Within-groupst tisticalanalyse(be w0d8h ub t e 24hours)arebyWilcoxonsigned-ra ktest;etwe n-groupstatisticala alyseswANCOVAu ga elinv uvari te,unb i el l wereund tectableonotperf rmed(tMWUt stins ndafr inglime-point);*P<0.05,*P .005** 0.0 5. 197
Chapter 5: Results of Study C
5.9 THE EFFECTS OF MNC DEPLETION AS MEASURED IN BAL FLUID
a) BAL volume and total cell count
Similar volumes of BAL fluid were retrieved from the subjects in the two groups
during bronchoscopy (mean BAL volume of 86 (SD 25) ml in the sham group,
compared to 83 (37) ml in the depletion group; P=0.78) (Figure 5f). These
volumes were similar to those collected in Studies A and B (see Chapter 3, Page
124 and Chapter 4, Page 158).
Cell viability was identical in both groups (mean of 92 (SD 4) %). MNC depletion
did not significantly reduce the total viable cell count in BAL fluid, which was 4.5
(SD 2.1) xl05/ml in the sham group and 3.9 (1.3) xl05/ml in the depletion
group; P=0.39 (Figure 5f). Total viable cell counts were similar, possibly even
slightly higher, than those seen in the LPS group from Study A (see Chapter 3,
Page 124).
b) Levels of LPS detectable in BAL fluid supernatant
A semi-quantitative LAL test was used to determine the levels of LPS detectable
in BAL fluid supernatant from the subjects in each study group. LPS was
detectable in all the BAL fluid supernatant samples and at an equivalent
concentration in all subjects (>0.25 but <0.50 endotoxin units/ml).
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Figure 5f: BAL volumes retrieved (Panel A) and total viable cell counts per ml of
BAL fluid (Panel B)
Data are presented as box (median/IQR) and whiskers (range); n=14 for the sham group (one
subject did not undergo bronchoscopy due to a >10% fall in FEVi pre-procedure); n=15 for the
depletion group; statistical analysis was by 2-sample t-test.
c) BAL cell content (light microscopy)
BAL cell content was calculated by examination of cytospins using light
microscopy to obtain differential cell counts. The proportions of each cell type
are shown in Table 5F. Alveolar macrophages represented the majority of BAL
cells in both the sham and depletion groups. As expected after LPS inhalation,
there was also a relatively high neutrophil content in BAL from the sham group
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BAL neutrophil content was very similar in the depletion group and MNC
depletion therefore did not appear to reduce LPS-induced BAL neutrophilia (a
major secondary end-point of the study). The proportion ofmononuclear cells
present in BAL was slightly lower in the depletion group than the sham group.
Table 5F: Relative proportions of each cell type present in BAL fluid
CELL TYPE SHAM GROUP DEPLETION GROUP
Alveolar macrophages 62(19) 66 (17) NS
Mononuclear cells 4.8 (2.2) 3.5 (1.6) *
Neutrophils 33(18) 31 (17) NS
Data are expressed as mean (SD) % of total BAL cells; n=14 [sham group) and n=15 (depletion
group); statistical analysis was by 2-sample t-test; * P<0.05.
Estimated absolute numbers of each cell type (per ml of BAL fluid) were
obtained by adjusting the cell proportion data for total cell count (Figure 5g).
The estimated numbers ofAMs remained similar between groups, with a
median of 231 [IQR 180 - 302] xl03/ml in the sham arm and 238 [190 - 292] in
the depletion arm (P=0.95). Adjusting for total cell count revealed wide
variations in the estimated numbers of neutrophils in BAL fluid, with a median
of 160 [IQR 33.6 - 240] xl03/ml in the sham arm compared to 120 [64.5 - 152]
xl03/ml in the depletion arm (P=0.47). In line with the cell proportion data, the
estimated number ofmononuclear cells in BAL fluid was also smaller in the
depletion group (median 13.5 [IQR 7.4 - 18.8] xl03/ml) compared to the sham
group (25.0 [7.6 - 32.8] xl03/ml; P=0.02).
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Figure 5g: Estimated absolute numbers of (A) AMs, (B) MNCs and (C) neutrophils
in BAL fluid
Data are presented as box (median/IQR) and whiskers (range) plots; n=14 from the sham group
and n=15 from the depletion group; statistical analysis was by 2-sample t-test; * P<0.05.
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d) BAL cell content (flow cytometry)
As demonstrated in the preliminary studies, flow cytometry enabled accurate
distinction of PMLCs from AMs and lymphocytes by plotting cell size and
granularity. As before, relative cell surface antigen expression of CD14 and
CD16 was then used to distinguish the two PMLC subtypes.
In the sham group subjects, the FSC-A versus SSC-A flow cytometry plots
demonstrated prominent populations of neutrophils and PMLCs similar to that
seen after LPS inhalation in Study A (an example plot is shown in Figure 5h); a
visually identical pattern was seen in the depletion subjects.
As before, the HLA-DR+ PMLCs could be easily divided by relative CD14 and
CD16 expression into rPMLCs (CD14++CD16+, similar to intermediate blood
monocytes) and iPMLCs (CD14++CD16-, similar to classical blood monocytes)
(Figure 5h). In both the sham and depletion groups, iPMLCs made up the major
PMLC subtype, with relatively few rPMLCs (Table 5G). The relative proportions
of PMLC subtypes were very similar to those in the LPS group from Study A (see
Table 3F, Page 131) and, as in the preliminary study, there was no clear PMLC
population equivalent to CD14+CD16++ (non-classical) blood monocytes.
Table 5G: Relative proportions of each PMLC subtype in BAL fluid
PMLC SUBTYPE SHAM GROUP DEPLETION GROUP
rPMLC 8.8 (3.9) 8.4 (4.6) NS
iPMLC 91.2 (3.9) 91.6(4.6) NS
Data are expressed as mean (SD) % of total PMLCs in BAL; n=14 (sham group) and n=13
(depletion group); statistical analysis was by 2-sample t-test.
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There was no significant difference in the mean proportion of Treg cells in BAL
from sham group subjects (4.8 (SD 2.8) %) compared to depletion group
subjects (4.8 (2.1) %; P=0.97) and these proportions were similar to that found
in the LPS group from Study A (see Chapter 3, Page 132).
e) Levels of protein in BAL fluid supernatant
The mean concentration of BAL protein in the sham group subjects was 0.24
(SD 0.13) g/L, a similar level to that seen after LPS inhalation in Study A. MNC
depletion had no significant effect on mean BAL protein content (0.20 (SD 0.05)
g/L; P=0.30) (Figure 5i). Urea levels in plasma and BAL supernatant were used
to calculate the volume of ELF within each BAL sample (see Methods, Chapter 2,
Page 103). Even after adjusting for BAL dilution, the mean ELF protein content
did not differ significantly between groups (median of 2.40 [1.34 - 3.46] g/L in


































Figure 5i: Protein content within (A) BAL fluid supernatant and (B) within ELF
Data are presented as box (median/IQR) and whisker (range) plots; n=13 or n=14 (sham group,
BAL and ELF results respectively) and n=15 (depletion group, all data); statistical analysis was
by 2-sample t-test.
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f) Markers of inflammation and cellular injury in BAL fluid supernatant
The levels of several pro-/anti-inflammatory and chemotactic cytokines, soluble
cell adhesion molecules, markers of neutrophil activation and markers of
epithelial and endothelial cell injury were measured in BAL fluid supernatant
(Table 5H).
Table 5H: BAL fluid supernatant concentrations of cytokines, cell adhesion
molecules and markers of neutrophil activation and cell injury
CYTOKINE/MARKER SHAM GROUP DEPLETION GROUP
IL-1P (pg/ml) 14.5 [8.30-26.7] 13.3 [10.2-15.4]
IL-6 (pg/ml) 338 [149-538] 293 [228-738]
IL-8 (pg/ml) 60.5 [50.0-180] 123 [100-133]
TNFa (pg/ml) 3.80 [x-4.75] x [x-4.90]
IL-10 (pg/ml) Undetectable Undetectable
IL-12p70 (pg/ml) 2.65 [2.30-3.10] 2.70 [x- 3.0]
MCP-1 (pg/ml) 285 [156-502] 283 [183-329]
MlP-la (pg/ml) 93.0 [22.5-110] 78.0 [49.0-175]
SDF-la (pg/ml) x[x- 48.0] x [x- 29.1]
HNE (ng/ml) 150 [83.5-248] 112 [56.0-149]
MPO (ng/ml) 381 [187-733] 300 [192-441]
sE-selectin (ng/ml) Undetectable Undetectable
sL-selectin (ng/ml) 10.3 [4.05-16.1] 7.70 [5.30-10.0]
CC-16 (ng/ml) 1280 [810-1970] 1400 [825 - 2120]
RAGE (pg/ml) 2910 [1970-4290] 3360 [1800-6000]
SP-D (ng/ml) 3420 [2540 - 5990] 4140 [3130-5870]
vWF (mil/ml) 3.40 [x- 7.24] x [x- 4.17]
Data are expressed as median [IQR] concentrations; n=14 (sham group) and n=15 (depletion
group); x denotes a value below the lower limit of detection of the assay; between-groups
statistical analysis was by MWU test and demonstrated no significance for any of the
cytokines/markers (even after adjustment for BAL dilution).
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5.10 THE EFFECT OF MNC DEPLETION AS MEASURED BY 18F[FDG] PET
PET-CT scans were performed on 20 subjects (n=10 each group]. Baseline
characteristics for each sub-group remained well matched between the sham
and depletion arms and were representative of overall parent group. The mean
amount of 18F[FDG] administered was consistent between the groups [190 (SD
17.3) MBq in the sham arm, compared to 188 (16.9) MBq in the depletion arm).
In both groups, there was a mean time of 27 (SD 1) hours between baseline and
commencing the PET-CT scan.
As discussed in Chapter 2 (Page 91), several methods were used to estimate
pulmonary uptake of [18F]FDG: Patlak analysis-derived influx constant (Ki) and
intercept-adjusted K; (to account for the initial volume of [18F]FDG distribution)
(Figure 5j) and also SUV and tissue-to-plasma activity ratio (TPR). With each
method, estimates of [18F]FDG uptake were performed for whole lung
(incorporating the regions of interest from both lungs) and for left lung alone
(to exclude any effect from prior BAL of the right middle lobe).
a) Patlak-analysis derived influx constant (K;)
Figure 5k illustrates how Ki and intercept are derived from a Patlak plot. MNC
depletion had no significant effect on mean whole lung Ki (1.34 (SD 0.5) xlO3 ml
blood ml lung-1 minute 1 in the sham sub-group and 1.43 (0.8) xlO3 ml blood ml
lung1 minute-1 in the depletion sub-group; P=0.78) (Figure 5k, Panel A). Mean Ki
for left lung alone (i.e. excluding any potential BAL-induced inflammation within
the right lung) was also unaffected by MNC depletion, with a mean of 1.26 (SD
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0.6) xlO-3 ml blood ml lung-1 minute 1 for the sham sub-group compared to 1.48
(1.0) xlO"3 ml blood ml lung"1 minute-1 for the depletion sub-group (P=0.54)
(Figure 5k, Panel B). Similarly, comparing a single lobe (left lower lobe) also
demonstrated no significant difference in mean Ki between the two sub-groups
(1.43 (SD 0.8) xlO 3 ml blood ml lung1 minute 1 compared to 1.74 (0.1) xlO-3 ml









Figure 5j: Deriving influx constant (Ki) and intercept from a Patlak plot
The Patlak plot shown is an example from a subject in the sham group; the integrals of plasma
[18F]FDG activity divided by plasma [18F]FDG activity are plotted on the x axis; the lung [18F]FDG
activity divided by plasma [18F]FDG activity is plotted on the y axis; Ki is derived from the slope
of the resultant line (where it becomes straight); the intercept of the straight line with the y axis
can be used to adjust Ki for the volume of distribution of [18F]FDG.
b) Intercept-adjusted Kj
MNC depletion did not significantly alter intercept-adjusted whole lung Ki (4.63
(SD 1.9) xlO-3 minute-1 in the sham sub-group and 5.62 (3.9) xlO-3 minute-1 in
the depletion sub-group; P=0.48) (Figure 5k, Panel C). Mean intercept-adjusted
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Ki for left lung alone also did not differ significantly between the sham and
depletion subjects (4.16 (SD 2.1) xlO-3 minute-1 compared to 5.99 (5.0) xlO-3
minute-1 respectively; P=0.30) (Figure 5k, Panel D). Furthermore, MNC
depletion had no significant effect upon mean intercept-adjusted Ki for left
lower lobe (4.04 (SD 2.1) xlO-3 minute-1 in the sham sub-group and 5.77 (4.4)
xlO-3 minute-1 in the depletion sub-group; P=0.27).
c) Standardised uptake value (SUV)
MNC depletion had no effect on mean whole lung SUV, which was 0.67 [IQR 0.58
- 0.78] in the sham sub-group and 0.67 [0.60 - 0.81] in the depletion sub-group
(P=0.63) (Figure 5k, Panel E). Adjusting for the potential effect of BAL within
the right lung did not alter the results, as mean SUV for left lung alone was also
very similar between the groups (0.68 [IQR 0.57 - 0.79] and 0.66 [0.60 - 0.82]
in the sham and depletion subjects respectively; P=0.80) (Figure 5k, Panel F).
d) Tissue-to-plasma activity ratio (TPR)
Mean whole lung TPR was also unaffected by MNC depletion (40.0 (SD 4.6) % in
the sham sub-group and 39.7 (4.4) % in the depletion sub-group; P=0.86)
(Figure 5k, Panel G). Mean TPR for left lung alone did also not differ significantly
between the groups (39.9 (SD 5.5) % and 40.4 (5.0) % in the sham and
depletion sub-groups respectively; P=0.85) (Figure 5k, Panel H).
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Figure 5k: Patlak analysis-derived K; ([18F]FDG uptake) in (A) whole lung and (B)
left lung, intercept-adjusted K| in (C) whole lung and (D) left lung, mean SUV in (E)
whole lung and (F) left lung and TPR in (G) whole lung and (H) left lung
Data are presented as box (median/IQR) and whisker (range) plots; n=10 each group; statistical
analysis was by 2-sample t-test or MWU test.
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e) CT radiographic appearances
There was no clear difference between the groups in CT radiographic
appearances. Three subjects from the sham group demonstrated inflammatory
changes (nodular inflammatory changes in the left lower lobe in two subjects;
nodular inflammatory change in the right lower lobe, with some ground glass
opacification in the right middle lobe in the third subject). Four subjects in the
depletion group had visible inflammatory changes on CT (ground-glass changes
in the right middle lobe in three subjects, one ofwhom - together with the
fourth subject - had nodular inflammatory change in the right lower lobe).
5.11 FURTHER ANALYSIS OF PMLC PHENOTYPE BY FLOW CYTOMETRY
The control (sham) group in Study C presented a valuable opportunity to
further compare the phenotype of the resident and inducible PMLC subtypes
present in BAL fluid after LPS inhalation, using flow cytometry.
The expression of several cell surface markers was first compared between the
two PMLC subtypes in BAL fluid from the sham group subjects, who had inhaled
LPS but who had not undergone MNC depletion (Table 51). The iPMLC sub-type
demonstrated significantly lower expression of the proliferation marker, Ki-67.
The iPMLC population also demonstrated significantly lower expression of two
markers ofmacrophage maturation: CD71 and CD206.
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Expression of the macrophage scavenger receptor CD163 (a marker of
maturation and anti-inflammatory activation) was very variable and did not
differ significantly between the two PMLC subtypes.
Table 51: Expression of cell surface markers of proliferation and macrophage
maturation by the two PMLC subtypes in the sham group subjects
MARKER rPMLC iPMLC
Ki-67 19.0 [18.5-42.1] 2.1 [0.7-8.4] **
CD71 20.3 [15.7-31.7] 2.8 [1.5-3.6] ***
CD206 86.7 [72.8-97.9] 61.9 [40.6-73.9] *
CD163 92.2 [56.4-98.5] 69.6 [29.1-91.9] NS
Data are expressed as median [IQR] % of cells expressing each surface marker; n=12 (sham
group only); statistical analysis was by MWU test; *P<O.OB, **P<0.005, ***P<0.0005.
Expression of the same PMLC surface markers was also analysed in BAL fluid
from the depletion group subjects: MNC depletion appeared to have no effect
upon the differential patterns of Ki-67, CD71, CD206 and CD163 expression
between the two PMLC subtypes.
5.12 FUNCTIONAL ANALYSIS OF FLOW-SORTED, CULTURED BAL CELLS
In addition to the phenotype data described above, some preliminary functional
data relating to pro-inflammatory cytokine production were obtained by flow
sorting and culturing BAL cell populations. The cell culture supernatants were
extracted and levels ofIL-6, IL-8 and TNFa were analysed using the CBA kits.
Flow sorting was not performed in some subjects due to staff availability or
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technical issues and flow sorting or cell culture were unsuccessful on some
occasions, meaning that data are only complete for n=8 of the sham group. This
sub-group did, however, remain representative of its parent group in terms of
baseline characteristics.
There were insufficient cell numbers collected by flow sorting to obtain
functional data for the rPMLC population. Functional data for flow sorted,
cultured BAL cells from the depletion group were only available for a sub-group
of n=6 and it was not therefore possible, with such a small sample number, to
determine whether MNC depletion had any direct effect on BAL cell function in
terms of pro-inflammatory cytokine release.
In the sham sub-group (where subjects had inhaled LPS but had not undergone
MNC depletion), levels of spontaneous IL-6, IL-8 and TNFa production were
very similar in the sorted iPMLC and AM populations. Levels of spontaneous
pro-inflammatory cytokine production were compared to the levels recorded
after dexamethasone suppression in the two cell types, per 10,000 cells
cultured. IL-6 production demonstrated significant dexamethasone suppression
in the AM population, compared to a much lesser (non-significant) extent in the
iPMLC population (Figure 51, Panels A and B). There was also significant
dexamethasone suppression of IL-8 production by AMs, but not by iPMLCs
(Figure 51, Panels C and D). Finally, there was a non-significant trend towards
dexamethasone suppression of TNFa production by the AM population,
compared to no apparent effect in the iPMLC population (Figure 51, Panels E and
F).
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Figure 51: Log concentrations of IL-6 (Panels A-B), IL-8 (Panels C-D) and TNFa
(Panels E-F) in supernatants from flow-sorted, cultured AMs and iPMLCs
Data are shown paired (with/without incubation with dexamethasone} per 10,000 cells
cultured; n=8 (sham group only); statistical analysis was by Wilcoxon signed rank test; *P<0.05.
213
Chapter 5: Results of Study C
5.13 CONCLUSIONS FROM STUDY C
a) Primary end-point
Mean circulating blood neutrophil count rose by 6.15 xl09/L at 8 hours in the
sham group subjects (i.e. similar to the rise of 5.2 xl09/L seen in the Study A
subjects who inhaled LPS). Contrary to my hypothesis, MNC depletion did not
attenuate the LPS-induced rise in peripheral blood neutrophil count (the mean
circulating neutrophil count rising by 6.16 xl09/L in the depletion group
subjects at 8 hours).
Small numbers of neutrophils were sequestered during leukapheresis in the
depletion group subjects. For each subject, an adjusted 8-hour blood neutrophil
count was calculated (to account for the number of neutrophils depleted by
leukapheresis). This gave a mean rise in adjusted blood neutrophil count by 8
hours of 6.53 xl09/L in the depletion subjects, with no significant difference
compared to the sham group.
Furthermore, comparison of the overall pattern of LPS-induced change in blood
neutrophil counts between baseline and 8 hours, incorporating the intermediate
time-points of 2, 4 and 6 hours using a repeated-measures analysis, also
demonstrated that MNC depletion had no significant effect.
b) Secondary end-points
Firstly, MNC depletion had no effect on mean SaCh, with small and comparable
falls noted in both the depletion and sham groups (these occurred around or
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after the time of bronchoscopy, rather than as a clear direct effect of LPS
inhalation).
Secondly, leukapheresis did not affect any of the measures of LPS-induced
systemic inflammation measured in plasma. The rise in plasma CRP levels by 24
hours was not attenuated by MNC depletion. Similarly, the small rises in plasma
IL-6 and IL-8 and the rise in plasma RAGE levels seen after LPS inhalation were
not altered by leukapheresis.
Thirdly, MNC depletion had no effect on measures of LPS-induced alveolar
inflammation, in particular BAL neutrophilia, which was around 30% in both
groups. The higher levels of protein in BAL supernatant typically seen after LPS
inhalation were not reduced by MNC leukapheresis. Furthermore, after LPS
inhalation, the BAL supernatant levels of a variety of pro-inflammatory
cytokines (IL-6 and IL-8), chemotactic cytokines (MCP-1 and MlP-la), markers
of neutrophil activation (HNE and MPO) and markers of cellular injury (RAGE
and SP-D) were unaffected by MNC depletion.
Finally, the use of PET-CT in this study also allowed us to evaluate 'whole lung'
inflammation, both in terms of anatomy (all lobes of both lungs) and pulmonary
compartments (alveoli and interstitium) (Chen etal, 2006; Jones etal, 1997).
MNC depletion did not influence any of the measures of LPS-induced pulmonary
[18F]FDG uptake. Values for Ki, intercept-adjusted Kj, mean SUV and TPR were
similar in the sham and depletion sub-groups, even when BAL-induced changes
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in [18F]FDG uptake within the right lung were excluded by analysing data from
left lung only.
c) Safety
There were no SAEs. As in the preliminary studies reported in Chapters 3 and 4,
all reported symptoms or adverse events were attributable to LPS inhalation,
leukapheresis/sham or other study procedures. As noted in the Study A LPS
group, the majority of subjects in Study C reported pyrexial symptoms or
developed a temperature >37.4 °C after LPS inhalation, but these symptoms
were not sustained in any subject. Other symptoms attributable to LPS
inhalation, including cough and headache, were also short-lived. Headache was
a much more frequently reported symptom than in Study A, perhaps due to the
combined effect of LPS inhalation followed by leukapheresis/sham.
Unlike in Study A, where FEVi readings all remained within 10% of baseline,
there were four subjects in Study C (all from the sham group) whose FEVi fell by
>10% below baseline. Although each subject reported associated cough or chest
tightness, there was no audible wheeze on auscultation and these drops in FEVi
resolved spontaneously without treatment in all four subjects. Overall, mean
maximal % falls in FEVi and FVC were greater in Study C than in the Study A
subjects who had inhaled LPS. Falls in FEVi and FVC similar to those seen in
Study C (and after an equivalent dose of inhaled LPS) have been reported widely
in previous literature (Kline eta/., 1999; Shyamsundar etai, 2009; Thorn and
Rylander, 1998).
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Approximately half the subjects in Study C developed citrate-induced
paraesthesiae during leukapheresis; all episodes resolved with IV calcium
supplementation. This was very similar to Study B, with the relatively high
frequency presumably due to the large volumes of blood processed.
Importantly, there were no complications that could be attributed to infection in
any of the subjects. Eight of the Study C subjects (n=4 from each group)
reported light-headedness during or directly after leukapheresis and there was
one vasovagal event, although the subject made a rapid recovery. This is in
contrast to Study B, where there were no reports of light-headedness. This may
be coincidence due to the smaller sample size; it is however possible that the
effects of prior LPS inhalation might increase the frequency of light-headedness
or vasovagal events. Vasovagal events are a well-recognised adverse event
during leukapheresis, albeit usually only transient as was the case in this subject
(Gasova etal., 2010; Reik etal, 1997; Strauss, 1996).
Study C thus confirmed that LPS inhalation and MNC leukapheresis are
associated with a variety of predictable, short-lived side effects [as seen in the
preliminary studies), but that they appear safe to use in healthy subjects.
d) Monocyte yield and subsets
As in Study B, a median volume of >20 litres of blood was processed during
leukapheresis in both the sham and depletion groups. A mean of 7.7 xlO9
(median 7.3 xlO9) monocytes were retrieved in the MNC collections of subjects
from the depletion group. This was higher than the median of 5.6 xlO9
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monocytes retrieved during Study B, but the total number of circulating
monocytes at baseline was also slightly higher (mean of 3.3 xlO9 compared to
2.9 xlO9 in Study B). There remained a very strong correlation between baseline
circulating monocyte count and the number ofmonocytes retrieved by
leukapheresis, as seen in Study B and previously reported in the literature
(Nguyen et al., 2002; Strasser et al., 2003; Wolf et al., 2005). Indeed, the
monocyte yield in Study C was identical to that in Study B, at 2.3 (i.e. the number
ofmonocytes collected during leukapheresis was more than twice the number
circulating in blood at baseline).
e) Monocyte recruitment into circulating blood
I again found evidence of rapid recruitment ofmonocytes into the circulating
blood pool during leukapheresis, as documented in Study B and by several other
authors previously (Alteri and Leonard, 1983; Knudsen etal., 2001; Nguyen et
al., 2002; Strasser et al., 2005; Wolf et al., 2005). Indeed, the depletion group
subjects' mean circulating blood monocyte count fell to a much lesser extent
than would be predicted from the number ofmonocytes removed during
leukapheresis, indicating active monocyte recruitment into circulating blood
during the procedure. In contrast to Study B, the mean circulating blood
monocyte count in the depletion group fell by only 10% (compared to about
35% in Study B). This is almost certainly because LPS inhalation caused a rise in
the mean circulating blood monocyte count by 8 hours, an effect that was clearly
evident in the sham group subjects (where no monocytes had been removed by
leukapheresis). This confirms the trend towards a rise in circulating blood
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monocyte count that 1 had observed in the Study A subjects after LPS inhalation.
In the Study C depletion group, the fall in circulating blood monocyte numbers
(due to their depletion by leukapheresis) was therefore partially offset by this
LPS-induced rise in blood monocyte counts. Both leukapheresis and LPS
inhalation appear to cause monocyte recruitment, possibly from spleen and/or
the marginating pool, into circulating blood.
f) Other effects of LPS inhalation
LPS inhalation was associated with marked rises in mean HR and mean
temperature similar to those seen in the Study A subjects who had inhaled LPS.
MNC depletion did not alter the LPS-induced rise in HR or temperature.
As noted in previous studies using LPS challenge (Michel etal., 1995; O'Grady et
al., 2001), many of the cytokines and markers of cellular injury measured in
plasma remained undetectable (for example, TNFa, 1L-10, SP-D and vWF). LPS
inhalation was, however, associated with significant rises in plasma markers of
neutrophil activation and function (HNE and MPO), and to the same degree in
the depletion group as the sham group. Interestingly, LPS inhalation appeared
to result in a fall in the plasma levels of MCP-1 and SDF-la (chemotactic
cytokines) by 8 hours, a pattern not altered by MNC depletion. Previous studies
have also commented upon chemokine down-regulation in inflammation (Fedyk
etal., 2001; Kim etal., 2007). There was also an LPS-induced fall in circulating
plasma sL-selectin levels in both groups that could potentially reflect selectin-
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mediated neutrophil sequestration in the pulmonary vasculature (Kuebler et al.,
2000).
g) Pulmonary monocyte-like cells
There were no clear differences in flow cytometry plots of BAL cell size and
granularity when comparing the two groups or when comparing these subjects
with the LPS subjects from Study A. Compared to sham, MNC depletion was
associated with a small fall in the proportion and estimated numbers of MNCs in
BAL fluid, but had no effect upon the proportions of PMLC subsets. As seen in
Study A after LPS inhalation, the large majority of PMLCs were of the 'inducible'
subtype.
As discussed in Chapter 3 (Page 136), the dramatic rise in the proportion of
iPMLCs present in BAL fluid after LPS inhalation may reflect transmigration of
classical blood monocytes across the pulmonary endothelium. Further analysis
of PMLC phenotype and function supports this theory.
Firstly, the iPMLC population demonstrated less dexamethasone-induced
suppression of pro-inflammatory cytokine release when compared to AMs.
Secondly, the weaker expression ofmacrophage maturation markers (CD71 and
CD206) by the iPMLC subset suggests these cells may be less mature than the
rPMLC subset. Furthermore, the rPMLC subset appeared to show greater
proliferation potential than the iPMLCs, supporting the theory that this subset
matures into alveolar macrophages or DCs (Gordon and Taylor, 2005;
Landsman et al, 2007; Landsman and Jung, 2007; Thomas et al., 1976).
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h) [18F]FDG PET
As demonstrated above and discussed in Chapter 1, performing BAL provides
the invaluable means to study the phenotype and function of inflammatory cells
in the alveolar space. Although it does not provide equivalent information at a
cellular level, [18F]FDG PET has the advantage ofmeasuring pulmonary
inflammation within the interstitial as well as the alveolar compartment
(including any cells adherent to the alveolar wall). Indeed, a study in rats given
intratracheal LPS 18 hours earlier demonstrated that, within the lung, 94% of
radiolabeled monocytes and 80% of radiolabelled neutrophils were located in
the interstitium (as opposed to 6% and 20% respectively in BAL) (Li etal.,
1998).
Paired [18F]FDG PET scans, before and after segmental LPS challenge, have
previously been used to measure LPS-induced 'whole lung' inflammation within
a single lobe by comparing subtraction to control images (Chen etal, 2006;
Chen etal, 2009). In this study, I have shown for the first time that [18F]FDG
PET can also be used to quantify the more diffuse pulmonary inflammation
produced by LPS inhalation, without the requirement for a baseline scan, and
with no apparent interference by earlier BAL. Furthermore, the Ki values I
obtained (of around 0.001 - 0.002 ml blood ml lung1 minute"1), are comparable
with the segmental model and approximately ten times greater than control
values (Chen et al., 2009).
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5.14 LIMITATIONS OF STUDY C
a) Sample size
This study was statistically powered to detect a significant reduction (of at least
2 xl09/L) in the LPS-induced rise in circulating blood neutrophil count by 8
hours. This was a relatively small study in healthy subjects, using an
experimental model of lung inflammation. As such, one of the limitations of this
study is that it is difficult to predict the degree of reduction in blood neutrophil
count that might translate to a clinically significant effect in patients with ALL
A larger sample size may have also been useful to clarify any possible trends
towards differences between the groups. The study may not have been
sufficiently powered to detect subtle differences in, for example, the cytokines
and cell injury markers that were measured.
PET-CT data was only obtained for a sub-group of twenty subjects, whereas
ideally I would have performed PET-CT scans on all thirty subjects.
Unfortunately, unavoidable delays and overall time constraint meant that study
days had to proceed without PET-CT scans in ten subjects.
Similarly, functional data for iPMLCs and AMs in BAL were only available for a
sub-group of 8 subjects from the sham group and this has to be taken into
account when considering my results. I was also unable to accurately assess the
effect of MNC depletion upon PMLC function.
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b) Incomplete leukapheresis
I aimed to process 4 TBVs during leukapheresis (or sham) for each subject. In
practice, some subjects had <4 TBVs processed (n=6 in depletion arm and n=5
in sham arm). Of these, the majority had >3.5 TBVs processed, with only 2
subjects from each arm having <3.5 TBVs processed. The reasons for incomplete
(sham) leukapheresis were unavoidable and included the vasovagal event,
venospasm or symptoms of citrate toxicity necessitating a lower flow rate.
c) Nature and efficacy of monocyte depletion
In Study B, analysis of the cellular content of three MNC collections indicated
that leukapheresis may preferentially deplete the smaller, less dense, CD16+
(intermediate and non-classical) monocyte subsets. This observation was
supported by a rise in the proportion (equating to a smaller fall in estimated
numbers) of classical monocytes in blood immediately post-Ieukapheresis in
Study B. LPS inhalation, on the other hand, caused a rise in the estimated
numbers of circulating classical monocytes, as shown in the LPS group from
Study A and the sham group in Study C. Consistent with the combined effects of
LPS inhalation followed by leukapheresis, estimated numbers of circulating
classical monocytes remained static in the depletion group during Study C. I was
unfortunately unable to analyse the monocyte content of the MNC collections in
Study C (these were instead discarded), as this would have made it impossible
to maintain blinding of the investigating team. Further work is therefore
required to ascertain whether MNC leukapheresis preferentially removes CD16+
monocyte subsets.
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It could be argued that the small reduction in circulating monocyte numbers
achieved by leukapheresis would not be sufficient to affect neutrophil influx or
transmigration. Leukapheresis did, however, prevent the LPS-induced rise in
circulating blood monocyte count that was seen in the sham group subjects.
Furthermore, the depletion group subjects demonstrated a small reduction in
the estimated numbers of MNCs in BAL fluid, suggesting that leukapheresis may
have an impact, at least to some extent, upon LPS-induced pulmonary monocyte
influx.
A longer duration of leukapheresis would have practical and safety implications.
Fewer than four TBVs are processed during leukapheresis in standard clinical
practice for collection of PBSCs. I chose to process four TBVs in order to
maximise monocyte depletion within the available time, while prioritising
subject safety and tolerance (keeping side effects, such as severe or prolonged
citrate-induced paraesthesiae, to a minimum).
Although leukapheresis is readily available and safe for human use, methods of
monocyte depletion employed in mice, including liposomal clodronate, anti-
CCR2 monoclonal antibody and DT in CDllb-DTR transgenic animals, achieve
much more effective and persistent monocyte depletion. Furthermore, methods
ofmurine monocyte depletion affect other monocyte pools, for example bone
marrow, splenic and patrolling monocytes, in addition to the circulating pool.
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d) Depletion of other cells
As discussed in Chapter 4, MNC leukapheresis is not selective for monocytes and
does deplete other cells, mainly lymphocytes, platelets and RBCs, but also (to a
much lesser extent) neutrophils, basophils and eosinophils.
As in Study B, lymphocyte yield was >1 (indicating lymphocyte recruitment
during the procedure) and strongly predictable from baseline circulating
lymphocyte counts. The exact role of lymphocytes in ALI is unclear but Treg cells
may be key to the resolution of lung inflammation (D'alessio et ai, 2009). In
Study A, I found a reduced proportion of Treg cells in BAL fluid after LPS
inhalation, although (as discussed in Chapter 3, Page 132) the absolute numbers
of Treg cells may have actually risen. An equivalent proportion of BAL Treg cells
was seen in both groups from Study C, appearing unaltered by MNC
leukapheresis. Further work is required to establish whether absolute numbers
of Treg cells in BAL rise after LPS inhalation; the most accurate approach would
probably involve the use of microbeads during flow cytometry to enable
quantification of the Treg population.
As expected, circulating blood lymphocyte counts fell significantly by 8 hours in
the depletion group. Unexpectedly, they also fell (and to almost the same extent)
in the sham group by 8 hours, raising the question of whether circulating
lymphocytes were damaged by sham leukapheresis or somehow sequestrated
in the centrifuge or tubing, although there are no previous reports of this in the
literature. The much greater recovery in circulating blood lymphocyte counts by
24 hours in comparison to the depletion group is reassuring in this regard and
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suggests more reversible reasons are responsible. Firstly, LPS inhalation may
cause a fall in circulating blood lymphocyte counts; indeed, there was a trend
towards this in the LPS subjects in Study A, although it did not reach
significance. Secondly, the ACD-A anticoagulant infused during leukapheresis
causes considerable expansion of circulating blood volume and a dilutional
reduction in cell counts in the sham arm (as well as the depletion arm). Small
falls in circulating blood platelet and RBC counts were also seen in the sham
arm by 8 hours, almost certainly for this reason. Thirdly, circulating blood
lymphocyte counts are known to vary on a diurnal basis, peaking around
midnight and reaching a nadir around midday (Kronfol et al., 1997; Lange et al.,
2010; Ritchie etal., 1983; Sennels etal., 2011), which may have contributed to
my finding (the 8-hour time-point occurring in the early afternoon).
As in Study B, leukapheresis also depleted significant numbers of platelets, in
proportion to circulating counts at baseline. Circulating blood platelet counts
fell dramatically by 8 hours in the depletion group, but again to a lesser extent
than would be predicted from the platelet yield of 0.8 (indicating active
recruitment during the procedure). Evidence from murine models indicates that
platelets also play a key role in the pathogenesis of AL1 (Caudrillier et al., 2012;
Grommes et al., 2012; Kornerup et al., 2010; Looney et al., 2009; Zarbock and
Ley, 2009); retrospective studies of critically ill patients have also shown that
platelet transfusions increase the risk of developing ALI (Khan et al., 2007) and
that aspirin therapy may reduce the risk (Erlich, 2011; Kor et al., 2011); a multi-
226
Chapter 5: Results of Study C
centre RCT of aspirin therapy for the prevention ofALI is currently underway
(Kor etal., 2012).
A large number of RBCs were retrieved into the MNC collections from
leukapheresis. As in Study B, however, this represented only a very small
proportion (0.7%) of total circulating RBCs at baseline. Transfusion of RBCs has
been noted to predispose to the development ofALI and increase subsequent
mortality in a dose-dependentmanner (Gong et al., 2005). Duffy antigen
(expressed on RBCs) has been shown to scavenge pro-inflammatory
chemokines and prevent excessive neutrophil transmigration into the alveolar
space in a murine model ofALI (J S Lee etal., 2006; Reutershan etal., 2009). Red
cell storage is associated with loss of Duffy antigen expression (Mangalmurti et
al., 2008). Furthermore, oxidised haemoglobin has pro-inflammatory actions,
including disruption of the endothelial barrier.
It is therefore possible that the depletion of lymphocytes, platelets and RBCs by
leukapheresis could have had an impact upon LPS-induced inflammation in this
study. It does seem likely, however, that their depletion would if anything
accentuate rather than mask any beneficial effect ofmonocyte depletion.
Neutrophils were sequestered from 9 out of the 15 depletion group subjects
during MNC leukapheresis. Although neutrophil depletion occurred more
frequently than expected compared to Study B (where only 1 out of the 6
subjects demonstrated neutrophil depletion by leukapheresis), its extent was
limited, representing on average only 0.05 times the number of neutrophils
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circulating in blood at baseline. The increased frequency of neutrophil depletion
is probably partly due to the LPS-induced rise in blood neutrophil counts.
Another potential reason for neutrophil contamination of MNC collections is
usually due to fluctuations in venous flow during leukapheresis, which was
noticeable in several of the subjects and probably the main explanation for
neutrophil sequestration. Venospasm disrupts the interface by altering the
height of the cell sediment, thus requiring the operator to perform frequent
readjustments to maintain the collect line haematocrit between 1-3% (to
optimise MNC collection and minimise neutrophil contamination) (Feige and
Sorg, 1984; Linenberger, 2005a; Strasser and Eckstein, 2010). Reducing the cell
collection rate or using online sampling during leukapheresis (to improve
adjustment of the interface) can both help to minimise neutrophil
contamination, but have practical implications, particularly in terms of
procedure duration and consequent tolerability (Faradji etal., 1994; Svensson
etal., 2005).
e) Effects of sham leukapheresis
Sham leukapheresis is not a true 'placebo', as it involves extra-corporeal blood
diversion, anticoagulation and centrifugation with resultant cell sedimentation.
Although whole blood is then returned into the circulation (without any cell
collection), it is possible that sham leukapheresis may cause cellular activation
or have other immune-modulating effects. As discussed in Chapter 4, sham
leukapheresis does not appear to affect monocyte chemotaxis (Alteri and
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Leonard, 1983) but other literature on this topic is scant. When compared to the
Study A subjects who had inhaled LPS (but who did not undergo sham
leukapheresis), there was a slightly higher rise in mean blood neutrophil count
(6.15 xl09/L versus 5.24 xl09/L), higher mean total BAL cell count (4.5 xl05/ml
versus 3.1 xl05/ml), higher mean BAL protein content (0.24 g/L versus 0.15
g/L) and higher mean maximum rise in temperature (1.9 °C compared to 1.4
°C), that could represent augmentation of LPS-induced inflammation by sham
leukapheresis. Conversely, the sham group subjects demonstrated a similar
mean total number of BAL neutrophils (160 xl03/ml versus 172 xl03/ml) and
similar median BAL IL-8 concentrations (61 pg/ml compared to 79 pg/ml).
If it does have unintended effects, sham leukapheresis is most likely to
potentiate the inflammatory effects of LPS inhalation in the sham group, rather
than conceal any beneficial effect ofmonocyte depletion in the intervention
group. Sham leukapheresis had a distinct advantage over using a control group
with no leukapheresis, as it enabled double blinding ofmy study, so that both
subjects and the investigating team were unaware of randomisation status, thus
avoiding any associated bias.
f) Limitations of the LPS model
The limitations of the LPS model were discussed at the end of Chapter 3 (Page
143). Very similar concentrations of LPS were detectable in BAL fluid samples
from all subjects in Study C. Furthermore, PET-derived measures of global lung
inflammation were not affected by analysing data from the left lung alone, or
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even the left lower lobe alone, compared to both lungs. These findings suggest
reasonably even and consistent distribution of inhaled LPS by this method.
g) Timing of end-points and intervention
The timing of the primary end-point was chosen because the rise in blood
neutrophil count after LPS inhalation tends to peak at around 8 hours. This time
point coincided with the end of leukapheresis and, crucially, preceded BAL
(which can itself influence blood neutrophil counts, as noted in the preliminary
studies). It is possible that the timing of the primary end-point was too early to
detect an effect of MNC depletion, but no significant differences were seen in
either of the two secondary end-points measured on day 2 (plasma CRP levels
and PET-derived Ki and mean SUV).
Leukapheresis temporarily caused a reduction in the circulating monocyte pool,
with no improvement in various measures of LPS-induced inflammation. This
may be because leukapheresis did not influence other monocyte pools. Firstly,
for example, there is evidence that patrolling monocytes (present in the
pulmonary vasculature) play a key role in early neutrophil recruitment to the
lung in ALI (Auffray et al., 2007). Secondly, LPS inhalation may induce splenic
monocyte release, as has been shown in other models of inflammation (Swirski
et al., 2009). Leukapheresis may then augment any mobilisation of the splenic
monocyte population, accounting for the rapid and striking repopulation of the
circulating monocyte pool during leukapheresis.
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5.15 SUMMARY OF STUDY C
This RCT was designed to build upon murine studies, where monocyte
depletion has been shown to substantially reduce LPS-induced lung
inflammation, to test whether this finding can be extrapolated to humans. 1 have
shown that, contrary to my hypothesis, MNC depletion by leukapheresis does
not attenuate LPS-induced systemic or pulmonary inflammation in healthy
human subjects.
It does, however, remain likely that monocytes play a significant role in the
complex pathogenesis ofALL The final chapter ofmy thesis outlines the need
for more human studies, both to further define the exact role ofmonocytes in
human lung inflammation and to investigate other potential methods of
modulating monocyte migration and/or function in lung inflammation, with the
aim of identifying new therapeutic options for patients with ALL
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CHAPTER 6: FUTURE WORK
6.1 METHODOLOGICAL CONSIDERATIONS
Firstly, leading on from my earlier discussion on the limitations of all three
studies, I shall reflect on how using alternative or additional controls may have
improved my study design.
In relation to Study A, a randomised crossover-type study design (incorporating
a suitable washout period between inhalation challenges) would have enabled a
within-subject comparison of LPS and saline inhalation. This would, however,
necessitate two separate study days and therefore significantly increase the risk
of subjectwithdrawal mid-way through the study. It would have been
interesting to perform PET-CT scans in the Study A subjects, to compare the
differences in PET-derived measures of global lung inflammation after LPS
inhalation when compared to saline inhalation.
In retrospect, it would have been extremely useful to examine the effects of
sham leukapheresis in a control group within Study B (i.e. without the
potentially confounding effects of LPS inhalation as were present in Study C).
This could have utilised a randomised double-blind design, with six subjects
undergoing sham leukapheresis as well as six subjects undergoing true
leukapheresis and MNC collection. Alternatively, Study B could also have been
performed using a crossover design with suitable washout period, allowing
comparison of true and sham leukapheresis within each subject. As discussed
previously, sham leukapheresis may have subtle modulating effects on systemic
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and pulmonary inflammation. Close scrutiny of the effects of sham
leukapheresis to qualify its use as a 'negative control' would have been useful
prior to proceeding with the RCT.
Within Study C, as stated in Chapter 5, it would have been preferable to perform
PET-CT scans in all thirty subjects had time constraints allowed. An alternative
study design would have involved four-way randomisation, firstly to either LPS
or saline inhalation and then to either MNC depletion or sham leukapheresis.
Such an approach may have enabled more precise comparisons of the effects of
MNC depletion and sham leukapheresis and also the effects of LPS compared to
saline inhalation, specifically with regards to PET-derived measures of global
lung inflammation. The use of PET-CT scanning limits the use of crossover
studies in healthy volunteers due to the need to avoid repeat doses of radiation.
A further possible methodological alteration within Study C would have
involved employing a second control group of healthy subjects who also inhaled
LPS but who did not undergo sham leukapheresis. Although this additional
group's treatment could clearly not be blinded, it would have provided a useful
means to compare the effects of sham leukapheresis with no leukapheresis (and
with MNC collection).
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6.2 FUTURE WORK
a) The role of monocytes in lung inflammation
As discussed in Chapter 1, the pathophysiology ofALI is extremely complex and
translation of findings from animal studies into pharmacological treatments for
ALI has proved problematic. There is, at least in mice, substantial and wide-
ranging evidence suggesting that monocytes play an important role in the
pulmonary neutrophil transmigration that typically occurs as ALI evolves
(Dhaliwal et al, 2012; Ebner et al., 2010; Henderson, 2003; Janardhan et al.,
2006; Maus etal., 2001).
More work is needed to elucidate the exact role ofmonocytes in human lung
inflammation and thus to guide potential future interventions. Very little is
known about pulmonarymonocyte influx, subsequent maturation and cell
phenotype, as is illustrated by the varying descriptions of'monocytes',
'monocyte-like cells' and 'small macrophages' in BAL or sputum from patients
with lung inflammation. As discussed in earlier chapters, cellular identification
by light microscopy is not straightforward. With the studies described in this
thesis, I have shown that flow cytometry can be employed to define and further
characterise these cells (PMLCs) according to their cell surface marker
expression. Furthermore, LPS-induced pulmonary inflammation appears to be
accompanied by an influx of iPMLCs, the PMLC subtype that resembles classical
monocytes in circulating blood, by 9 hours.
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In terms of further work, it would firstly be interesting to study BAL at other
(both earlier and later) time-points after LPS inhalation to more precisely define
changes in PMLC populations over time. It could also potentially be useful to
compare PMLC populations in BAL in the same subject before and after LPS
inhalation (thus providing a within-subject control) although this would
necessitate two bronchoscopy procedures per subject and a suitable 'washout'
period after initial BAL.
The second step in future work would be to use flow cytometry to clarify
whether equivalent populations of PMLCs are present in BAL from patients with
ALI (and other inflammatory lung conditions) and whether these correspond to
the 'alveolar monocytes' described by Rosseau et al (2000). It would also be
useful to study the kinetics of PMLC populations (especially in relation to
neutrophil populations and other markers of alveolar inflammation) at varying
time-points in patients with ALL In addition to flow cytometry, it would also
then be interesting to perform further functional studies of flow-sorted PMLC
populations, ideally obtaining sufficient numbers of rPMLCs to enable direct
comparisons between the two PMLC subtypes, and also with AMs and
neutrophils.
With respect to circulating monocytes in blood, my findings from flow
cytometry support recent evidence for three human monocyte subsets
distinguishable by their cell surface marker expression. My results also indicate
a rise in the numbers of circulating classical monocytes in blood after LPS
inhalation. The next challenge is to demonstrate whether the apparent influx of
235
Chapter 6: Future work
CD14++CD16_ iPMLC present in BAL after LPS inhalation is due to the
accompanying rise in circulating CD14++CD16" (classical) monocytes and their
subsequent pulmonary transmigration. XH MRI represents an expanding non¬
invasive imaging modality that does not necessitate the use of radioactive
tracers. One possibility for tracking and imaging circulating monocytes is to
label them (ex-vivo) with superparamagnetic iron oxide (SPIO) particles.
Reassuringly, there is no evidence that this alters monocyte function or
migration and MRI can then be used to track monocyte migration to sites of
inflammation (Richards etal., 2012). SPIO particles do, however, reduce MR
signal and this therefore limits their use in low-density lung tissue. An
alternative is to intravenously administer 19F perfluorocarbon nanoparticles,
which are then phagocytosed by circulating monocytes. These are biochemically
inert, have a good safety profile for clinical use and result in more persistent
cellular labelling detectable by MRI scanning (Ebner et al., 2010; Flogel et al.,
2008; Srinivas et al., 2012).
Assuming monocytes do play an exacerbating role in neutrophilic lung
inflammation, there are a number of potential reasons (as discussed in Chapter
5) why monocyte depletion by leukapheresis proved ineffective in Study C.
Potential methodological adjustments and alternative strategies are discussed
below.
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b) Timing of monocyte depletion
In this study, leukapheresis was designed to begin 2 hours after LPS inhalation
and the effect on circulating blood monocyte counts only therefore became
noticeable at around 4 hours from baseline. As discussed in Chapter 1, there is
evidence of pro-inflammatory cytokine release and both a rise in BAL cell
numbers and blood neutrophils within 4 hours of LPS inhalation. It may be that
earlier leukapheresis would prove to be a more effective strategy, although this
may at the same time make it less clinically translatable, as it is difficult to
identify patients with ALI at an early stage. A pre-emptive approach might prove
more practical, but would limit the clinical applicability to patients at high risk
ofALI, rather than those with established lung inflammation.
In mice (albeit in a peritoneal model of inflammation], patrolling resident
monocytes have been reported to extravasate within 1 hour of tissue damage
(Auffray eta/., 2007]. Further research is required to determine whether early
extravasation of patrolling monocytes in pulmonary endothelium is important
in the pathogenesis ofALI. Interestingly, in humans, rapid and high-volume
mobilisation of 'marginating' CD14+ CD16+ monocytes into the circulating pool
has been described after strenuous exercise (Steppich et a/., 2000]. As I have
shown in Studies B and C, removing circulating monocytes by leukapheresis
induces rapid monocyte recruitment, presumably from other monocyte pools. It
is therefore feasible that the pre-emptive use of leukapheresis could interfere
with the pathogenesis of lung inflammation by recruiting patrolling monocytes
into the circulation and thus preventing their extravasation.
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Alternatively, it is possible that I missed a later effect of leukapheresis; although
I did not measure BAL at later time-points, there was no indication that
leukapheresis had a significant effect upon other markers of systemic or
pulmonary inflammation that were measured at/after 24 hours (including
plasma CRP levels and [18F]FDG PET-derived Ki). In the same vein, it could also
be argued that I timed leukapheresis to occur too early after the initiation of
LPS-induced lung inflammation. It is possible that chemokine release stimulates
the initial neutrophil transmigration that occurs in ALI and that monocytes are
only involved in the second, later phase of pulmonary neutrophil influx that
peaks at 24-48 hours (Dhaliwal et al., 2012; Petty et al., 2007).
c) Nature of monocyte depletion
Safety is one of the most important considerations when translating research
into clinical practice (especially when studying healthy volunteers). This is
particularly relevant to ALI, where the normal, protective host response to an
injurious stimulus appears to evolve into excessive and uncontrolled
inflammation; clearly any intervention that compromises the protective nature
of the host response could ultimately prove harmful. As discussed earlier,
leukapheresis had the advantage of being a readily available technique, with
some evidence of effect in other inflammatory conditions and, crucially, a good
safety profile. However, compared to the methods ofmonocyte depletion that
have been described in mice, it provided a relatively limited, transient and non¬
selective effect. Research is therefore needed into other potential methods of
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human monocyte depletion that may have a more profound, sustained and
selective effect than leukapheresis.
One possible area for such research includes the use ofmonoclonal antibodies
that interfere with monocyte function or migration. The use of monoclonal
antibodies represents a rapidly expanding field, with a growing list of
applications including autoimmune inflammatory conditions, viral diseases,
transplant rejection, cancer, asthma and stroke (Hansel etal, 2010; Hudson and
Souriau, 2003). For example, with relevance to monocyte chemotaxis, one group
tested whether an anti-MCP-1 monoclonal antibody could reduce disease
severity in patients with RA (Haringman et al., 2006). Following administration,
they noted a quick fall in circulating free levels of MCP-1 in blood, but
demonstrated no clinical or histological improvement. Indeed, at the highest
dose, they noted a possible trend towards increased inflammation; the authors
attributed this paradoxical finding to an unexpected, steep rise in circulating
levels of antibody-bound MCP-1 in blood (hypothesised to reflect reduced
antibody clearance) (Haringman etal., 2006).
Another group, this time in mice, reported that using a monoclonal antibody to
block junctional adhesion molecule-C receptors reduced net monocyte influx to
inflammatory tissues (Bradfield et al., 2007). These authors argued that higher
circulating levels of monocytes that had lost CD62L expression reflected
increased monocyte reverse transmigration across the endothelium (Bradfield
etal., 2007).
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There are many potential targets for monoclonal antibody therapy in patients
with AL1; however, safety is again a key consideration. A variety of potentially
serious or even fatal adverse reactions to monoclonal antibody therapy have
been reported, including immune reactions such as anaphylaxis and serum
sickness, infections, cancer, autoimmune disease and cytokine release syndrome
(Hansel etal., 2010). For example, severe cytokine release syndrome occurred
in six healthy volunteers given a superagonist anti-CD28 monoclonal antibody
in a now notorious phase I human trial in 2006 (Suntharalingam et al., 2006).
This has lead to a more cautious approach to deciding the initial dose for
biological agents being used in humans for the first time (Hansel et al., 2010).
Another possible area for research relates to the contribution of other monocyte
pools. The difficulty in achieving a sustained effect from leukapheresis was
partly due to time constraints relating to tolerability but also due to marked
recruitment ofmonocytes into circulating blood during the procedure that may
have negated the intended effect. Indeed, in monocyte-depleted mice given
intratracheal LPS, Dhaliwal et al (2012) showed that adoptive transfer of freshly
isolated MNCs lead to a prompt rise in BAL neutrophil numbers. Extensive work
in mice has demonstrated the presence of a splenic pool ofmonocytes and it is
certainly possible that splenic monocyte depletion may have partly contributed
to the attenuation of LPS-induced lung injury in previous murine studies.
Research done in mice and rats employing coronary ligation to induce
myocardial infarction demonstrated a reduction in the splenic monocyte pool
(compared to no reduction in monocyte numbers present in bone marrow), a
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rise in both subtypes of circulating monocytes and very high Ly6Chish monocyte
content in ischaemic myocardium (Swirski et al., 2009). Splenectomy prevented
the rise in circulating blood monocytes and reduced the numbers of Ly6Chish
monocytes in ischaemic myocardium by 75% (Swirski etal., 2009). Swirski etal
also provided evidence that monocytes were released from the spleen under the
control of angiotensin II and that these monocytes are biologically active. This is
in contrast to CCR2-dependent monocyte exit from bone marrow (Serbina and
Pamer, 2006). Another paper confirmed the early accumulation of Ly6Chi§h
monocytes in ischaemic myocardium, compared to a later rise in Ly6Clow
monocytes that peaked at about 7 days (Nahrendorf et al., 2007). Ongoing
splenic monopoiesis appears to occur in both the myocardial infarction and a
cerebral infarction model (Leuschner etal., 2012). This group have
demonstrated, using time-lapse intravital fluorescence microscopy in GFP
knock-in mice, that inhibition of angiotensin converting enzyme (ACE)
prevented the release of splenic monocytes after coronary ligation (Leuschner
etal., 2010). Furthermore, ACE inhibition attenuated the rise in circulating
monocytes and also their accumulation in ischaemic myocardium, in particular
the early peak in Ly6Chish monocytes (Leuschner et al., 2010). A similar but less
marked effect was achieved by splenectomy.
It would be extremely interesting to study splenic monocyte kinetics in mice
with experimental ALI, especially as the renin-angiotensin system has been
implicated in neutrophil influx in animal models of lung inflammation. For
example, using both a sepsis and acid aspiration model, one group showed that
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lung injury was less severe in mice deficient in ACE; furthermore recombinant
ACE2 (which blocks the angiotensin II receptor) protected mice against lung
injury (Imai et al., 2005). Arndt et al (2006) went on to demonstrate a
significant reduction in pulmonary neutrophil recruitment after LPS in mice
pre-treated with either an ACE inhibitor (enalapril) or an angiotensin II
receptor blocker (losartan).
d) Summary
In conclusion, the priorities for further research in this field include firstly
establishing whether PMLC populations are present in BAL fluid from patients
with ALI, secondly using imaging to establish monocyte kinetics after inhaled
LPS in healthy volunteers and, thirdly, confirming whether splenic monocyte
release is relevant to animal models of lung injury.
If an equivalent population of splenic monocytes can be confirmed in humans,
then targeting their release using ACE inhibition or blockade of the angiotensin
II receptor would appear to be the most promising area for further translational
research. This would also provide an excellent candidate treatment (with a
good, established safety profile) for a further phase II study employing the LPS
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